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Ziqing Liu 
 
Characterization of Hepatitis C Virus Infection of Hepatocytes and Astrocytes 
 
Approximately 2.8% of the world population is currently infected with hepatitis C virus 
(HCV).  Neutralizing antibodies (nAbs) are often generated in chronic hepatitis C 
patients yet fail to control the infection.  In the first two chapters of this study, we focused 
on two alternative routes of HCV transmission, which may contribute to HCV’s immune 
evasion and establishment of chronic infection.  HCV was transmitted via a cell-cell 
contact-mediated (CCCM) route and in the form of exosomes.  Formation of HCV 
infection foci resulted from CCCM HCV transfer and was cell density-dependent.  
Moreover, CCCM HCV transfer occurred rapidly, involved all four known HCV receptors 
and intact actin cytoskeleton, and led to productive HCV infection.   Furthermore, live cell 
imaging revealed the temporal and spatial details of the transfer process.  Lastly, HCV 
from HCV-infected hepatocytes and patient plasma occurred in both exosome-free and 
exosome-associated forms and the exosome-associated HCV remained infectious, even 
though HCV infection did not significantly alter exosome secretion.   
 
In the third chapter, we characterized HCV interaction with astrocytes, one of the 
putative HCV target cells in the brain.  HCV infection causes the central nervous system 
(CNS) abnormalities in more than 50% of chronically infected subjects but the underlying 
mechanisms are largely unknown.  We showed that primary human astrocytes (PHA) 
were very inefficiently infected by HCV, either in the free virus form or through cell-cell 
contact.   PHA expressed all known HCV receptors but failed to support HCV entry.  
HCV IRES-mediated translation was functional in PHA and further enhanced by miR122 
expression.  Nevertheless, PHA did not support HCV replication regardless of miR122 
vii 
 
expression.  To our great surprise, HCV exposure induced robust IL-18 expression in 
PHA and exhibited direct neurotoxicity.  In summary, we showed that CCCM HCV 
transfer and exosome-mediated HCV infection constituted important routes for HCV 
infection and dissemination and that astrocytes did not support productive HCV infection 
and replication, but HCV interactions with astrocytes and neurons alone might be 
sufficient to cause CNS dysfunction.  These findings provide new insights into HCV 
infection of hepatocytes and astrocytes and shall aid in the development of new and 
effective strategies for preventing and treating HCV infection.    
 
     
 
Andy (Qigui) Yu, M.D., Ph.D., Co-Chair 
     Johnny J. He, Ph.D., Co-Chair 
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INTRODUCTION 
 
1. HCV AND HEPATITIS C 
 
1.1 Hepatitis C – global perspective, vaccines and therapeutics 
The latest global epidemiology studies indicate that more than 185 million people, which 
account for about 2.8% of the world population, are infected with hepatitis C virus (HCV) 
(1), among which 4.1 million are in the U.S (2).  Although the incidence of new infections 
has become much lower since the development of blood screening tests in early 1990s, 
the morbidity and mortality due to HCV infections contracted in 1970s and 1980s are 
rising and are expected to continuously increase over the next ten years (3).  HCV 
infection frequently leads to hepatitis (inflammation of the liver) and steatosis (fatty liver), 
and it is considered a leading cause for life-threatening chronic liver diseases such as 
liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (4).  It also presents the 
primary cause for liver transplantation in the U.S. and the Europe (5).  Despite intensive 
research efforts during the last two decades, no HCV vaccines have become available 
(6, 7).  The standard of care (SOC) for HCV infection used to be pegylated interferon α 
plus ribavirin (PEG-IFN/RBV) before May 2011.  The treatment modality is not well 
tolerated and only has a less than 50% response rate for HCV genotype 1, the most 
prevalent HCV subtype (8, 9).  The first two direct-acting antivirals (DAAs), the HCV 
protease NS3/NS4 inhibitors telaprevir and boceprevir, were approved by the FDA in 
2011.  The combinatorial treatment of these inhibitors with PEG-IFN/RBV has greatly 
improved the response rate from 50% to 70% in HCV genotype 1 patients (8, 9), 
although this response rate is not optimal.  It is evident that a better understanding of 
HCV infection and pathogenesis is required to enable the development of new anti-HCV 
therapeutic and prophylactic strategies. 
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1.2 HCV pathogenesis in the liver 
About 20% of HCV infections are spontaneously cleared within six months after the 
initial infection, which is termed as acute infection.  The strong and specific cytotoxic T 
cells (CD8+) response observed in acute HCV infection is correlated with the control of 
viremia and is very likely the reason for acute liver damage (10).  The remaining 80% of 
HCV infections are not cleared by the host immune system and these patients become 
chronically infected.  In a timeframe of 10–40 years, these patients may progressively 
develop chronic hepatitis, steatosis and fibrosis, and 20% of them will progress to the 
end stage: liver cirrhosis.  Each year, 5% of those with cirrhosis develop hepatocellular 
carcinoma (HCC) (11, 12).  Chronic hepatitis is the inflammation of the liver 
characterized by the infiltration of immune cells into the liver after the host immune 
system fails to control viral replication during the acute phase.  Steatosis is the 
production and accumulation of excessive fatty acids in liver cells, and it is observed in 
more than half of chronic HCV patients.  Patients with chronic hepatitis and/or steatosis 
are at high risk of developing fibrosis, cirrhosis, and hepatocellular carcinoma (13).  
Many factors contribute to the stepwise development of liver diseases in chronic HCV 
patients.  Besides risk factors like age, ethnicity, sex, co-infection with hepatitis B virus 
or human immunodeficiency virus type 1 (HIV-1) and host genetics, e.g., IL-28B gene 
variants, direct effects of HCV proteins and indirect impact of infiltrated immune cells are 
the two most important contributors to the disease progression.  For example, HCV 
proteins exert direct impact by interacting with a variety of cellular processes.  Several of 
the HCV proteins such as core, NS3, and NS5A target multiple cellular proteins in innate 
cellular antiviral pathways, so as to disarm the front line of antiviral defense and to 
hamper/delay the effective induction of adaptive immune response (14).  Individual HCV 
proteins (core, NS3, and NS5A) are also reported to increase reactive oxygen species 
(ROS) production and induce oxidative stress in both cell culture and chronic HCV 
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patients.  Cellular environment under oxidative stress favors the expression of 
profibrogenic genes/cytokines and induces cellular DNA mutations, both of which 
accelerate the development of fibrosis, cirrhosis, and HCC (15).  In addition, the HCV 
core protein is known to interact with key regulators in lipid metabolism and induce 
steatosis (13).  At last, core, NS3, NS5A and NS5B can interfere with the p53 and pRb 
pathways to exert their impacts on cell proliferation and apoptosis: a shortcut to 
oncogenesis (15).  On the other hand, the infiltrated immune cells in liver still cannot 
effectively control viral infection, which leads to exhaustion of CD4+ and CD8+ effector T 
cells and continuous infiltration of immune cells.  Although the HCV-specific immune 
response in chronic HCV patients is weak and ineffective in controlling virus infections, 
the repeated inflammation induces oxidative stress and causes destruction of liver tissue.  
The damaged liver tissue is then replaced through fibrogenesis, and the cycle of liver 
damage and re-building perpetuates until the development of fibrosis/cirrhosis (10, 16-
18).  All together, the potential host-related risk factors, the altered hepatocyte 
proliferation capacity by HCV proteins (15) and the “stressed” and growth-promoting 
microenvironment shaped by both HCV proteins and ineffective immune response in the 
liver (13, 15, 19) ultimately contribute to HCC development.   
 
1.3 HCV genome 
HCV is an enveloped, single-stranded (ss), and (+) sense RNA virus with a diameter of 
55 – 65 nm.  It belongs to the Flaviviridae family and has six subtypes, with HCV 1a, 1b 
and 2a to be the most prevalent (20).  The HCV virion is composed of a RNA genome 
enclosed by capsid formed by core protein and an envelope embedded with HCV 
glycoprotein E1, E2 heterodimers (Fig. 1A).  The HCV RNA genome is 9.6 kb in length 
and consists of 5’ and 3’ untranslated regions (UTR), and a single open reading frame 
(ORF) encoding all structural proteins and nonstructural proteins (Fig. 1B).  The 5’ UTR 
4 
 
and 3’ UTR harbor several RNA secondary structures with essential functions in 
replication and translation.  Among them is the internal ribosome entry site (IRES).  It 
extends from 5’ UTR into the core-encoding region and is responsible for 5’ cap-
independent translational initiation.  Structural proteins include the envelope proteins E1, 
E2, the capsid protein core and a small 63 aa peptide p7 with putative ion channel 
function.  During translation, these structural proteins are cleaved by two cellular 
proteases, the signal peptidase and the signal peptide peptidase (Fig. 1B, SP and SPP, 
blue and green arrow head).  Non-structural (NS) proteins are NS2, NS3, NS4A, NS4B, 
NS5A, and NS5B.  NS2 is a protease which, together with the N-terminal portion of NS3, 
cleaves the NS2-NS3 junction (Fig. 1B, black arrow head).  NS3 has two distinct 
domains.  Its N-terminal portion is a protease domain, which cleaves all the downstream 
junctions between NS proteins with the assistance of its cofactor NS4A (Fig. 1B, orange 
arrow head).  Its C-terminal portion is a helicase which functions to unwind double-
stranded RNA (dsRNA) substrate and secondary RNA structures during HCV replication.  
NS4A, as mentioned above, is a co-factor for NS3 protease.  NS4B induces the 
formation of a specialized membrane structure, the “membranous web”, where it serves 
as the scaffold protein for the HCV replication complex.  NS5A is a hydrophilic 
phosphoprotein whose phosphorylation status is crucial to HCV replication.  NS5B is a 
RNA-dependent RNA polymerase (RdRp) responsible for HCV genome replication (15, 
21).   
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Figure 1.  HCV virion and genome.   (A) HCV virion.  (B) HCV genome.  Cleavage 
sites of HCV polypeptide processing by different proteases are indicated in colored 
arrowheads: SP (signal peptidase, blue), viral proteases NS2/3 (black) and NS3/4A 
(orange).  SPP (signal peptide peptidase) cleavage of SP-cleaved core (green 
arrowhead and *) generates mature core protein.    
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1.4 HCV life cycle 
 
1.4.1 HCV entry and its cellular receptors 
Generally, the HCV life cycle can be divided into the following stages: attachment, entry 
and fusion, translation and replication, assembly and secretion (15, 21).  First, the 
attachment of virus to host cell is mediated by glycosaminoglycans (GAGs, e.g., heparin 
sulfate) (22) and the low density lipoprotein receptor (LDLR) (23, 24).  Next, specific 
interactions between the viral glycoprotein E2 and cellular receptors induce receptor-
mediated endocytosis (Fig. 2).  This “entry” step has been intensively studied and four 
HCV entry receptors/ co-receptors have been discovered.  The first one is a tetraspanin 
protein, CD81, which was discovered by screening for HCV E2-interacting proteins (25).  
The scavenger receptor class B type 1 (SR-B1) was subsequently found to also interact 
with HCV E2 and to play a role in HCV entry (26, 27).  SR-B1 normally functions as a 
LDL/HDL receptor and is highly expressed in the liver and other steoidogenic tissues.  
Recently, two tight junction (TJ) proteins, claudin-1 (CLDN1) and occluding (OCLN) were 
discovered to confer susceptibility to HCV infection in human embryonic kidney cell line 
293T (28) and mouse embryonic kidney fibroblast cell line NIH3T3 (29), respectively, 
even though they were not found to directly bind HCV envelope proteins.  The current 
HCV cell entry model suggests roles of CD81 and SR-B1 in the early entry step and 
roles of CLDN1 and OCLN in the late entry steps.  After attachment, HCV E2 interacts 
with cellular receptors CD81 and SR-B1, and their interaction triggers signaling 
cascades essential for entry and downstream events (30, 31).  The virus is then 
transferred to CLDN1 and OCLN via CLDN1’s association with CD81 (32-34) and 
internalized by endocytosis, followed by pH-dependent fusion (35, 36).  Interestingly, 
none of these four receptors are exclusively expressed in the liver, the primary target of  
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Figure 2.  The HCV life cycle.  First, virus attaches to the primary docking sites (GAGs 
or LDLR), interacts with cellular receptors SR-B1, CD81, CLDN1, and OCLN, and 
undergoes endocytosis and pH-dependent membrane fusion.  Viral proteins are then 
translated and processed in the cytoplasm.  The viral replication complex assembles on 
the membranous web to generate genomic viral RNA.  Finally, HCV virions assemble 
on/close to lipid droplets and are released through unknown mechanisms.  
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HCV.  Nevertheless, restrictions on steps other than entry can also shape the liver 
tropism of HCV, such as the requirement of liver-specific microRNA miR122 for HCV 
replication (37).  Thus, it is possible that only human hepatocytes express all the cellular 
factors required for a complete HCV life cycle.   
 
1.4.2 HCV translation and replication and miR122 
Following fusion and release of HCV RNA into the cytoplasm, HCV translation is initiated 
on endoplasmic reticulum (ER) by binding of ribosomes to IRES.  A single polypeptide of 
about 3,000 amino acids is synthesized and processed by both cellular proteases and 
viral proteases.  The processed viral NS proteins, together with cellular co-factors, form 
a replication complex (RC) on the intracellular membranous web (38).  The NS5B RdRp 
uses HCV (+)-strand genomic RNA as the template to produce (-)-strand intermediate 
RNA and then (+)-strand RNA can be produced in large quantity with (-)-strand RNA as 
the template.  The ratio of (+)-strand RNA: (-)-strand RNA is always kept between 
1000:1 and 100:1 in HCV infected cells and the presence of (-)-strand RNA is 
considered as the marker of active HCV replication (39-41).   
 
Throughout HCV translation and replication, the role of miR122 is essential.  In 2005, the 
liver-specific microRNA-122 was first discovered to be required for HCV replication (37).  
The mechanisms of action of miR122’s role in HCV life cycle have been intensively 
studies since then.  Generally, miR122 positively regulates HCV infection at three levels 
at least: stimulation of HCV translation (in both cell culture and in vitro translation 
systems) (42-44), enhancement of HCV RNA stability (45-47), and promotion of HCV 
replication and infectious virus production (37, 48-50).  The current model stipulates that 
it mainly functions via binding to two target sequences in HCV 5’UTR.  This binding 
relieves HCV IRES from an inhibitory long-distance RNA loop formed through base-
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paring between 5’UTR and the core sequence, and hence stimulates HCV translation 
(44).  This binding also recruits Argonaute 2 (Ago 2), the catalytic components of the 
RNA-induced silencing complex to HCV 5’UTR (47).  But recruitment of Ago 2 does not 
lead to cleavage of HCV RNA, which is very common in RNA silencing of cellular 
mRNAs; instead, it stabilizes HCV RNA and slows its degradation by 5’ exonuclease   
Xrn I (46).  Nevertheless, how this binding promotes HCV RNA replication remains 
unclear.  Besides the mechanistic studies, the clinical implications of miR122’s 
involvement in HCV life cycle have also been widely explored.  Serum miR122 level was 
recently suggested as potential biomarkers for chronic hepatitis C (51); treatment of 
HCV infection by targeting miR122 with antisense oligonucleotide was shown to lead to 
prolonged dose-dependent reductions in HCV RNA levels without evidence of viral 
resistance (52). 
 
1.4.3 HCV assembly and release 
After translation and processing, HCV proteins are targeted to lipid droplets (LD), a lipid 
storage organelle mainly consisting of triglycerols in preparation for viral assembly (53).  
Both HCV core and NS5A are targeted to LD after being processed.  Their LD targeting 
changes LD distribution in the cells and is required for HCV infectivity (54-57).  A recent 
study shows that disruption of microtubule network prevents HCV core-mediated LD 
redistribution and decreases viral titer in HCV-infected cells, indicating potential roles of 
microtubule network/transport in virus assembly (58).  Additionally, the putative ion 
channel protein p7 and non-structural protein NS2 are not required for RNA replication, 
but are necessary for infectious virus production (59-63), suggesting their possible 
involvement in virus assembly or release.  HCV assembly and release have also been 
stipulated to converge with the very-low density lipoprotein (VLDL) production pathway 
based on the findings that HCV virions are associated with LDL/VLDL in vivo and that 
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HCV proteins re-localize to LD after processing (53).  Moreover, recent studies 
demonstrate that apolipoprotein E (ApoE) interacts with HCV NS5A and this interaction 
is important for HCV assembly and infectious virus production (64).  Mouse hepatocyte 
cell lines can support HCV assembly upon ectopic expression of ApoE (65), suggesting 
that ApoE may present the last limiting factor for a complete HCV life cycle besides HCV 
receptors (limiting entry) and miR122 (limiting translation and replication).  Taken 
together, the current model of HCV assembly is stipulated as follows.  While HCV 
genome RNA is continuously produced from the replication complex in the 
membraneous web and HCV core are lined up on LD, the genome RNA and core are 
simultaneously recruited to the site of assembly (either on LD or on ER and close to LD) 
and nascent viral budding towards ER lumen, where HCV E1/E2 are already residing, 
takes place (66).  During this process, viral proteins p7, NS2 and NS5 and cellular 
protein ApoE all play important roles.  Nevertheless, the late steps in HCV life cycle are 
still not completely understood and await to be elucidated. 
 
1.5 HCVpp and HCVcc model systems 
HCV research has been long hampered by the lack of an in vitro reproducible HCV 
infectious system.   To study HCV entry and other earlier steps in HCV life cycle, a 
pseudotyped HCV system (HCVpp) was created (Fig. 3A).   It consists of an envelope-
defective HIV core and HCV envelopes or other viral envelopes (67).   This system has 
contributed in a great deal to the identification of HCV receptors and defining of HCV 
tropism.  It leads to successful identification of the HCV co-receptors CLDN-1 (28) and 
OCLN (29) and better understanding of other earlier steps of HCV infection (34, 68, 69).  
The HCVpp system has several advantages.  First, the HIV reporter virus is defective in 
HIV envelope gene, thereby only capable of single round infection (replication-defective), 
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Figure 3.  In vitro HCV culture systems.  (A) The HCV pseudoparticle (HCVpp) 
system.  HCVpp contains an envelope (replication)-defective HIV core and a functional 
HCV envelope and has been used to study HCV glycoproteins-mediated cell entry.  The 
HIV genomes have been engineered to express a reporter gene, such as luciferase or 
GFP, allowing for quantitative measurements of the virus entry.  To make the HCVpp, 
293T cells are co-transfected with HCV envelope expression plasmid HCV-E1E2 and 
envelope-defective HIV-luciferase (HIV-Luc) or HIV-GFP (HIV-GFP) reporter proviral 
DNA.  Culture supernatants are collected at 48 hr post-transfection, cleared of cell debris, 
and saved as the HCVpp stock.  Similarly, pseudotyped particles containing no envelope 
protein or vesicular stomatitis virus glycoprotein protein (VSV-G) are also prepared and 
used as negative and positive controls, respectively.  The titer of the virus can be 
determined by HIV reverse transcriptase assay.  (B) The HCV cell culture (HCVcc) 
system.  HCVcc represents the only available in vitro cell culture system that 
recapitulates the complete life cycle of HCV.  It requires a special JFH1 strain and the 
Huh7 or Huh7-derived hepatoma cell lines (Huh7.5 and Huh7.5.1 cells) to achieve 
efficient viral replication.  HCVcc is produced by inoculation of Huh7/Huh7-derived cells 
with viral stock or by transfection of these cells with in vitro synthesized JFH1 RNA.  
Culture supernatants containing high titers of HCVcc are used to infect naïve Huh7.5.1 
cells, and productive infections are monitored by qRT-PCR for HCV RNA or 
immunostaining of HCV antigens such as HCV core.  Viral titers can be determined 
using the foci formation assay.  
15 
 
which allows accurate determination of HCV envelope protein-mediated virus entry.  
Second, the titers of the viruses can be easily determined by HIV reverse transcriptase 
activity assay.  Third, because of insertion of the green fluorescent protein (GFP) or 
luciferase (Luc) reporter gene into the HIV genome, cell entry of pseudotyped viruses 
can be readily monitored on the basis of a single cell or a population of cells by simple 
reporter gene assays. 
 
Another breakthrough in HCV research occurred in 2005, i.e., establishment of the first 
productive in vitro HCV culture system by three independent research groups (HCVcc, 
Fig. 3B) (70-72).  Since then, as the only system that was capable of recapitulating the 
complete HCV life cycle in vitro, the HCVcc system and other derived systems have 
been widely used in HCV research.  The HCVcc system involves the use of a unique 
HCV JFH1 strain (HCV subtype 2a) and a unique human hepatoma cell line Huh7 that is 
defective in the innate anti-viral cellular response.  The JFH1 strain is able to replicate 
efficiently in Huh7 hepatoma cells and produce high titers of HCV.  Based on the original 
HCVcc system, modifications were made to achieve even higher levels of viral 
replication and infectious virus production.  Those modifications include the use of 
chimera HCV strains (e.g., J6/JFH1 chimera, H77/JFH1 chimera) and/or highly 
permissive cell clones derived from Huh7, such as Huh7.5, a subclone of Huh7 that was 
cured of a subgenomic HCV replicon by IFN-α treatment (73) and Huh7.5.1, a Huh7.5-
derived highly permissive cell clone.  Both the HCVpp and the JFH1 HCVcc systems 
have been established in our laboratory and have been extensively used throughout this 
study. 
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2. CELL-CELL CONTACT-MEDIATED VIRAL TRANSMISSION 
 
2.1 Cell-cell contact-mediated transmission of viruses 
Cell-cell contact-mediated (CCCM) viral infection and transmission has been 
demonstrated in many plant and animal viruses (74-76).  Different animal viruses adopt 
different strategies for CCCM transmission.  Herpesviruses, paramyxo-viruses and 
retroviruses can induce plasma membrane fusion between infected and uninfected cells 
followed by transfer of infectious viral materials into the uninfected target cell; this type of 
CCCM transmission frequently leads to syncytium formation (77-79).  Herpes simplex 
virus (HSV) can bud on the basolateral membrane of an infected epithelial cell, then fuse 
with and penetrate a neighboring uninfected cell by binding to the viral entry receptors 
located at the tight junctions between the two cells (80).  Some neurotropic viruses like 
rhabdoviruses, herpesviruses and paramyxoviruses can transfer across neural synapses 
(81-83).  Poxviruses such as vaccinia virus (VV) can induce the formation of actin tails to 
project progeny viruses or viruses adhered to the surface of infected cells to uninfected 
cells, in proximity or distance (84).  Retroviruses such as murine leukaemia virus (MLV) 
induce stable anchoring of filopodial bridges between infected and uninfected cells, 
allowing virions to travel from an infected cell to an uninfected cell in an actin‑myosin‑
dependent fashion; viral receptors are required for such transfer, indicating virus–cell 
membrane fusion (85).  HIV-1 can travel for up to 300 μm to infect a distant cell along 
nanotubes, a new form of intercellular communication and exchange of materials like 
protein and organelles by actin-motored movement (86, 87).  This type of CCCM 
transmission is also receptor ‑ dependent, indicating virus–cell membrane fusion.  
Additionally, retroviruses such as HIV-1 and human T cell leukemia virus type 1 (HTLV-1) 
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can induce the formation of virological synapses (VS) between infected and uninfected 
cells that subsequently facilitate CCCM viral infection and transmission (88, 89).  
 
Viruses that utilize CCCM transfer often capitalize on one or more cellular processes to 
accomplish the transfer and in most cases the type of infected cell/tissue dictates the 
processes that become appropriated.  In immune cells, HIV-1 and HTLV-1 subvert the 
immunological synapse machinery in the infected cells and induce cytoskeleton 
reorganization and polarized viral budding towards an uninfected receptor-expressing 
cell in a structure named virological synapse (90, 91).  HIV-1 also “hijacks” the nanotube 
structures for intercellular communication in macrophages and T cells for CCCM virus 
transfer (86, 87), while HSV exploits the tight junctions among epithelial cells for viral 
spread (80).  Most of the cellular machineries/physiological processes capitalized by 
viruses for their CCCM transmission involve actin and/or microtubule cytoskeleton, so 
that virus budding could be polarized towards uninfected targets, or the subcellular 
structure for CCCM transfer could be supported, or the virus could be delivered from 
infected cells to uninfected cells by actin/tubulin-motored transport. 
 
2.2 Cell-free virus infection vs. CCCM viral transmission 
Both cell-free virus infection and CCCM viral transmission have advantages and 
disadvantages.  Cell-free virus infection enables host-to-host transmission of virus 
[except HTLV-1 which requires infected T cells to transmit between host (92)] and rapid 
transit of virus in biofluid circulation once inside a new host to spread to distant 
tissue/organ.  However, cell-free virus infection usually encounters various biophysical 
and immunological barriers.  Biophysical barriers include mucous membranes and a 
progressive loss of viral infectivity over time.  In addition, in cell-free virus infection 
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involving random fluid-phase diffusion of the virus, the “searching” process for a target 
cell and viral attachment and binding to receptors on the target cell is probably the most 
rate-limiting step during the complete viral life cycle.  Particularly, for viruses with low 
binding affinity/avidity to their receptors and viruses binding to more than one receptor 
(e.g. HIV-1 and HCV) or binding to receptors expressed at low levels, cell-free virus 
infection is disadvantageous.  Immunological barriers to cell-free virus infection include 
innate humoral and cellular defenses during acute infection and adaptive immune 
responses such as neutralizing antibodies (nAbs), antibodies that specifically recognize 
viral antigens and “neutralize” the virus by clearing them out from circulation and virus-
specific cytotoxic T lymphocytes during subsequent rounds of infection.   
 
To the contrary, CCCM viral transmission and spread has several advantages by 
avoiding many of the obstacles described above for cell-free virus infection.  Virus 
transmission between hosts via infected cell-associated virus could be more efficient 
than cell-free virus because the infected cell could adhere to and cross biophysical 
barriers like the mucous membranes in the new host while cell-free virus could not.  
Once inside the target tissue/organ in the new host, the virus spread by CCCM 
transmission could also be more efficient than spread by cell-free virus infection.  First, 
direct viral transfer from an infected cell to a neighboring cell can avoid the rate-limiting 
random fluid phase diffusion step to search for and bind to viral receptors.  Second, if 
viral receptors are recruited to the site of cell-cell contacts, which is true under most 
circumstances, the virus-receptors binding and viral entry can be even more efficient.  A 
final advantage of CCCM viral transmission is the protection that provides for the 
infection from immunological barriers such as above-mentioned neutralizing antibodies.  
The protection could be either spatial because of limited or abolished accessibilities of 
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immune effectors to the virus, or temporal due to shorter or no exposure time of the virus 
to immune effectors, or both.   
 
Among various types of CCCM transmission observed in different viruses, HIV-1 CCCM 
transmission across virological synapse has been well-characterized and serves as a 
great example for summarizing the common features of CCCM viral transmission.   First, 
HIV-1 transmission across VS between T cells is suggested to occur much more rapidly, 
i.e., within 1 hour, and 18,000 fold more efficiently than cell-free virus infection (93).  In 
addition, both viral envelope proteins and viral entry receptor CD4 are required for HIV-1 
transfer.  Moreover, the formation of VS involves aggregation of talin (actin-binding 
protein mediating interaction of integrin with F-actin) and other cell adhesion molecules 
at the cell-cell contact site and polarization of the microtubule organizing center (MTOC); 
the integrity of actin and microtubule cytoskeleton is absolutely required in HIV-1 VS (90, 
94).  Finally, HIV-1 transmission across VS is demonstrated to be resistant to trypsin 
treatment and patient-derived neutralizing antisera; it is thereby proposed to be the 
predominant route of HIV-1 dissemination in vivo and to contribute to HIV-1 persistence 
(93).  Taken together, HIV-1 transmission across VS is featured by a rapid kinetics, the 
dependence on viral envelope proteins, viral receptors and intact actin and microtubule 
cytoskeletons, and the resistance to neutralizing antibodies.  All these features point to 
the fundamental roles of CCCM HIV-1 transfer in viral dissemination and establishment 
of chronic infection (immune evasion).  It is expected that other types of CCCM viral 
transmission share at least some of these features. 
 
2.3 Evidence for CCCM HCV transmission 
HCV research has been focused on cell-free virus infection for the past two decades, 
whereas there is some indirect evidence for CCCM HCV infection.  Since the infectious 
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HCV cell culture system HCVcc was developed in 2005, HCV researchers have 
observed the formation of infection focus in HCVcc-infected hepatocyte culture (70).  
Infection focus is a focal area of infected cells containing about 20-100 cells.  Its 
formation is strongly suggestive of localized viral spread between adjacent cells.  
Additionally, staining for HCV viral antigen in HCV patient liver biopsy also exhibits the 
pattern of discrete, localized HCV infection focus; another study with HCV RNA in situ 
hybridization even shows a gradient dispersion of viral genome around the center of 
infectious focus in patient liver biopsies (95-97).  Moreover, a recent study demonstrates 
that CCCM HCV infection is relatively less sensitive to nAbs and neutralizing patient 
sera than cell-free HCV infection (98).  In fact, if the extremely high cell density [2-
3.0x105 hepatocytes/cm2 (99)] and presence of nAbs and other immunological 
responses (100) in the liver of chronic hepatitis C patients are considered, it is not 
difficult to conceive the advantages of CCCM HCV spread within the liver over cell-free 
virus spread.   
 
3. EXOSOMES 
 
3.1 Exosomes 
 
3.1.1 Definition, cargo, biogenesis, and uptake 
In both cell culture supernatants and body fluids, there are abundant extracellular 
vesicles (EV) of different sizes, origins, and compositions (101).  Among them, 
exosomes are, by definition, 30 nm – 120 nm small vesicles originated from endosome-
derived MVB with a series of exosome markers (102).  There are generally two types of 
exosome markers, cell-specific exosome markers and universal markers present in 
almost exosomes derived from any cell types.  Cell-specific markers are usually 
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selectively enriched on exosomes derived from particular types of cells only (103, 104); 
exosomes with those markers are proposed to be used as biomarkers for disease 
diagnosis and prognosis.  To the contrary, universal exosome markers are usually 
related to exosome biogenesis pathways and include endosome-associated proteins 
(e.g. Rab GTPase), tetraspanin membrane proteins (CD9, CD63, CD81, CD82), heat 
shock proteins (e.g., Hsp70), and acetylcholinesterase (AchE) (101, 105, 106).  Besides 
exosome protein markers and protein cargos, other components of exosomes include 
lipids and nucleic acids (mRNA, miRNA, mtDNA) (Fig. 4A).  Comparison of RNA profiles 
in exosomes and their originating cells reveals a selective enrichment of mRNAs and 
miRNAs in exosomes; these RNA can be functionally transferred to target cells for 
various effects, e.g. mRNA translation or target gene silencing following uptake of 
mRNA- or miRNA- contained exosomes (101). 
 
Exosome biogenesis pathways are not completely understood.  By definition, exosomes 
are formed by inward budding on the limiting membrane of endosome to form 
intraluminal vesicles (ILV) inside MVB (Fig. 4B).  These MVBs either merge with 
lysosome and become degraded (lysosomal MVBs) or fuse with the plasma membrane 
and release the contained ILVs/exosomes (secretory MVBs) (Fig. 4B); these two distinct 
fates are suggested to result from distinct populations of coexisting MVBs in the same 
cell.  Three pathways have been suggested to be involved in exosome biogenesis.  
RNAi knockdown of endosomal sorting complex responsible for transport (ESCRT) 
components or their accessory proteins leads to decreased ILVs in MVBs and/or 
decreased secretion of exosomes (101, 107), suggesting an ESCRT-dependent 
pathway for exosome biogenesis.  However, ESCRT-independent pathways have also 
been suggested.  Ceramide or tetraspanin are believed to play central roles in these 
alternative exosome biogenesis pathways (108-111). 
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Figure 4.  Exosome cargos and biogenesis.  (A) Exosome cargos.  Schematic 
diagram of exosomes showing lipid bilayer, typical protein markers and contents of 
exosomes.  (B) Biogenesis of exosomes.  The limiting membrane of endosome buds 
inwards to form multivesicular bodies (MVBs) and the contained vesicles are called 
intraluminal vesicles (ILVs).  Distinct MVB populations predispose their distinct fates: 
lysosomal MVBs are targeted to lysosomes for degradation; secretory MVBs traffic to 
and fuse with the plasma membrane.  The ILVs released upon the fusion are now called 
exosomes. 
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Functions of exosomes depend on their ability to interact with the recipient cells to either 
trigger signal transduction upon binding or to deliver their contents of proteins, lipids, and 
RNAs.  However, exosome uptake by or effects on the recipient cells are still not clear, 
although it has been proposed that direct contact with target cell surface receptors and 
ensuing signal transduction, fusion with the cell membrane and release of cargos, and 
endocytosis followed by signal transduction or cargo release may all contribute to 
exosome entry into and effects on recipient cells (112, 113).  The binding specificity of 
exosomes to the target cells has been documented (114, 115).  It is likely mediated by 
cell surface adhesion molecules (116) and tetraspanin complexes (117), probably 
through their associated integrins (118).  After binding to the target cells, stable 
association of exosomes with the plasma membrane is possible, especially on cells that 
display little endocytic activity (114).  Alternatively, after binding to target cells, fusion of 
exosomes with the plasma membrane could take place, as detected by labeling 
exosomes with the lipophilic dye R18 (119); endocytosis of exosomes by the target cells 
could also take place, as demonstrated by accumulation of captured exosomes in 
endocytic or phagocytic compartments in various cells (120-122).   
 
3.1.2 Physiological functions and therapeutic potentials 
As an essential hallmark of multicellular organisms, intercellular communication had 
been believed to be mediated by direct cell–cell contact or transfer of secreted 
molecules.  However, in the last two decades, exosome-mediated intercellular 
communication has emerged as a third mechanism.  Since exosomes have a very broad 
range of producing cells and target cells, the physiological functions of exosomes almost 
extend to every discipline of biomedical science: immunology (123),  cancer biology (124, 
125), neurobiology (126-128) and prion diseases (129, 130).  As mentioned earlier, 
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exosomes selectively incorporate cell-type specific proteins/nucleic acids.  This is also 
true in cancer patients or individuals with Alzheimer’s disease.  Therefore, identification 
of disease-specific exosomal proteins or exosomal RNA/miRNA profiles as biomarkers 
has become a new area of exosome research (131-133).  Lastly, because of the natural 
ability of exosomes to harbor proteins and nucleic acids of therapeutic potential and to 
reduce the susceptibility of those proteins/nucleic acids to degradation, both cell culture-
produced exosomes and artificial exosome-resembling liposomes have been actively 
investigated for their potential as delivery vehicles for therapeutic proteins/nucleic acids 
(134).  
 
3.2 Exosomes and viruses 
Viruses, especially enveloped viruses, share many common characteristics with 
exosomes, including biophysical properties such as the size and density, biogenesis 
pathways, and uptake by cells.  Therefore, exosomes and their biogenesis pathways are 
frequently usurped by viruses to transfer viral proteins (e.g., tegument of herpes simplex 
virus), viral RNA/miRNAs (e.g., Epstein-Barr virus), or even virions themselves (e.g., 
HIV-1) to uninfected cells (135-138), leading to viral spread, pathogenesis and immune 
evasion (139).  Of particular note, “trans-infection” of T cells by HIV-1-loaded dendritic 
cells (DC) or macrophages to T cells has been found to be resistant to nAbs and 
contributing to immune evasion and viral dissemination in lymph nodes during early 
stages of the infection, while the above-mentioned HIV-1 transmission across virological 
synapse massively disseminates the virus within lymph nodes from T cells to T cells at 
later stages of the infection (138, 140-142). 
 
3.3 Exosome interactions with HCV 
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A few studies suggest potential roles of exosomes and their biogenesis pathways in 
HCV infection.  Using recombinant HCV envelope proteins, one study shows that CD81, 
one of the exosome markers and also one of the HCV entry receptors, could direct the 
secretion of HCV envelope proteins in the form of exosomes in CHO cells (143).  
Another study demonstrates the requirement of endosomal sorting complex responsible 
for transport (ESCRT)-0 components for HCV budding (144).  Both studies suggest that 
HCV may usurp ESCRT-dependent exosome biogenesis pathway for its secretion.  In 
addition, HCV RNA has been recently found to be secreted in exosomes and these 
exosomes, when taken up by plasmacytoid dendritic cells, could trigger innate immune 
response (145).  Moreover, a recent study demonstrates by cryo-electron microscopy 
that 5.6% of cell culture-produced HCV particles are surrounded by an additional layer of 
“envelope”; but the biological nature of this extra “envelope” was not investigated (146).  
However, it is not clear whether infectious HCV virions can be secreted and transmitted 
to target cells in the form of exosomes. 
 
3.4 Exosome purification – current protocols 
Exosome research has been hampered by lack of a widely accepted “unifying” 
purification protocol.  There are a few protocols that are currently used in the exosome 
research.  Each has its pros and cons. 
 
3.4.1 Precipitation with polymers 
PEG polymers, e.g. PEG 8000, are widely used in precipitation of viral particles, 
including HCV (71).  Some biotech companies provide “exosome isolation” kits which 
are based on water molecules’ exclusion effect of polymers.  In our own hands, PEG 
8000 successfully precipitates both HCV virions and exosomes from culture supernatant 
(see below).  However, it is not certain whether polymer-based precipitation of 
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exosomes also co-precipitate macromolecules like protein complexes in the 
supernatants. 
3.4.2 Ultracentrifugation 
Ultracentrifugation was the first method used to isolate extracellular vesicles (147), it 
remains the “gold standard” of exosome isolation method and is often used as a 
reference for any newly developed methods.  Following ultracentrifugation, further 
purification of exosomes can be performed by gradient density centrifugation.  Sucrose 
density centrifugation was initially used to purify viruses in 1951 (148).  It is probably the 
oldest and most widely used virus/particles/vesicles purification method.  However, the 
recently developed iodixanol density gradient (the brand name is Opti-prep) has also 
been used in fractionation and purification of exosomes, viral particles and subcellular 
organelles; it could generate more consistent results compared to the conventional 
sucrose density gradient (149), probably due to the intrinsic properties of iodixanol such 
as neutral pH and physiological osmolarity.  
 
3.4.3 Immunocapture 
Immunocapture of exosomes using beads coated with antibodies against exosome 
surface marker is also used in exosome isolation (150).  The advantage of this method 
compared to ultracentrifugation is its purity, as it is based on the specificity of the used 
antibody.  However, the specificity also leads to the lack of diversity in this case.  
Exosomes are heterogeneous in nature.  None of the known exosome markers have 
been confirmed to be expressed on every single exosom.  Thus, immunocapture of 
exosomes with antibodies against any of these “markers” might result in selective 
isolation of only a fraction of the exosome population. 
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4. HCV INTERACTION WITH THE BRAIN 
 
4.1 CNS abnormalities in HCV patients 
HCV infection-related central nervous system (CNS) abnormalities including reduction of 
health-related quality of life (HRQL), chronic fatigue and cognitive impairments have 
been observed in about half of the chronically infected subjects and their daily lives are 
severely affected (151-155).  Even in those who have been cleared of HCV infection in 
periphery spontaneously or after treatment, CNS abnormalities could still exist (156, 
157), raising the possibility of extra-hepatic (CNS) HCV persistence/ latency.  In addition, 
HCV-associated CNS abnormalities are observed less frequently in patients with other 
chronic liver diseases such as chronic hepatitis B and are independent of the severity of 
liver diseases (158-160), suggesting that hepatic encephalopathy commonly seen in 
severe liver diseases such as cirrhosis is not responsible for the HCV-related CNS 
abnormalities.   Moreover, the correlation between HCV infection and CNS dysfunction 
is further confirmed with neuroimaging studies using cerebral proton magnetic 
resonance spectroscopy (160-162), suggesting that a cerebral biological/metabolic 
cause underlies the abnormalities.  Taken together, the above psychometric and 
neuroimaging evidence implies that the HCV per se could cause CNS abnormalities.      
 
4.2 HCV infection of PBMC 
CNS abnormalities are not the only extra-hepatic manifestations of HCV infection.  Since 
HCV’s initial discovery as the etiologic agent responsible for non-A non-B hepatitis in 
1989 (163), there are little doubts that human hepatocytes are the primary target cells for 
HCV infection.  Nevertheless, clinically, HCV infection has been long associated with 
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immune dysfunction and lymphoproliferative disorders (LPD) such as mixed 
cryoglobulinemia (MC) and non-Hodgkin's lymphomas (NHL) (164-168).  The prevalence 
of HCV in patients with NHL is reported to be 15%, much higher than that in healthy 
controls (1.5%) and also in patients with other hematologic malignancies (2.9%) (169).  
All these observations indicate a role of HCV in the etiology of the above-mentioned 
immune diseases.  In addition, there is a growing body of evidence showing the 
detection of both (+)-strand HCV genomic RNA and (-)-strand HCV replication 
intermediate in all subsets of peripheral blood mononuclear cells (PBMC), macrophages, 
and monocyte-derived DCs from chronic HCV patients (156, 157, 165, 170-172), 
suggesting active viral replication in the immune cells of HCV-infected patients.  
Furthermore, several recent studies report successful infection of human primary T cells, 
monocyte-derived macrophages, and a few B-cell and T cell lines with HCV patient 
plasma and production of infectious progeny viruses (173-178); one study even identifies 
human CD5 as the entry receptor of HCV in human T lymphocytes (179).  However, 
attempts to infect human PBMC or lymphoid cell lines with cell-culture produced HCV 
including the HCVpp and JFH1 HCVcc have proven to be difficult (180-182), even 
though efficient HCV IRES-dependent translation and polyprotein processing were 
shown in these cells (182), suggesting the lack or inadequacy of certain essential host 
factor(s) for HCV JFH-1 infection and replication in these cells. 
 
4.3 HCV infection of the brain and pathological evidence  
Pathological evidence for HCV infection of the brain has also been found.  Positive 
strand HCV RNA in cerebrospinal fluid (CSF) and both (+)-strand and (-) -strand HCV 
RNA in various regions of brain have been found in post-mortem brain samples of HCV 
patients, suggesting HCV CNS invasion and active HCV replication in the brain (183-
185).  In addition, using the laser capture microscopy (LCM), a recent study successfully 
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identifies the HCV target cells in the brain to be astrocytes and microglia cells as both 
HCV RNA and viral proteins are detected in these cells but not in neurons or 
oligodendrocyte (186, 187).  In the same study, HCV proteins-positive astrocytes are 
found to be only positive for the (+)-strand HCV RNA, while HCV proteins-positive 
microglia cells are found to be positive for both (+) and (-)-strand HCV RNA, indicating 
that active HCV replication is only occurring in microglia but not astrocytes.   Moreover, 
microglia in HCV-infected subjects are shown to be highly activated and produce pro-
inflammatory cytokines such as TNF-α, IL-1β and IL-8 (188); in vitro infection of primary 
macrophages with HCV patient plasma also induces TNF-α and IL-8 production (178), 
suggesting the potential role of microglia in causing neuronal dysfunction in chronic HCV 
infection, likely via secretion of neuron-toxic cytokines.  However, how astrocytes are 
infected and what roles do astrocytes play in HCV-induced CNS abnormalities remain to 
be addressed.  Of particular note is that almost all studies on HCV infection of the CNS 
are based on examination of post-mortem brain samples.  There are currently no studies 
on molecular mechanisms of HCV infection of the CNS and its role in HCV 
neuropathogenesis. 
 
4.4 HCV entry into the CNS – the “trojan PBMC hypothesis” 
Under normal physiological conditions, the human brain is believed to be protected by 
the blood-brain barrier (BBB) from bacterial or viral pathogen invasion.  So a natural 
question arises about HCV CNS invasion: how does the virus enter the brain?  To 
approach this question, sequence analysis of RNAs derived from serum, PBMC and 
CNS of HCV patients is performed.  The results show that RNA sequences from CNS 
are closer to those from PBMC, rather than RNA sequences from serum (183, 185).  A 
“trojan PBMC hypothesis” was then proposed (152) and could be summarized as follows.  
HCV can infect PBMC in the periphery, especially T cells or monocytes/ macrophages.  
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The infected immune cells can cross the BBB and bring the virus into the CNS.  
Thereafter, active replication of HCV in these cells could release more viruses and 
cause a secondary spread of HCV to target cells in the brain.  Those target cells could 
be brain microglia cells, the resident macrophages of blood monocytic origin in the brain, 
or astrocytes, the cell type most abundant in the brain and most intimately linked to 
neuronal function.  The infected microglia can also support active HCV replication and 
become another source of virus production in the CNS.  HCV infection then starts to 
spread in the brain and the subsequent production of cytokines, viral proteins and other 
toxic factors from infected cells and bystander uninfected cells could lead to impairment 
of neuronal functions by direct impact on neurons or indirect impact on the neuron-
supporting astrocytes.  However, until today, the above hypothesis remains to be 
experimentally tested and substantiated.  It also remains unclear at the molecular level 
whether and how HCV gains entry into these brain cells and whether the infection of 
these brain cells results in any demise in neurons. 
 
4.5 HCV infection of the CNS in HIV-1/HCV co-infected individuals  
HCV infection of the CNS is further complicated by the frequent occurrence of HIV-1/ 
HCV co-infection.  The prevalence of HCV in HIV-1-positive individuals is about 30% in 
the U.S. and Europe, likely due to shared transmission routes, both through blood 
product and injection drug use (189).  In HIV-1/HCV co-infected patients, progression of 
the diseases caused by one virus is potentiated by the other.  In HIV-1-infected patients, 
liver diseases are now the No.1 cause of death; in HIV-1/HCV co-infected patients, 
chronic HCV progresses into liver fibrosis or even HCC in a much faster pace (189, 190).  
Even if HCV infection alone does not cause severe dementia as seen in untreated HIV-1 
patients, several studies have demonstrated that HIV-1/HCV co-infection causes further 
neurocognitive impairments compared to those with HIV-1/HCV mono-infection (191, 
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192).  In addition, a recent study demonstrates that detection of HCV in the brain is 
unrelated to HCV viremia, but active HIV-1 disease and detectable CSF HIV-1 in HIV-
1/HCV co-infected patients (193). 
 
4.6 Astrocytes in CNS function 
As the most abundant CNS cells, astrocytes play an essential role in maintaining 
homeostasis and normal function of the CNS (194).  Among the well-recognized 
astrocytes functions are uptake and recycling of neurotransmitters, secretion of 
neurotrophic factors, antioxidant defense and being an integral part of the blood brain 
barrier (195).  More importantly, astrocytes are also one of the major participants in CNS 
immune responses under various disease conditions including neurodegenerative 
diseases and pathogen invasions, when they produce key immune mediators such as 
cytokines, proteases, protease inhibitors, adhesion molecules, and extracellular matrix 
components (195, 196).  Human astrocytes express toll-like receptors (TLR) 1-5, TLR9 
and many other intracellular receptors for the recognition of viral antigens (197-199).  
During viral invasion of CNS, susceptible to the infection or not, astrocytes can usually 
recognize one or more viral antigens via TLRs and other receptors and mount an innate 
immune response, e.g. secretion of proinflammatory cytokines and other immune 
mediators (200).  However, although the attempt of the response is to clear the infection, 
it can be a double-edged sword on neuron survival and functions, as many of the 
effectors in the response are also neurotoxic (200, 201).  Nevertheless, it is not known 
yet whether HCV infection of the CNS changes cytokine expression profiles in astrocytes 
and if changes, how neurons are affected.   
   
5. SUMMARY OF THE BACKGROUND AND HYPOTHESES 
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HCV is highly capable of evading the immune system, which leads to establishment of 
chronic infection in about 80% of infected people (202).  Neutralizing antibodies are the 
main effectors of the humoral response against viral infections and one of the most 
important defense mechanisms in controlling viral spread within a host.  However, 
although nAbs are generated in chronic HCV patients, they often fail to control the 
infection (203).  Frequent alterations of HCV epitopes have been proposed to contribute 
to viral escape from recognition and elimination by the immune system (204, 205), yet it 
is highly conceivable that other immune evading mechanisms are involved.  Since the 
isolation and identification of HCV in 1989 (163), a great deal of progresses have been 
made in our understanding of HCV virology and pathogenesis; examples include the 
discoveries of several HCV entry receptors/co-receptors: CD81, SR-BI, CLDN1, and 
OCLN (25, 27-29).  However, HCV research has been mainly focused on cell-free virus 
infection.  In contrast, CCCM viral transmission has been discovered and characterized 
in many other viruses and proposed to contribute to the immune evasion and 
establishment of chronic infection in many of those viruses (74).  In addition, exosome-
mediated viral protein/RNA/virion transfer has been observed in many other viruses and 
demonstrated to contribute to immune evasion and disease progression in virus-infected 
patients (139).  Although HCV RNA was recently demonstrated to transfer intercellularly 
in the form of exosomes (145), interaction and relationship between infectious HCV 
virions and exosomes are not clear.  Thus, our first two hypotheses are that CCCM viral 
transmission constitutes an important route for HCV dissemination among hepatocytes 
(Fig. 5 and the Results section, CHAPTER 1), and that HCV can be secreted in the form 
of exsomes and that exosome-mediated HCV transmission constitutes an alternative 
route for the spread of HCV in hepatocytes (Fig. 5 and the Results section, CHAPTER 
2).  
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CNS abnormalities are observed in more than half of HCV-infected individuals 
regardless of the stage of liver diseases (152).  Both HCV (+)-strand and (-)-strand RNA 
are found in the brain of HCV patients.  The target cells of HCV in the CNS are 
suggested to be astrocytes and microglia cells because both of them are HCV RNA- and 
protein-positive (186, 187).  Nevertheless, it is not known how HCV gains entry into 
these nonhepatic cells, whether HCV can productively infect these cells, whether HCV 
infection changes cytokine expression profiles in these cells and if changes, how 
neurons are affected.  Considering the essential role of astrocytes, the most abundant 
cell type in the brain, in CNS function, our third hypothesis is that HCV infects astrocytes, 
leading to neuronal dysfunction (Fig. 5 and the Results section, CHAPTER 3). 
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Figure 5.  HCV infection of target cells and transmission routes: summary of 
hypotheses.  HCV enters a host and infects hepatocytes and/or monocytes/PBMCs.  
HCV spreads in liver through cell-free virus infection, CCCM transmission (Results 
section CHAPTER 1) and exosome-mediated infection (Results section CHAPTER 2).  
On the other hand, the monocytes carrying HCV enter the CNS and differentiate into 
microglia.  HCV virions produced by these actively replicating cells then infect astrocytes 
and resulting changes in cytokine production from astrocytes affect neuron survival 
(Results section CHAPTER 3).  Crosstalks between hepatic and extra-hepatic HCV-
targeted cells are possible but currently unknown. 
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MATERIALS AND METHODS 
 
MATERIALS 
Media and supplements 
Dulbecco Modified Eagle Medium (DMEM), Roswell Park Memorial Institute 1640 
(RPMI-1640) medium, Hank’s balanced solution (HBSS), and hepatocyte culture media 
(PHH) were purchased from Lonza (Walkersville, MD).  Neurobasal TM Medium, B27 
Supplement, Ham’s F-12 Nutrients Mixture (Ham’s F-12), streptomycin-penicillin-
glutamine (S. P. G., 100X), and 0.25% trypsin-EDTA (1X) were from GIBCO (Grand 
Island, NY).  Fetal bovine serum (FBS) was from Hyclone (Logan, UT).  F-12K Nutrient 
Mixture Kaighn's Mod. (F-12K) and 0.25% Trypsin were from Cellgro.  Opti-MEM 
reduced serum media was from Invitrogen (Carlsbad, CA).  Ampicillin sodium salt and 
kanamycin sulfate were from United States Biological (USB, Swampscott, MA).  All the 
culture media described below were prepared in house.  Luria Broth (LB) liquid medium 
contained 0.01 g/ml Bacto Tryptone, 0.005 g/ml Bacto yeast extract, 0.01 g/ml NaCl.  LB 
agar plate was prepared with 7.5 g agar per liter of the liquid LB.  Working 
concentrations of antibiotics for liquid and solid LB were 100 µg/ml for ampicillin and 50 
µg/ml for kanamycin.    
 
Plasmids and siRNAs 
HCV receptors: pCMV-SPORT-Claudin1 and pCMV-SPORT-occludin expression 
plasmids were purchased from Open Biosystems (Lafayette, CO).  pcDNA3-CD81 and 
pcDNA3-SR-B1 were constructed previously in our lab (206).  Briefly, the coding DNA 
sequences (CDS) of CD81 and SR-B1 were amplified from pOTB7-CD81 and pOTB7-
SR-B1 (Open Biosystems) by PCR and cloned into pcDNA3 with EcoR I and Xho I, Kpn 
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I  and EcoR V, respectively.  The sequences of the primers used are: 5’-CCC GAATTC 
ATG GAG CGA GCG CGC AAC GGC-3’ and 5’-CCC CTCGAG CTA CTG AGG GAC 
TGC ACA GGC-3’ for CD81; 5’-CCC GGTACC GAC ATG GGC TGC TCC GCC-3’ and 
5’-CCC GATATC CTA CAG TTT TGC TTC CTG-3’ for SR-B1.              
 
JFH1-core177-GFP and related plasmids: The full-length core and GFP fusion protein 
plasmid pJcore-GFP was previously constructed in our lab (unpublished data).  Briefly, 
the full HCV core-encoding sequence was PCR amplified from pJFH1 (kindly provided 
by Dr. Takaji Wakita, Japan) with the primers 5’-CGC GG GAATTC ACC ATG AGC ACA 
AAT CCT AAA CC-3’ and 5’-CGC GG GGATCC AGA GAC CGG AAC GGT GAT G-3’, 
and then inserted into pEGFP-N3 plasmid at the N-terminus of GFP by EcoR I and 
BamH I.  The other core-GFP fusion protein plasmid containing only the N-terminus 177 
amino acids of core, the pCore177-GFP, was constructed in a similar fashion.  Amino 
acids 1 to 177 of HCV core was PCR amplified using JFH1 as template, and with the 
forward primer 5’-CGCGG GAATTCA CCA TGA GCA CAA ATC CTA AAC C-3’ and the 
reverse primer 5’-CGC GG GGATCC G AAG ATA GAA AAG GGG AAA CCG-3’.  The 
PCR products and the pEGFP-N3 plasmid were digested with EcoR I and BamH I and 
ligated to obtain the pCore177-GFP plasmid.  To insert GFP into JFH1 genome right 
after the 177 amino acid of core and obtain pJFH1-c177-GFP plasmid, a four-step 
strategy was adopted.  First, the 3 kb sequence from the 5’ untranslated region (5’UTR) 
to the nonstructural protein 2 (NS2) on pJFH1 was cloned into pBlueScript KSII 
(Stratagene, California) using EcoR I and Not I to obtain the much shorter intermediate 
cloning vector pBS-core-NS2 (6 kb).  Secondly, Bgl II and Mlu I sites were introduced 
into both the two sides of GFP (based on pEGFP-N3) and the 177 position of core in 
pBS-core-NS2 vector by PCR with primers 5’-GA AGATCT G TGA GCA AGG GCG 
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AGG AGC-3’ and 5’-ACC G ACGCGT CT TGT ACA GCT CGT CCA TGC-3’ for GFP, 
and 5’-ACC G ACGCGT TT GCT GGC CCT GTT GTC CTG-3’ and 5’-GA AGATCT G 
AAG ATA GAA AAG GGG AAA CCG-3’ for pBS-core-NS2.  Both PCR products were 
cloned directly to the pSC-A-Amp/Kan vector by TA cloning with the TOPO TA cloning 
kit.  Thirdly, the pSC-A-MluI-GFP-Bgl II and pSC-A-Bgl II-pBS-core-NS2-Mlu I plasmids 
were digested with Bgl II and Mlu I and the two inserts GFP and pBS-core-NS2 were 
ligated to obtain pBS-core177-GFP-NS2.  Lastly, the HCV sequence from 5’UTR to NS2 
containing GFP at core 177 position was cut out from the pBS-core177-GFP-NS2 
plasmid by EcoR I and Not I and inserted back into pJFH1 to obtain the pJFH1-c177-
GFP. 
 
JFH1-TCcore and intermediate plasmids: The JFH1-TCcore plasmid was constructed by 
mutagenesis using JFH1 as the template.  A full-length (FLNCCPGCCMEP) 
tetracysteine (TC) tag (207) was inserted into the pBS-core-NS2 intermediate plasmid 
described above right after the third amino acid of the core (208) using the QuickChange 
mutagenesis kit XL II (Stratagene).  The primers containing the inserted sequences are: 
forward primer 5’-GAC CGT GCA CCA TGA GCA CAT TTC TCA ATT GTT GTC CTG 
GCT GTT GTA TGG AAC CTA ATC CTA AAC CTC AAA GAA AAA CC-3’ and reverse 
primer 5’- GGT TTT TCT TTG AGG TTT AGG ATT AGG TTC CAT ACA ACA GCC 
AGG ACA ACA ATT GAG AAA TGT GCT CAT GGT GCA CGG TC-3’ (TC tag shown 
in bold).  Afterwards, the region from the 5’UTR to NS2 containing the TCcore was 
cloned back into the pJFH1 plasmid using EcoR I and Not I to obtain pJFH1-TCcore. 
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pcDNA3-GFP-miR122 and intermediate plasmids: pcDNA3-GFP was constructed as 
follows.  Briefly, GFP was digested from pEGFP-N1 (Clontech) by EcoR I and Xba I and 
inserted into pcDNA3.  To obtain a miR122 expression plasmid, the coding sequence of 
human pri-miR122 was PCR amplified using pCSII-EF-RfA-pri-miR122 (a kind gift from 
Dr. Yoshiharu Matsuura, Osaka University, Japan) as the template with the forward 
primer 5’-AAG GAA AAA A GCGGCCGC CCT TAG CAG AGC TGT GGA-3’ and reverse 
primer 5’-AAG GAA AAA A GCGGCCGC GCC TAG CAG TAG CTA TTT AG-3’.  The 
amplified pri-miR122 PCR product was cloned into the pcDNA3-GFP plasmid at the Not 
I site right after the stop codon of GFP, which was named as pcDNA3-GFP-miR122.   
 
Other plasmids: pcDNA3.1 was purchased from Invitrogen.  pEGFP-N3 was purchased 
from Clontech (Mountain View, CA).  HIV-Luc and HIV-GFP were previously constructed 
(209); both are pNL4-3-based HIV-1 reporter virus with a frameshift in the envelope 
gene and Luc/GFP expressed in place of nef.  pCon1-E1E2 was generously offered by 
Dr. Charley Rice from Rockefeller University and encodes HCV envelope proteins E1 
and E2 from the Con1 (HCV subtype 1b) strain.  pHCMV-G was a kind gift from Dr. 
Joseph Sodroski of Harvard School of Medicine and encodes the glycoprotein from 
Vesicular Stomatitis Virus (VSV-G) downstream of the CMV promoter.  HCV-Rluc 
subgenomic replicon (HCV 1b) was a generous gift from Dr. Seng-Lai Tan from EMD 
Serono Research & Development Institute (163).  pEgr1-Fluc was constructed 
previously in our lab (210); it contains the firefly luciferase reporter gene downstream of 
Egr-1 promoter.  All recombinant plasmids were verified by sequencing. 
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siRNAs: SiGENOME SMARTPool siRNAs against human CD81 (siCD81), SR-B1 (siSR-
B1), CLDN1 (siCLDN1) and OCLN (siOCLN), and scrambled control siRNA (siCtrl) were 
purchased from Dharmacon (Lafayette, CO). 
 
Antibodies 
Mouse anti-HCV core (MA1-080, Affinity Bioreagents, Golden, CO), mouse anti-CD81 
1.3.3.22 (sc-7637, Santa Cruz), mouse anti-CD81 (JS81, BD Bioscience), mouse anti-
SR-B1 (610882, BD Bioscience), rabbit anti-CLDN1 (51-9000, Zymed/Invitrogen), 
mouse anti-OCLN (33-1500, Invitrogen, Carlsbad, CA), rabbit anti-OCLN (#42-2400, 
Invitrogen), mouse anti-MAP-2 (AP20, Santa Cruz), mouse anti-GFAP (Sigma), rabbit 
anti-GFAP (DAKO), goat anti-E2 (Meridian Life Science Inc, Memphis, TN), rabbit anti-
CD63 (Systems Biosciences, Mountain View, CA), mouse anti-β actin (A1978, Sigma, St. 
Louis, MO), mouse anti-tubulin (Sigma), mouse anti-Hsp 70 (Santa Cruz), mouse normal 
IgG, rabbit normal IgG (Santa Cruz), monoclonal human anti-E2 clone CBH-5 and 
isotype-matched control human anti-cytomegalovirus monoclonal antibody R04 (both 
kindly provided by Dr. Steve Foung of Stanford University, California), goat anti-human 
IgG-phycoerythrin (PE) (Santa Cruz), goat anti-mouse IgG-Alexa488/Alexa555/ 
Alexa647 (Invitrogen), goat anti-rabbit IgG-Alexa555 (Invitrogen), sheep anti-mouse IgG-
HRP (Sigma), goat anti-rabbit IgG-HRP (Systems Biosciences), donkey anti-goat/rabbit 
IgG-HRP (Sigma), and mouse anti-CD81 (JS81) FITC conjugated (BD Bioscience).  
 
Reagents 
RNase A, phenylmethanesulphonylfluoride (PMSF), 4',6-diamidino-2-phenylindole 
(DAPI), acetylthiocholine (ATC), 5,5-dithio-bis(2-nitrobenzoic acid) (DTBNBA), Opti-prep 
density gradient medium, cytochalasin D (dissolved in DMSO), nocodazole, phalloidin-
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TRITC, polyethylene glycol 8000 (PEG8000), poly-L-Lysine hydrobromide, polybrene, 
and the PKH26 cell labeling kit were purchased from Sigma.  [Methyl-3H]-thymidine 
5’triphosphate (3H dTTP) was from PerkinElmer (Boston, MA).  Ficoll-PaqueTM was from 
Amersham Biosciences (Piscataway, NJ).  Restriction endonucleases, heparinase I and 
exonuclease I were from New England Biolabs (Beverly, MA).  Rat-tail type I collagen 
was from BD Bioscience (Bedford, MA).  T4 DNA ligase was from USB (Cleveland, OH).  
The 5-chloromethylfluorescein diacetate (CMFDA) cell labeling dye, ReAsH TC tag 
labeling kit, TRIZOL, TRIZOL LS, and lipofectamine 2000 were from Invitrogen.  
Mounting solution fluoromount-G was from SouthernBiotech (Birmingham, AL).  
Bactotryptone, Bacto Yeast Extract, Bacto agar for LB bacteria culture were from Becton 
Dickinson (Sparks, MD).  RNase inhibitor and deoxynucleotide triphosphates (dNTPs –
dATP, dCTP, dTTP, and dGTP-) were from Promega Corporation (Madison, WI).  
Protease inhibitor cocktail set V was from Calbiochem (LaJolla, CA).  Protein G agarose 
beads was from EMD Millipore (Billerica, MA).  Recombinant human cytokines 
interleukin 1β (IL-1β), IL-4, IL-6, IL-10, tumor necrosis factor α (TNF-α), interferon γ (INF-
γ), and the chemokine monocyte chemotactic protein 1 (MCP-1) were purchased from 
R&D Systems (Minneapolis, MN).  G418 sulfate was from Santa Cruz Biotechnologies 
(Santa Cruz, CA).  All other chemicals were from Fisher (LaGrange, KY). 
 
Kits 
The QIAamp Viral RNA Kit was from QIAGEN.  The Annexin V Apoptosis Detection Kit 
APC was from eBioscience (San Diego, CA).  The TaqMan One-Step RT-PCR Master 
Mix Reagents Kit, TaqMan MicroRNA Assays, TaqMan MicroRNA Reverse Transcription 
Kit, and the AmpliTaq Gold PCR system were from Applied Biosystems (Branchburg, 
NJ).  The Quickchange II XL Site directed mutagenesis kit and Strataclone PCR cloning 
kit were from Stratagene (Cedar Creek, TX).  The TOPO TA cloning kit and MEGAscript 
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T7 Kit were from Invitrogen.  The plasmid DNA purification kits, the firefly and renilla 
luciferase assay systems, the Wizard SV Gel and PCR clean-up system for purification 
of DNA fragments from agarose gels, the GoTaq Flexi DNA Polymerase, and the 
ImProm II reverse transcriptase were from Promega Corporation.  Bio-Rad DC Protein 
Assay and iQ SYBR Green Supermix was from Bio-Rad Laboratories.   
 
METHODS 
Cells and cell cultures 
Cell lines 
Huh7.5.1 hepatoma cell was obtained from Dr. Charles Rice’s laboratory of Rockefeller 
University, New York; human embryonic kidney 293T cell, human hepatoma HepG2 cell, 
human neuroblastoma SH-SY5Y cell and human astrocytoma U373 cell were from 
American Type Culture Collection (ATCC, Manassas, VA); NKNT3 and CYNK10 human 
hepatoma cells were kindly provided by Dr. Ira Fox of the University of Pittsburgh School 
of Medicine, Pittsburgh, Pennsylvania.  Huh7.5.1, 293T, HepG2, NKNT3, CYNK10 and 
U373 were maintained in DMEM supplemented with 10% heat-inactivated FBS and 1% 
S.P.G at 37°C with 10% CO2.  SH-SY5Y cell was maintained similarly in half Ham’s F-12 
and half DMEM. 
 
Establishment of stable cell lines 
A killing curve for Huh7.5.1 and U373 was performed to determine the G418 
concentration to be used in the later selection process.  Briefly, 1 x 104 Huh7.5.1/ U373 
cells were plated in triplicate in a 96-well plate.  After 24 hr incubation, the medium was 
replaced with fresh DMEM medium containing increasing concentrations of G418 (0 
μg/ml, 100 μg/ml, 200 μg/ml, 300 μg/ml, 400 μg/ml, 500 μg/ml, 600 μg/ml, 700 μg/ml, 
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800 μg/ml, 900 μg/ml, 1000 μg/ml, 1200 μg/ml), and cell survival was determined during 
a period of 6 days.  The medium was replaced every 72 hr.  The appropriate 
concentration of G418 for selection of stable expressing cells was determined to be 400 
μg/ml for Huh7.5.1 and 800 μg/ml for U373.  
  
Huh7.5.1 cells (1 x 105/ well) were plated in a 12-well plate and transfected with 2 μg of 
pEGFP-N3 plasmid using Lipofectamine 2000 according to the manufacturer’s 
instructions.  The medium was replaced with fresh DMEM containing 400 μg/ml G418 at 
24 hr post-transfection, and the cells were selected for two weeks with medium changed 
every 72 hr.  At the end of the selection process, a single clone of GFP-positive cells 
were chosen and expanded.  This clone was named Huh7.5.1-GFP and maintained in 
DMEM containing 200 μg/ml G418.   
 
U373 cells stably expressing GFP or GFP-miR122 were established in a similar fashion.  
Briefly, U373 cells were transfected with pcDNA3-GFP or pcDNA3-GFP-miR122 and 
selected with 800 μg/ml G418 for two weeks.  Two single clones of GFP-expressing 
U373 (named as U373-cDNA3-SC2/ SC4) and three single clones of GFP- and miR122-
expressing U373 (named as U373-miR122-SC1/ SC2/ SC3) were selected and 
maintained in DMEM containing 200 μg/ml G418; the pooled clones of cells survived 
from the two week selection were also maintained similarly and named as U373-cDNA3-
PC and U373-miR122-PC.  The percentage of GFP-positive cells are >99% for all the 
single clones, 48% for U373-cDNA3-PC and 22% for U373-miR122-PC by flow 
cytometry.   
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Competent cells for cloning 
GC5TM chemically competent E. coli for cloning was purchased from GeneChoice 
(Frederick, MD). 
 
Primary human hepatocyte cultures 
Cryopreserved human primary hepatocytes (Lonza) were plated on rat-tail type I 
collagen-coated plates and maintained in hepatocyte culture media (Lonza) as instructed 
by the supplier. 
 
Primary human brain cell cultures 
Human fetus cortex tissue (12-20 weeks) was obtained from Advanced Bioscience 
Resources (ABR, Alamada, CA).  The tissue was first washed in ice-cold HBSS and 
removed of blood vessels and mininges with forceps, then dissociated by scissor 
dissection followed by repeated pipetting to obtain small pieces of tissue about 5 
millimeters in size.  The dissociated tissue pieces were digested with two volumes of 
0.25% trypsin at 37°C for about 30 minutes.  The digestion was stopped by adding 
DMEM medium containing 10% FBS and the tissue was washed for two more times with 
the medium.  The digested tissue pieces were further dissociated into homogenous cell 
suspension by repeated pipetting with 25 ml, 10 ml, and then 5 ml pipettes.  Lastly, the 
homogenous cell suspension was passed through 230 µm (60 mesh) and 94 µm (150 
mesh) tissue sieves (Bellco Glass, Vineland, NJ) sequentially, to obtain single cell 
suspension.  These cells were then extensively washed and seeded as below.  To 
obtain pure astrocyte culture, cells were seeded at 1-1.5 million/ cm2 in F-12K medium 
containing 10% FBS and 1% S.P.G. and replated with fresh medium for twice.  To obtain 
pure primary neuron culture, cells were seeded into a 24-well plate at 1 x 105 cells/ well 
in neurobasal medium supplemented with B27 and 1% S.P.G.; cells were never replated 
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and medium was change every three days.  To obtain primary mixed brain cell culture, 
DMEM media containing 10%FBS and 1% S.P.G. was used.   
 
HCV patient plasma samples   
Plasma from chronic hepatitis C patients were kindly provided by Dr. Andy (Qigui) Yu 
from Indiana University School of Medicine, IN.  They were collected in heparinized vials 
(15U heparin/ml) and frozen immediately in -70°C.  HCV RNA titers in plasma 1, 3 and 5 
were determined by quantitative RT-PCR (qRT-PCR) as described later and they were 
6.8 x 105, 2.1 x 107, and 2.1 x 105 vge/ml (viral genome equivalent per ml), respectively.  
All plasma samples were treated with Heparinase I (6 U/ 140 μl plasma) with the 
presence of RNase inhibitor (20 U/ 140 μl plasma) at 30°C for 2-3 hr before any further 
processing or assays. 
 
Bacterial transformation 
Twenty-five microliters of GC5TM competent cells were mixed with 2 µl DNA ligation 
product or 10 ng plasmid DNA, and incubated in ice for 30 min.  The mixture was heat-
shocked in a 42°C water bath for 45 sec and incubated on ice for 2 min.  Five hundred 
microliters of 37°C pre-warmed LB medium was added to the mixture and they were 
incubated at 37°C for 1 hr with shaking at 150 rpm.  Fifty to five hundred microliters of 
the culture were spread out evenly on an agar plate containing the appropriate selection 
antibiotic.  The plate was incubated in a 37°C incubator upside down for 12-20 hr.  
 
HCV RNA synthesis by in vitro transcription 
pJFH1 and pJFH1-TCcore were linearized by Xba I; HCV-Rluc plasmid was linearized 
by ScaI.  These linearized DNA were purified by phenol/ chloroform extraction followed 
by ethanol precipitation and used as templates to transcribe viral RNAs in vitro using the 
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MEGAscript T7 Kit according to manufacturer’s instructions.  The synthesized viral RNA 
was purified by acidic phenol/chloroform extraction followed by isopropanol precipitation 
and frozen in ready-to-use aliquot in -70°C. 
 
Cell transfections 
Calcium phosphate precipitation 
Plamid DNA transfection into 293T cells and primary astrocytes were performed with the 
standard calcium phosphate precipitation method.  For one 6 cm dish, 5 x 105 of 293T or 
primary astrocytes were seeded and cultured for 24 hr to achieve 40-50% confluency at 
the time of transfection.  At this point, a 180 µl mixture of 8 µg total plasmid DNA and 
0.22 M CaCl2 was added dropwise to 180 µl of a 2XHBS (50 mM HEPES, 280 mM NaCl, 
10 mM KCl, 1.5 mM Na2HPO4, 12 mM Glucose, pH 7.1).  The transfection mixture was 
incubated on ice for 20 min and then added dropwise into the cells.  The culture medium 
was replaced after overnight (16 hr) incubation.  Unless otherwise specified, the cells 
were cultured for another 48 hr before gene expression was examined. Transfection 
efficiencies were routinely monitored by adding a small amount of pEGFP-N3 (1/10 of 
the total plasmid DNA) into the transfection mixture and were usually 80-90% for 293T 
and 40-50% for primary astrocytes.  When a different tissue culture plate was used, the 
number of cells and the amount of all solutions were scaled up or down based on the 
cultural surface area. 
 
Lipofectamine transfection 
Plasmid DNA transfections into cells other than 293T or primary astrocytes and RNA 
transfections (viral RNA, siRNA, or viral RNA and plasmid DNA) into all cells were 
performed with Lipofectamine 2000 according to the manufacturer’s instructions.  Briefly, 
in one 6 cm dish, 0.5-2 x 106 cells were plated and incubated for 24 hr to reach 80-90% 
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confluency at the time of transfection.  Culture medium was replaced with the cell’s 
culture medium without antibiotics right before transfection.  Meanwhile, 8-20 µl 
lipofectamine was added into 500 µl Opti-MEM and the mixture was incubated at RT for 
5 min.  During this time, 8 µg viral RNA, or 3.2 µg plasmid DNA and 6 µg viral RNA, or 8 
µg plasmid DNA were diluted in 500 µl Opti-MEM.  The diluted nucleic acids and 
lipofectamine mixtures were combined and further incubated at RT for 20 min.  
Thereafter, the transfection mixture was added to the cells and medium was replaced 
after 6 hr of incubation.  For RNA and RNA/DNA co-transfection, gene expression was 
examined starting from 6 hr post-transfection, while for DNA transfection, gene 
expression was not examined until 48 hr post-transfection.  Transfection efficiencies 
were routinely monitored by adding a small amount of pEGFP-N3 (1/10 of the total 
plasmid DNA) into the transfection mixture or by simply utilizing the GFP-expressing 
plasmid already included in the transfection mixture.  Transfection efficiencies vary with 
the cell type being transfected and the nature of the transfection (RNA, DNA, or co-
transfection) and usually fall within a range of 40-80%.  When a different tissue culture 
plate was used, the number of cells and the amount of all solutions were scaled up or 
down based on the cultural surface area. 
 
Reverse transcriptase activity assay 
Viruses in 1 ml cell culture supernatant was pelleted by spinning at 14,000  x g  and 4°C 
for 90 min.  The pellet was suspended in 10 µl dissociation buffer (0.25% Triton X-100, 1 
mM DTT, 0.25 M KCl, 20% glycerol, and 50 mM Tris-HCl pH 7.5) followed by three times 
of freezing and thawing.  A 40 µl mixture containing 34 µl RT assay buffer (0.083% 
Triton X-100, 8 mM DTT, 12.5 mM MgCl2 and 0.083 M Tris-HCl pH 7.5), 1 µl 3H dTTP, 
and 5 µl 5 units/ml of Poly (A)x(dT) was added to the 10 µl virus suspension mentioned 
above.  The total 50 µl mixture was incubated at 37°C for 1 hr and then spotted onto 
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DE81 filter paper (Whatman, England).  After three washes with 2XSSC (0.3 M NaCl, 
0.03 M Sodium citrate, pH 7.0) and two washes with 95% ethanol, the filter paper was 
air-dried and determined of radioactivity in a Beckman LS6000IS scintillation counter.  
The virus titer was expressed as cpm/ml. 
 
Preparation of pseudotyped viral particles and infection 
All the pseudotyped viral particles were prepared in 293T cells as described below.  Two 
million 293T cells were seed into a 10 cm dish and transfected with 21 µg HIV-Luc and 3 
µg pcDNA3 (Env-pp), or 3 µg pCon1-E1E2 (HCVpp) or 3 µg pHCMV-G(VSVpp) by 
standard calcium phosphate transfection.  At 72 hr post-transfection, culture 
supernatants were harvested, removed of cell debri by centrifugation at 1000 x g for 5 
min, aliquoted and stored at -70°C.  The viral titer was determined by reverse 
transcriptase assay as described in the previous section. For infection with these 
pseudotyped viruses, 5 x 104 Huh7.5.1, SH-SY5Y, U373, or 1 x 105 mixed primary brain 
cells were plated in a 24-well plate, or 2.5 x 105 primary astrocytes were plated in a 6-
well plate.  After 24 hr incubation, 200,000 cpm Env-pp or HCVpp, or 2, 000 cpm VSVpp 
were added to the cells for infection at 37°C for 2 hr or spinoculation at RT and 1000 x g 
for 2 hr.  The cells were removed of viruses, extensively washed with PBS, and cultured 
for 72 hr before harvest for the luciferase activity assay. 
 
Luciferase assay 
Firefly or renilla luciferase activities were measured with the luciferase assay systems 
from Promega according to the manufacturer’s instructions.  Briefly, cells were harvested 
by trypsinization, washed once with ice-cold PBS, frozen and thawed once (only 
required for renilla luciferase, not firefly luciferase), lysed with 25 µl 1X firefly or renilla 
luciferase lysis buffer at RT for 5 min, centrifuged at 12, 000 x g for 30 sec to remove cell 
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debri, and the supernatants were used as cell lysates.  5 µl cell lysates were mixed with 
20 µl firefly or the renilla luciferase substrate and the luciferase activity was immediately 
measured using an Opticomp Luminometer (MGM Instruments, Hamden, CT).  For 
pseudotyped virus infection or spinoculation, firefly luciferase activity was measured at 
72 hr post-infection.  For HCV-Rluc RNA co-transfection with pEgr1-Fluc plasmid in 
U373-cDNA3 or U373-miR122 stable cells, both renilla and firefly luciferase activities 
were measured at 72 hr post-transfection and Rluc reading was normalized to Fluc 
reading (transfection efficiency).  For HCV-Rluc RNA co-transfection with pcDNA3-GFP 
or pcDNA3-GFP-miR122 in all other cells, renilla luciferase activity was measured at 6, 
24, 48, 72, or 120 hr post-transfection and Rluc reading was normalized to % of GFP-
positive cells (transfection efficiency) from flow cytometry analysis at 48 or 72 hr post-
transfection. 
 
HCVcc production, titration and infection 
Huh7.5.1 cells were either transfected with viral RNAs (JFH1 or JFH1-TCcore) as 
described above, or inoculated with JFH1 viral stock (a generous gift from Dr. Wenzhe 
Ho of Temple University, Philadelphia, PA) at a multiplicity of infection (MOI) of 0.2 - 1.  
Supernatants containing HCV virions were collected 30 - 40 days post-transfection or 5 
days post-infection, removed of cell debris by low speed centrifugation at 1000 x g and 
4oC for 10 min, passed through a 0.22 μm filter, and aliquoted and stored at -70°C and 
used as the virus stock.  To obtain higher viral titer, the filtered culture supernatant was 
sometimes concentrated by the addition of 1/5 volume of 40% PEG8000 (final 
concentration of 8%) and precipitation at 4oC overnight, followed by centrifugation at 
3500 g and 4oC for 30 min.  The precipitated virus was suspended, stored at -70°C and 
used as the virus stock.  The virus stock was titrated by the foci formation assay as 
previously described (211).  Briefly, 10-fold serially diluted stock was added to Huh7.5.1 
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cells and medium was changed after two hours.  Immunostaining against HCV core was 
performed at 72 hr post-infection and the number of foci formed at the highest dilution 
was used to calculate the virus titer, which was expressed as focus-forming units per 
milliliter (FFU/ml).  The titers of our JFH1 viral stock were usually in a range of 104 to 106 
FFU/ml.  Unless stated otherwise, HCVcc infection was performed by incubation of 
HCVcc stock with target cells for 2 hr at 37°C at a multiplicity of infection of 0.1. 
 
Co-culture assay and transwell assay 
In the co-culture assay, Huh7.5.1 were infected with HCV for 3 days and used as the 
donor cells.  The donor cells or the target cells were first labeled with PKH26 or CMFDA 
according to the manufacturer’s instructions.  Briefly, cells were trypsinized and labeled 
with 2 μM PKH26 for 5 min at RT followed by incubation with 1% FBS/phosphate-
buffered saline (PBS) to stop the labeling reaction and four extensive washes to remove 
any residual dye.  Alternatively, media containing 1.25 μM (for flow cytometry) or 5 μM 
(for confocal imaging) CMFDA were directly added to cells growing in culture dishes.  
The cells were labeled at 37oC and 5% CO2 for 30 min followed by a medium change to 
normal growth media and an extra 30 min incubation.  The labeled donor/target cells 
were counted (or trypsinized and counted for CMFDA-labeled cells) and mixed with 
unlabeled target/donor cells and seeded to a 24- or 12-well plate at >90% confluence.  
Unless stated otherwise, the donor/target cells were allowed to co-incubate for 
approximately 20 hr, followed by collection for immunostaining and flow cytometry or 
confocal analysis.  The transwell assay was carried out in a similar fashion except that 
neither donor nor target cells were labeled and the donor and target cells were seeded 
into the upper and lower chambers of the transwell (Corning, Lowell, MA), respectively. 
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Flow cytometry 
CD81 surface expression 
For detection of CD81 surface expression, cells were removed from culture dishes with 
0.5 mM EDTA/PBS and directly labeled with mouse anti-CD81 (JS81) –FITC conjugated 
(1:100)  for 30 min at 4°C, or labeled by incubation with mouse anti-CD81 (2 μg/ml) at 
4°C for 30 min first and then with goat anti-mouse IgG-Alexa488 (1:500) at 4°C for 30 
min.  The labeled cells were suspended in PBS and analyzed by flow cytometry 
immediately.  Between each step, the cells were extensively washed with PBS.  Where 
appropriate, cell labeling with mouse normal IgG (2 μg/ml) or mouse normal IgG-FITC 
conjugated (1:100) was included as control. 
 
HCV CCCM transfer 
Cells from the co-culture assay, or the target cells from the transwell assay were 
trypsinized and fixed with 4% paraformaldehyde (PFA) for 10 min, followed by 
permeabilization with 50 μg/ml saponin for 15 min.  Staining was performed with mouse 
anti-core primary antibody for 60 min followed by goat anti-mouse IgG-Alexa647 (for 
CMFDA-labeled or Huh7.5.1-GFP co-culture) or goat anti-mouse IgG-Alexa488 (2 μg/ml, 
for PKH26-labeled co-culture) secondary antibody for 60 min.  All primary and secondary 
antibodies were diluted to 2 μg/ml in 1% FBS/PBS.  All the steps for immunostaing of 
fixed cells were performed at room temperature.  Between each step, the cells were 
extensively washed with PBS.  Flow cytometry analysis was performed on a BD FACS 
Calibur or BD Accuri C6; only live cells were gated and cell debris were excluded from 
analysis.   
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Immunofluorescence staining and confocal imaging 
Cells from the co-culture assay were fixed with 4% paraformaldehyde on coverslips, 
permeabilized with saponin and blocked in 1% FBS/PBS at RT for 30 min.  Cells were 
stained with mouse anti-core primary antibody (2 μg/ml) at RT for 60 min followed by 
goat anti-mouse IgG-Alexa488 or Alexa555 (2 μg/ml) secondary antibody at RT for 60 
min.  The nuclei were stained with 0.25 μg/ml DAPI in PBS at RT for 15 min.  The cover 
slips were mounted with Fluoromount G (Southern Biotech, Birmingham, Alabama) and 
microscopic images were taken using a Zeiss Axiovert 200 for epifluorescence or a 
Zeiss LSM510 for confocal images.  For the detection of OCLN, siCtrl- or siOCLN-
transfected Huh7.5.1 cells were fixed, permeabilized, and stained with mouse normal 
IgG (2.5 μg/ml) or mouse anti-OCLN (2.5 μg/ml) followed by goat anti-mouse IgG-
Alexa555 secondary antibody (2 μg/ml).  For F-actin staining, cells from the co-culture 
assay were fixed and permeabilized as above and then stained with 1 μg/ml phalloidin-
TRITC in PBS at RT for 30 min.  For the visualization of microtubules, cells from the co-
culture assay were fixed with -20°C methanol for 3 min and then permeabilized and 
stained with mouse anti-tubulin (2 μg/ml) followed by Alexa555-conjugated secondary 
antibody (2 μg/ml).  Cells were washed three times with PBS between each step. 
 
ReAsH labeling and 3D live cell imaging 
Culture supernatants were collected from JFH1-TCcore transfected Huh7.5.1 at day 42 
post-transfection and concentrated 30-fold by using PEG8000 precipitation and titrated 
as described above.  Huh7.5.1 cells were infected with the concentrated JFH1-TCcore 
virus (MOI=0.15) and labeled with ReAsH according to the instructions provided in the 
TC-tag detection kit (Invitrogen).  These labeled cells were then used as donor cells.  
Specifically, at day 3 post-infection, cells were washed once with Opti-MEM (Invitrogen) 
and labeled with the ReAsH dye (1 µM final concentration) in Opti-MEM.  Cells were 
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incubated at 37oC for 30 min, and then washed twice with 1X BAL (2,3-dimercapto-1-
propanol) wash buffer (supplied in the kit, Invitrogen) in Opti-MEM for 5 min each.  The 
wash buffer was removed, and the cells were washed once with PBS, trypsinized, and 
mixed at a 1:1 ratio with the Huh7.5.1-GFP target cells.  The mixed cells were seeded 
onto poly-lysine-coated 35 mm glass bottom dishes to 90% confluence, and the media 
were replaced with DMEM media without phenol red at 2 hr post-seeding.  Live cell 
imaging was set up after the media change.  Images were taken starting at 9 hr post-
seeding and continued for 18 hr.  All images were acquired with a Zeiss LSM 510 
confocal microscope fitted with a 20X air objective and a thermostatic stage incubator 
set at 37oC, 5% CO2.  ReAsH-labeled TCcore was visualized with the filter sets of 
excitation at 561 nm and emission at 620/80, and the GFP in target cells was detected 
using the filter sets of excitation at 488nm and emission at 528/45.  A 13 slice X 0.9 µm 
Z stack was taken at each selected field every 18 min using the LSM 510 LUO software.  
Images were later processed and analyzed with Image J 1.45s.  Unless otherwise 
specified, all red/green fluorescence images were Z projections (maximum intensity 
projection) from the original stack and all differential interference contrast (DIC) images 
were the most focused slice from the Z stack (the 7th slice). 
 
Western blotting 
At 48 hr post-transfection or 72 hr post-infection, cells were harvested by trypsinization, 
washed once with ice-cold PBS, pelleted at 4°C and 2000 x g for 5 min, and lysed on ice 
with a standard RIPA buffer (50 mM Tris-HCl pH 8.0, 0.5% NP40, 2 mM EDTA, 137 mM 
NaCl, and 10% glycerol) added with 1X protease inhibitor cocktail and 1X PMSF.  After 
30 min incubation, cell debri was removed by centrifugation at 4°C and 12, 000 x g for 
10 min and the supernatant (cell lysate) was determined of protein concentration with 
the Bio-Rad DC Protein Assay Kit.  An equal amount of protein in the whole cell lysates 
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(25 µg for CLDN1, 50-100 µg for HCV core, 100 µg for SR-B1 and 100-200 µg for OCLN) 
was separated on a 8% (SR-B1 and OCLN) or 12% (all others) polyacrylamide-SDS gel, 
and then transferred onto nitrocellulose membranes (GE Healthcare).  The membranes 
were blocked with 5% milk in TBST at RT for 30 min or at 4°C overnight, followed by 
probing with appropriate primary antibodies (1 μg/ml for mouse α-HCV core/Hsp70 and 
rabbit α-CLDN1/CD63, 2 μg/ml for mouse α-SR-B1 and rabbit α-OCLN, 0.5 μg/ml for β-
actin and 1:500 for goat α-HCV E2) at RT for 2 hr or at 4°C overnight, and secondary 
antibodies (0.5 μg/ml) at RT for 1 hr.  The protein bands were visualized by either adding 
homemade enhanced chemiluminescence reagents (for HRP-conjugated secondary 
antibodies) and imaging, or direct imaging for fluorescence intensity (for Alexa dyes-
conjugated secondary antibodies) with a Bio-Rad ChemiDot MD system.  For western 
blotting of exosome and/or virus fractions from Opti-prep gradient centrifugation, the 
fraction was diluted to 1.4 ml with PBS, centrifuged at 4°C and 20, 000 x g for 90 min, 
suspended in 20 µl 4X SDS-PAGE sample buffer (8% SDS, 0.4 M DTT, 0.25 M Tris. HCl 
pH 6.8, 40% Glycerol and 0.1% bromophenol blue) and separated on a 12% SDS-PAGE 
gel.  All the remaining steps were as same as cell lysates. 
 
RNA isolation and qRT-PCR 
RNA isolation 
Total RNA was isolated from cells or 50-200 µl culture supernatants removed of cell 
debris by centrifugation at 1000 x g for 5 min using TRIZOL or TRIZOL LS (Invitrogen), 
respectively, according to the manufacturer’s instructions.  The isolated RNA was 
suspended in 10 µl nuclease-free ddH2O and 200 ng cellular RNA or 2 µl supernatant 
RNA were used for downstream qRT-PCR detection.  For the detection of patient 
plasma-derived HCV, if the sample was more than 140 μl, it was first concentrated to 
140 μl with Amicon Ultracel-100K centrifugal filter device by centrifugation at 4000 x g 
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and 4°C for 25 min.  Total RNA was then extracted from the samples with the QIAamp 
Viral RNA Mini Kit (QIAGEN) and eluted with 60 μl AVE buffer.  Two microliters of the 
RNA were used for qRT-PCR.   
 
One-step Taqman qRT-PCR for HCV RNA 
HCV RNA in cells, culture supernatants, and patient plasma were detected using a 
TaqMan One-Step RT-PCR kit (Applied Biosystems) with HCV-specific primers and 
probe.  The primers and probe for detection of JFH1 (HCV subtype 2a) were described 
previously (212) and their sequences were: forward primer KK3-0, 5’-CTG TCT TCA 
CGC AGA AAG CG-3’; reverse primer KM3-1, 5’-CAC TCG CAA GCG CCC TAT CA-3’; 
probe R6-84, 5’-CAT GGC GTT AGT ATG AGT GTC GTA CA-3’.  The reverse primer 
was changed to KM3-1’, 5’-CAC TCG CAA GCA CCC TAT CA-3’, for the detection of 
patient plasma-derived HCV.  The qRT-PCR reaction was set up in a 10 μl volume with 
2 μl RNA template and a program as follows: 48°C for 30 min, 95°C for 10 min, and then 
40 cycles at 95°C for 15 sec, and 60°C for 1min.  Serially diluted in vitro transcribed 
JFH1 RNA was included as standards in parallel and used to calculate the absolute level 
of HCV RNA. 
 
Two-step Taqman qRT-PCR for miR122 
Cellular RNA (100 - 200 ng) was reverse transcbribed to cDNA with the reverse 
transcription primer from Taqman MicroRNA Assay hsa-miR122-5p using the Taqman 
MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer’s instructions.  An aliquot of the reverse transcription products (0.667 μl 
out of 7.5 μl) were then mixed with 0.5 μl miR122-specific primers and probes from the 
Taqman MicroRNA Assay hsa-miR122-5p, 3.84 μl ddH2O, and 5 μl 2X AmpliTaq Gold 
PCR Mastermix (Applied Biosystems).  The total 10 μl qPCR reaction was performed 
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with a program as follows: 95°C for 10 min, and 40 cycles at 95°C for 15 sec, and 60°C 
for 1min.  For endogenous expression level of miR122 in different cells, the small 
nuclear RNA U6 expression in these cells was also determined by two-step SYBR 
Green qRT-PCR using the ImProm II reverse transcriptase (Promega) and the iQ SYBR 
Green Supermix (Bio-Rad), and used for normalization of miR122 expression in these 
cells.  The primers used were: 5’-TCC CCC GGG GTG CTC GCT TGG GCA GCA CA-3’ 
and 5’-TCC CCC GGG AAA ATA TGG AAC GCT TCA CGA-3’.  The qPCR program was: 
95°C for 3 min, 40 cycles of 95°C for 15 s and 60°C for 1min. 
 
Two-step SYBR Green qRT-PCR for cytokine expression 
Cellular RNA (2.5 - 5 µg) was reverse transcbribed to cDNA using the GoScript Reverse 
transcription system (Promega).  qPCR was then performed in a 10 μl  volume with an 
aliquot of the cDNA (0.5 - 0.8 μl out of 20 μl) using the SYBR Green JumpStart Taq 
Readymix (Sigma).  The primers were described previously (213-217), and  their 
sequences were: β-actin: 5’-GGC ATC CTC ACC CTG AAG TA-3’ and 5’-AGG GCA 
TAC CCC TCG TAG AT-3’; IL-1α: 5’-CGC CAA TGA CTC AGA GGA AGA-3’ and 5’-
AGG GCG TCA TTC AGG ATG AA-3’; IL-1β: 5’-CCT GTC CTG CGT GTT GAA AGA-3’ 
and 5’-GGG AAC TGG GCA GAC TCA AA-3’;  IL-6: 5’-ACA ACA AAT TCG GTA GAT 
CCT CG-3’ and 5’-AGC CAT CTT TGG AAG GTT CAG G-3’; IL-8: 5’-TGC CAA GGA 
GTG CTA AAG-3’ and 5’-TCT CAG CCC TCT TCA AAA-3’; IL-18: 5’-GAC GCA TGC 
CCT CAA TCC-3’ and 5’-CTA GAG CGC AAT GGT GCA ATC-3’; TNF-α: 5’-TCT TCT 
CGA ACC CCG AGT GA-3’ and 5’-CCT CTG ATG GCA CCA CCA G-3’.  The program 
used for qPCR was: 95°C for 3 min, 40 cycles of 95°C for 15 s, annealing (55°C for β-
actin, 57.3°C for IL-1α, 59.8°C for IL-1β, 60.4°C for IL-6, 60.7°C for IL-8, 55.4°C for IL-18, 
and 58.6°C for TNF-α) for 15 s and 72°C for 45 s.  The temperature of the annealing 
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step for each cytokine has been pre-optimized to ensure only one peak seen in the 
melting curve and only one PCR product with the correct size seen on an agarose gel.  
All the qPCR reactions were set up in a 10 μl volume and performed on the C1000 
Touch Thermal Cycler with the signal detected by CFX96 real time system (both from 
Bio-Rad, CA). 
 
Preparation of bovine exosome-depleted medium and bovine exosome-depleted 
HCV   
Bovine exosomes were depleted from complete culture medium (DMEM supplemented 
with 10% FBS and 1% penicillin/streptomycin/L-glutamine) by ultracentrifugation 
overnight (~16 hr) at 4°C and 100,000 x g.  The supernatants were then collected and if 
needed, sterilized by passing through 0.22 µm filter and stored at 4°C as bovine 
exosome-depleted medium.  For the production of bovine exosome-depleted HCV, 
Huh7.5.1 was inoculated with JFH1 viral stock and cultured for 3-4 days.  Culture 
medium was then changed to bovine-exosome depleted medium; the cells were 
continued to culture for 24 hr and the culture supernatants were collected and saved as 
bovine exosome-depleted HCV. 
 
Exosome and HCV purification by Optiprep gradient ultracentrifugation  
Huh7.5.1 culture supernatants (30-400 ml) were removed of cell debri by centrifugation 
at 3000 x g for 10 min, passed through a 0.22 m filter, and concentrated by 
ultracentrifugation at 250,000 x g and 4°C for 90 min in a SW55Ti rotor or 130,000 x g 
and 4°C for 90 min in a SW28 rotor to obtain the exosome pellet.  Meanwhile, a 5 ml 6-
24% Opti-prep gradient was prepared with the Hoefer SG50 gradient maker.  
Specifically, 3 ml each of 2.4% and 24% iodixanol working solutions were prepared from 
the Opti-prep density gradient medium (60% w/v iodixanol in water) with the Opti-prep 
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diluent (235 mM KCl, 12 mM MgCl2, 25 mM CaCl2, 30 mM EGTA, 150 mM Hepes-NaOH 
pH 7.0).  The two 3 ml working solutions were loaded into the two chambers of the 
gradient maker, respectively.  A 5 ml 6-24% iodixanol continuous gradient was then 
generated with the gradient maker according to manufacturer’s instructions.  The 
exosome pellet was suspended in 500 µl PBS, loaded onto the Opti-prep gradient and 
centrifuged at 250,000 x g and 4°C for 2 hr in the SW55Ti rotor.  Eleven fractions (500 µl 
each) were collected from top to bottom; an aliquot of each fraction was subjected to 
AchE assay, Western blotting, qRT-PCR, or foci formation assay. 
 
Acetylcholinesterase assay 
Acetylcholinesterase (AchE) activity was measured as described previously (218). 
Briefly, 5 μl culture supernatant or iodixanol fraction was mixed with 12.5 μl 10 mM ATC 
and 82.5 μl PBS, and then 100 μl 0.1 mM DTBNBA/PBS in a 96-well plate.  The reaction 
was incubated at RT or 37°C for 5 to 30 min until yellow color appeared, at which point 
the absorbance of the reaction at 415 nm was measured with a plate reader 
spectrophotometer (Bio-Rad). 
 
MTT assay   
Human neuroblastoma SH-SY5Y cells were plated at a 96-well plate at  a density of 1x 
104/ well and cultured for 24 hr (40-50% confluence).  Then, the media was replaced 
with 80 µl supernatant being tested mixed with 40 µl serum-free SH-SY5Y-culturing 
media (half Nutrients Mixture Ham’s F-12 and half DMEM).  After 72 hr culturing, the 
cells were added with 30 µl 50 mg/ml MTT solution and incubated for additional 12-16 hr.  
Media was then removed and the violet crystals in the well were dissolved by adding 200 
µl of acid-isopropanol (a 3: 22 ratio mixture of 0.2 N HCl and isopropanol) and shaking 
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for 20 min at room temperature.  Absorbance at 655 nm and 595 nm was then taken and 
used to calculate the differences. 
 
Data acquisition and statistical analysis 
Where appropriate, values were expressed as mean ± SD of triplicate experiments.  All 
statistical analyses including one-way and two-way ANOVA followed by post hoc tests 
(bonferroni correction or Dunnett’s test), and two-tailed unpaired student’s t test were 
performed in Prism 5 (Graphpad Software, CA).  A p value of < 0.05 was considered 
statistically significant (*), p < 0.01 highly significant (**) and p < 0.001 strongly 
significant (***).  All data were representative of multiple repeated experiments. 
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RESULTS 
CHAPTER 1: Cell-Cell Contact-Mediated Hepatitis C Virus Transfer, Productive 
Infection and Replication and Its Requirement for HCV Receptors 
 
1.1 Formation of HCV infection foci in cell culture 
A number of recent studies have demonstrated the linkage between cell-cell contact-
mediated (CCCM) viral transmission and immune evasion (219); CCCM viral 
transmission has thereby attracted increasing attention and we are particularly interested 
in its potential usurpation by HCV as an alternative route of transmission.  Consistent 
with several clinical reports showing a focal pattern of infected cells in HCV patient liver 
biopsy (95-97), we and others repeatedly noticed that in cell culture, clustered HCV-
infected cells (the infection “foci”, usually with 10-50 cells) were observed at a very low 
MOI (Fig. 6, right column) and high cell density.  To the contrary, higher MOI gave rise 
to approximately 80-90% HCV core-positive cells and less distinctive foci (Fig. 6, middle 
column).  Formation of these infection foci at the lower MOI could result from division 
and proliferation of HCV-infected cells.  Alternatively, it could be due to the close 
proximity of uninfected cells to HCV-infected cells and subsequent CCCM HCV transfer 
to the neighboring uninfected cells resulting in infection. 
 
1.2 Spread of HCV in cell culture is dependent on cell density 
To distinguish these two possibilities, we infected Huh7.5.1 cells with JFH1 virus of a 
lower MOI, removed the excessive virus, and then re-plated the cells at different cell 
densities.  Following three days of continued culturing, the cells were processed for 
analysis of HCV core expression, a widely used marker for HCV infection.  We reasoned 
that if infection focus formation resulted from proliferation of HCV-infected cells, these  
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Figure 6.  Formation of HCV infection foci in cell culture.  Huh7.5.1 cells were 
inoculated with culture media (- HCV), or JFH1 virus at a high MOI of 0.4 (+ HCV), or 
JFH1 virus at a low MOI of 4 X 10-4 (+ HCV), cultured for 3 days and immunostained for 
HCV core (green) followed by DAPI counterstain (blue, for nuclei).   
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foci would be observed at any cell density and there would be no correlation between 
the number of infection foci and cell density; if infection focus formation resulted from 
CCCM HCV transfer, infectious focus would only be observed at high cell densities and 
there would be a positive correlation between the number of foci formed and cell density.  
To ensure the validity of the data, we assessed HCV core-positive cells by Western 
blotting for HCV core, immunofluorescence staining for HCV core followed by 
immunofluorescence microscopic imaging and manual counting of HCV core-positive 
cells under an immunofluorescence microscope, or flow cytometry analysis.  Western 
blotting showed that the expression level of HCV core protein exhibited a gradual 
increase with higher cell density (Fig. 7A).  Immunostaining of these cells for HCV core 
protein followed by immunofluorescence microscopic imaging showed an apparent 
increase in the number and intensity of core-positive cells with increased cell density 
(Fig. 7B).  The formation of core-positive cell foci appeared to only occur at higher cell 
densities (Fig. 7B).  Manual quantitation of core-positive cells showed a positive 
correlation between the number of core-positive cells and cell density (Fig. 7C).  The 
positive correlation was further quantified by flow cytometry analysis of core-positive 
cells (Fig. 7D), and a two variable linear regression analysis gave rise to the correlation 
coefficient of 0.9883.  In addition, we further show that this positive correlation between 
the percentage of infected cells and cell density is dependent on the MOI; when a higher 
MOI was employed for the initial infection, the overall much higher infection efficiency at 
all densities led to a decrease in the correlation between the percentage of infected cells 
and cell density (Fig. 8).  Taken together, these results suggest that HCV is capable of 
infecting target cells via a cell-to-cell mechanism, i.e., CCCM HCV infection and 
transmission. 
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Figure 7.  Cell density’s effects on HCV spread at a low MOI. Huh7.5.1 cells were 
inoculated with culture media (- HCV) or HCV JFH1 stock (+ HCV) at MOI = 0.05.  At 
day 1 post-infection, the infected cells were replated at different densities which gave 
rise to 30%, 50%, 70%, 85%, and 100% confluence 3 days post-replating at which time 
the cells were harvested and analyzed by (A) Western blotting against HCV core, (B) 
immunostained for HCV core (green) and DAPI (blue) (representative images), (C) 
counted for core-positive cells under a fluorescence microscope, or (D) analyzed by flow 
cytometry for core-positive cells (correlation coefficient R = 0.9883, which was derived 
from a standard two variable mathematical regression analysis: cell confluence vs. 
percentage of core-positive cells). 
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Figure 8.  Cell density’s effects on HCV spread at a high MOI.  The same with Fig. 7 
A-C except that Huh7.5.1 cells were inoculated with JFH1 stock at MOI = 0.5. 
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1.3 CCCM HCV transfer to Huh7.5.1 and primary hepatocytes 
 
1.3.1 Optimization of the labeling methods in co-culture assay 
To characterize the CCCM HCV infection, we devised a co-culture assay that involved 
incubation of HCV-infected Huh7.5.1 donor cells with uninfected Huh7.5.1 target cells for 
a certain period of time and determination of the number of core-positive target cells 
from CCCM HCV transfer by immunostaining.  One of the key elements in this co-culture 
assay was to identify an appropriate method to fluorescently label either the donor or 
target cells, so that they could be distinguished after immunostaining.  In order to be 
used in the co-culture assay, this labeling dye has to be plasma membrane-permeable, 
retained stably in the cell for at least 24-48 hr after the labeling, and not extracted during 
fixation or permeablization steps in the immunostaining.  Among the various cell-labeling 
strategies being tested, DAPI DNA labeling was not appropriate due to very faint live cell 
labeling and free diffusion between cells resulting from its poor plasma membrane 
permeability and the reversible nature of its binding to DNA, respectively (microscopic 
observations); cell surface labeling of CD81 (expressed on more than 99% of Huh7.5.1 
cells, Fig. 45A) with anti-CD81 primary antibody followed by Alexa488-conjugated 
secondary antibody was not suitable due to receptor recycling and thereby decreased 
fluorescence signal over time (difficult-to-separate peaks after 20 hr co-culture, Fig. 9);  
labeling with the cell-tracking dye CMPTX was not appropriate due to free diffusion of 
the dye between cells during co-culture (microscopic observations);  labeling with the 
mitochondria tracker Rhodamine 123 was again not suitable because it was washed out 
of cells during the fixation step in immunostaining, when the mitochondria potential was 
lost (microscopic observations);  labeling with the cell-tracking dye CFSE and 
subsequent co-culturing experiment was successful (Fig. 9) but its high sensitivity to  
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Figure 9.  Optimization of the labeling methods for co-culture assay – test of CD81 
surface labeling, CFSE labeling, and CMFDA labeling.  Huh7.5.1 cells were labeled 
with α-CD81 primary antibody (2 μg/ml, 4°C, 30 min) and then Alexa488-conjugated 
secondary antibody (2 μg/ml, 4°C, 30 min), 2.5 µM CFSE, or 1.25 µM CMFDA.  The 
labeled cells were mixed with unlabeled Huh7.5.1 cells at 1:1 ratio and fixed immediately 
(0 hr samples), or co-cultured at 37°C for 20 hr and then fixed (20 hr samples).  The 
cells were analyzed with flow cytometry for the percentage of labeled cells.  Both 
histogram and dot plots were shown for CD81 surface labeling and CMFDA labeling; 
only histogram was shown for CFSE labeling.  The numbers on each histogram 
represent the percentage of labeled cells (M1-gated cells) in that plot, where the M1 gate 
was determined based on the 0 hr sample. 
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photobleaching (microscopic observations) led us to consider its derivative, the much 
more photostable CMFDA.  At the end of the search, CMFDA and PKH26 labeling and 
stable GFP (Fig. 9, 12A, 31A) expression were found to be the most appropriate ways 
to label the donor/target cells, as they meet all the requirements to be used in the co-
culture assay. 
 
1.3.2 CCCM HCV transfer among Huh7.5.1 
CCCM viral transmission requires different lengths of co-incubation times for different 
viruses and is often dependent on the ratio of donor cells (D) to target cells (T) (74, 93).  
Therefore, we started the co-culture assay with a D: T ratio of 1:1 and a co-incubation 
time of 20 hr for HCV.  To distinguish target cells from donor cells, several cell-labeling 
strategies were exploited.  First, we established a GFP-expressing Huh7.5.1 stable cell 
line with more than 95% GFP-positive cells as determined by flow cytometry (Fig. 33A,  
the “GFP only” bar), and used this cell line as the target cells in the co-culture assay.  
Incubation of these cells with HCV-infected Huh7.5.1 cells gave rise to core-positive and 
GFP-positive target cells (arrowhead, Fig. 10A i, v, ix).  We also found two cell-tracking 
dyes, CMFDA (220) and PKH26, for labeling donor/ target cells to allow more flexibility in 
further experiments and to avoid the selection of stable GFP-positive cell lines for each 
cell to be tested.  The thiol-reactive CMFDA dye universally and covalently labels 
proteins in the cell and the PKH26 dye labels cell membranes; both of them are well-
retained, brightly fluorescent and relatively photostable.  Incubation of CMFDA-labeled 
target cells with HCV-infected Huh7.5.1 cells showed core-positive and CMFDA-positive 
target cells (arrowhead, Fig. 10A ii, vi, x).  Similar results were obtained using the 
PKH26 dye to label the target cells (arrowhead, Fig. 10A iii, vii, xi).  We also labeled 
HCV-infected cells with CMFDA and used them as the donor cells and naïve Huh7.5.1  
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Figure 10.  CCCM HCV transfer among Huh7.5.1 cells.  Huh7.5.1 cells were infected 
with JFH-1 virus at MOI = 0.1, cultured for 3 days, and co-cultured with GFP-expressing 
Huh7.5.1 (A i, v, ix), CMFDA-labeled Huh7.5.1 (A ii, vi, x) or PKH labeled Huh7.5.1 (A 
iii, vii, xi) target cells. Alternatively, the JFH-1-infected cells were labeled with CMFDA 
(A iv, viii, xii) and co-cultured with unlabeled Huh7.5.1 target cells.  The donor:target 
cell ratio was 1.  After 20 hr of co-culturing, the cell mixture was subjected to 
immunostaining against HCV core, followed by (A) confocal imaging (newly transferred 
target cells marked by arrowhead) or (B) flow cytometry analysis.  Nuclei were 
counterstained with DAPI. 
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cells as the target cells for the co-culture assay.  The results showed core-positive and 
CMFDA-negative target cells (arrowhead, Fig. 10A iv, viii, xii).  Quantitation analysis by 
flow cytometry showed a comparable level of CCCM HCV transfer. i.e., about 20% of the 
target cells, among the different labeling strategies (Fig. 10B).  Noticeably, in both GFP 
and CMFDA labeling strategies, the target cells exhibited less intense core staining 
when compared to the donor cells (Fig. 10B), potentially explained by the directionality 
of HCV transfer. 
 
1.3.3 CCCM HCV transfer to primary hepatocytes 
To ascertain that CCCM HCV transfer occurred in primary human hepatocytes (PHH), 
we performed the co-culture assay with CMFDA-labeled HCV-infected Huh7.5.1 as the 
donor cells and PHH as the target cells.  The results showed core-positive and CMFDA-
negative PHH target cells (arrowhead, Fig. 11 A), which were equivalent to 
approximately 20% of the total target cell population as determined by flow cytometry 
(Fig. 11 B).  Taken together, these results confirmed CCCM HCV transfer in both human 
hepatoma cells and primary hepatocytes. 
 
1.4 CCCM HCV transfer vs. cell-free HCV infection 
The core-positive target cells that were detected following 20 hr of co-culturing (Fig. 10 
& 11) could also result from infection of target cells with cell-free HCV virus from HCV-
infected donor cells.  To address this possibility, we determined the kinetics of CCCM 
HCV transfer and compared it to that of cell-free HCV infection.  We labeled uninfected 
Huh7.5.1 target cells with PKH26 and performed the co-culture assay at a D: T ratio of 
1:1 for 0, 3, 6, 9, and 20 hr.  Flow cytometry analysis showed that core-positive and 
PKH-positive target cells began to emerge within 3 hr of co-incubation and gradually 
increased in number up to 20 hr (Fig. 12A).  In parallel, we set up a transwell assay (Fig.  
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Figure 11.  CCCM HCV transfer between Huh7.5.1 and primary human hepatocytes.  
Human primary hepatocytes (PHH) were co-cultured with JFH-1-infected CMFDA-
labeled Huh7.5.1 cells at a 1:1 ratio for 20 hr.  The mixed culture was immunostained for 
HCV core and subjected to (A) confocal imaging or (B) flow cytometry.  The human 
primary hepatocytes with CCCM HCV transfer were marked with an arrowhead in (B). 
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12B), in which HCV-infected Huh7.5.1 donor cells were seeded on a 0.4 µm pore size 
permeable membrane on the transwell insert in the upper chamber and uninfected 
Huh7.5.1 cells were seeded in the lower chamber of the transwell.  The permeable 
membrane with 0.4 µm pore size functions as a physical barrier to separate the donor 
cells from the target cells, and therefore only allows cell-free HCV to diffuse from the 
upper chamber of the transwell insert into the lower chamber of the transwell to infect 
cells, and at the same time excludes CCCM HCV infection.  As the surface area of the 
insert is only half of that of the bottom of the lower chamber, a D: T ratio of 1:2 was used 
to achieve a comparable cell confluence between the upper and lower chambers.  The 
cells in the lower chamber were harvested at the same time points as those in the co-
culture assay, i.e., 0, 3, 6, and 20 hr, and stained for HCV core expression.  Compared 
to the results of the co-culture assay, the transwell assay gave rise to very few core-
positive target cells in the lower chamber of the transwell during the same time points 
(Fig. 12C).  Therefore, the core-positive target cells detected within 20 hr of co-culturing 
(Fig. 10 & 11) likely resulted from CCCM HCV infection and not from cell-free virus 
infection.  To ascertain that HCV virions can freely diffuse through the membrane on the 
insert, the transwell assay was extended to 48 and 72 hr.  HCV-infected cells in the 
lower chamber were similarly determined using core immunostaining.  Core-positive 
cells in the lower chamber only began to emerge at 24 hr and increased at 48 hr and 72 
hr (line graph, Fig. 12D), the kinetics was very similar to that of the cell-free HCV virus 
infection of Huh7.5.1 cells by direct inoculation (Fig. 12E), which was routinely 
performed in the laboratory.  These results not only support the notion that cell-free HCV 
infection takes a longer time than CCCM HCV infection but also confirm that cell-free 
HCV virus are capable of passing through the membrane and infecting target cells in the 
lower chamber.   In addition, qRT-PCR was performed to compare the HCV RNA level  
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Figure 12.  CCCM HCV transfer versus cell-free HCV infection.  (A) JFH1-infected 
Huh7.5.1 donor cells were co-cultured with PKH-labeled Huh7.5.1 target cells at 1:1 ratio 
for 0, 3, 6, 9 or 20 hr, followed by immunostaining for HCV core and flow cytometry 
analysis.  The HCV core-positive and PKH-positive cells in the upper right quadrant 
represent cells with CCCM HCV transfer; they were expressed as the percentage of the 
total number of the cells and shown in the upper right quadrant in each dot plot.  (B) 
Transwell assay.  JHF1-infected Huh7.5.1 donor cells were seeded on top of a 0.4 µm 
virus-permeable membrane in a transwell insert and Huh7.5.1 target cells were seeded 
in the lower chamber of the transwell.  The cells were cultured for 20 hr with the same 
total number of cells as the co-culturing assay.  The cells in the lower chambers were 
collected, immunostained for core protein and analyzed by flow cytometry.  The 
transwell is drawn at a scale of 2:1 based on the real size.  (C) CCCM HCV transfer 
kinetics in co-culturing and transwell assays at the same 1:2 ratio of D: T.   (D) Similar 
transwell experiments were performed as described above in (B) except for extended 
culturing times.  HCV RNA in the upper and lower chambers were determined by qRT-
PCR (left Y axis, bar graph), whereas the percentage of core-positive cells in the lower 
chamber was determined by flow cytometry (right Y axis, dotted line).  (E) Cell-free HCV 
infection kinetics.  Huh7.5.1 cells were infected with HCV JFH1 (MOI = 1); cells were 
harvested at indicated times and stained for core-positive cells.   
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between the upper and lower chambers at 24, 48, and 72 hr.  No differences of HCV 
RNA levels were found (bar graph, Fig. 12D), further confirming that HCV can diffuse 
through the 0.4 µm pore size permeable membrane on the insert and that CCCM 
infection, not cell-free HCV infection, is solely responsible for the newly infected target 
cells in 20 hr co-culture assay.  Next, we determined whether CCCM HCV transfer was 
dependent on the D: T ratio.  We performed the co-culture assay with the same co-
incubation time (20 hr) and the same total number of donor and target cells but with 
different D: T ratios.  The results showed that the percentage of core-positive target cells 
increased with increasing D: T ratios (Fig. 13), suggesting that a higher D: T ratio likely 
provided more opportunities for the target cells to be in contact with the HCV-infected 
donor cells.  The increase in CCCM HCV transfer over the donor/target ratio appeared to 
be modest, likely due to an already higher number (density) of the starting cells in the 
co-culturing assay and thereby non-proportional increase in donor-target contacts over D: 
T ratio increase.  In addition, our subsequent imaging data showed that CCCM HCV 
transfer did not necessarily occur between one donor cells and one target cell.  
Furthermore, in this co-culturing experiment, the same total number of cells was 
maintained when the donor to target (D: T) ratio was increased.  Thus, increase of the D: 
T ratio does not necessarily translate to proportional increase of the contact between 
donor cells and target cells.  In other words, there would be more cell-cell contact and its 
subsequent CCCM transfer among the donor cells themselves at a higher D: T ratio.  
But, the type of CCCM transfer was not accounted for in our experimental setting.  
Taken together, these results showed that CCCM HCV infection occurred more readily 
than cell-free HCV infection and was dependent on direct cell-cell contact. 
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Figure 13.  Effects of the Donor: Target ratio on CCCM HCV transfer.   20 hr co-
culturing experiments were performed as described in Fig. 12 with different ratios of 
donor: target cells. 
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1.5 Indispensable roles of CD81, SR-B1, CLDN1 and OCLN in CCCM HCV transfer 
 
1.5.1 Inhibition of CCCM HCV transfer by knockdown of HCV receptor(s) in target cells 
CD81, SR-B1, CLDN1, and OCLN have been shown to be involved in cell-free HCV 
infection (25, 27-29).  As an alternative route to cell-free virus infection, CCCM viral 
infection and transmission often require viral entry receptors that were originally defined 
for cell-free virus infection (93, 221, 222).  Thus, we determined the roles of these four 
major HCV receptors in CCCM HCV transfer.  First, we knocked down expression of 
each receptor individually with siRNA in Huh7.5.1 cells and used these cells as target 
cells in the co-culture assay.  A maximal knockdown of each receptor by siRNA was pre-
determined using different methods based on the availability of antibodies: 80% for 
CD81 by flow cytometry (Fig. 14A), 50% for SR-B1 and CLDN1 by Western blotting (Fig. 
14B), and 70% for OCLN by both Western blotting and confocal imaging (Fig. 14B 
arrowhead, 14C).  We labeled these siRNA-transfected Huh7.5.1 cells and used them to 
perform a 20 hr co-culture assay with HCV-infected Huh7.5.1 donor cells.  Compared to 
siRNA control, knockdown of CD81, SR-B1, CLDN1 and OCLN led to decreases in 
CCCM HCV transfer by 72%, 68%, 46% and 63%, respectively (Fig. 14D).  In addition, 
we also used siRNA to knockdown all four receptors simultaneously in the target cells 
and performed the co-culture assay.  Comparable knockdown efficiencies were achieved 
for each of these receptors as individual knockdown without apparent cyto- or geno-
toxicity (Fig. 15A-C).  Interestingly, CCCM HCV transfer was almost completely 
abolished to target cells with decreased levels of all four receptors (Fig. 15D).  Taken 
together, these data suggest that CD81, SR-B1, CLDN1 and OCLN are all indispensable 
for CCCM HCV transfer and provide evidence that they may function in a coordinated 
manner.  
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Figure 14.  Individual knockdown of CD81, SR-B1, CLDN1 and OCLN on Huh7.5.1 
by siRNA and their effects on CCCM HCV transfer.  Huh7.5.1 cells were transfected 
with 100 nM siRNAs specific for CD81, SR-B1, CLDN1, or OCLN.  Pre-experiments 
were performed to determine which siRNA concentration allowed maximal knockdown. 
At 48 hr post-transfection, cells were collected for analysis of (A) CD81 expression by 
flow cytometry, (B) SR-B1, CLDN1, and OCLN expression by Western blotting, and (C) 
OCLN expression by immunofluorescence staining and imaging.  Scrambled siRNA 
control and isotype staining controls were included in each set of experiments as shown.  
(D) The siRNA transfected cells at 48 hr post-transfection were labeled with PKH and 
then co-cultured with JFH1-infected Huh7.5.1 cells at a 1:1 ratio for 20 hr.  The mixed 
cells were then immunostained for HCV core and analyzed by flow cytometry for target 
cells with CCCM HCV transfer.   
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Figure 15.  Simultaneous knockdown of CD81, SR-B1, CLDN1 and OCLN on 
Huh7.5.1 by siRNA and its effect on CCCM HCV transfer.  Huh7.5.1 cells were 
transfected with all four siRNAs for CD81, SR-B1, CLDN1 and OCLN (50 nM each).  At 
48 hr post-transfection, cells were collected for analysis of (A) CD81 expression by flow 
cytometry, (B) SR-B1, CLDN1, and OCLN expression by Western blotting, and (C) 
OCLN expression by immunofluorescence staining and imaging.  Scrambled siRNA 
control (200nM) and isotype staining controls were included in each set of experiments 
as shown.  (D) The siRNA transfected cells at 48 hr post-transfection were labeled with 
PKH and then co-cultured with JFH1-infected Huh7.5.1 cells at a 1:1 ratio for 20 hr.  The 
mixed cells were then immunostained for HCV core and analyzed by flow cytometry for 
target cells with CCCM HCV transfer.   
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1.5.2 No CCCM HCV transfer from Huh7.5.1 to other hepatoma and non-hepatoma cell 
lines 
To further analyze the roles of these receptors in CCCM HCV transfer, we took 
advantage of a panel of human cell lines that constitutively express varied levels of HCV 
receptors and determined the relationships between HCV receptor expression and cell-
free HCV infection or CCCM HCV transfer.  The human hepatoma cell lines HepG2, 
NKNT3 and CYNK10 were used.  HepG2 lacks CD81 expression but expresses medium 
to high levels of the other three major HCV receptors (35, 223-225).  NKNT3 and 
CYNK10 both express very low levels of CLDN1, but have medium to high levels of the 
other HCV receptors (226, 227).  We also included the HCV-susceptible Huh7.5.1 cell 
line and the non-hepatoma cell line 293T as controls.  Huh7.5.1 expressed all four HCV 
receptors at a moderate to high level, while 293T expressed very high levels of CD81 
and OCLN, but low level of SR-B1 and no CLDN1.  Expression of all four receptors in 
these cells was confirmed (Fig. 16 and Table 1).  Of all cell lines, only Huh7.5.1 was 
susceptible to cell-free HCV infection (Fig. 17A and Table 1).  When each cell line was 
co-cultured with HCV-infected Huh7.5.1 cells, no CCCM HCV transfer was detected in 
cells other than Huh7.5.1 at 24 hr post co-culturing (Fig. 17B).  These results confirmed 
the important roles of all four HCV receptors in both cell-free and CCCM HCV infection.  
We then introduced into the cells the receptor(s) that were not expressed and/or 
expressed at a lower level by ectopic expression and assessed the possibility of the 
CCCM HCV susceptibility in those cells.  Ectopic expression of CD81 in HepG2 (Fig. 
18A) gave rise to little CCCM HCV transfer from HCV-infected Huh7.5.1 (Fig. 18B).  
Similarly, ectopic expression of CLDN1 in NKNT3 (Fig. 19A) gave rise to little CCCM 
HCV transfer from HCV-infected Huh7.5.1 (Fig. 19B); ectopic expression of CLDN1 in 
CYNK10 (Fig. 20A) gave rise to little CCCM HCV transfer from HCV-infected Huh7.5.1  
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Figure 16.  Expression of HCV receptors in different cells.   Expression of CD81 (A), 
SR-B1, CLDN1 and OCLN (B) in different cells were determined by flow cytometry (A) or 
Western blotting (B).  
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Figure 17.  Cell-free and CCCM HCV infection of HepG2, NKNT3 and CYNK10 cells.  
(A) Cell-free HCV infection.  JFH1 (MOI = 1) were used to infect different cells.  After 3 
days of infection, cells were immunostained for HCV core and confocal images were 
taken.  The nuclei were counterstained with DAPI.  (B) CCCM HCV infection.  JFH1-
infected Huh7.5.1 donor cells were mixed with each of PKH-labeled target cells at 1:1 
ratio and co-cultured for 24 hr.  The co-cultured cells were immunostained for core and 
analyzed by FACS for core-positive target cells.   
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Figure 18.  No CCCM HCV transfer from Huh7.5.1 to HepG2-CD81.  HepG2 cells 
were transfected with pcDNA3-CD81. At 48 hr post-transfection, the transfected cells 
were collected for analysis of CD81 expression by flow cytometry (A). Simultaneously, 
these receptor-expressing HepG2 were labeled with CMFDA and co-cultured with JFH1-
infected Huh7.5.1 cells at a 1:1 ratio for 20 hr.  The mixed cultures were immunostained 
against HCV core and analyzed by flow cytometry for target cells with CCCM HCV 
transfer (B).  Naïve Huh7.5.1 cells and pcDNA3-transfected HepG2 were included as 
controls in these experiments. NS: not significant.  
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Figure 19.  No CCCM HCV transfer from Huh7.5.1 to NKNT3-CLDN1.  NKNT3 cells 
were transfected with pCMV-CLDN1.  At 48 hr post-transfection, the transfected cells 
were collected for analysis of CLDN1 expression by Western blotting (A). 
Simultaneously, these receptor-expressing NKNT3 cells were labeled with CMFDA and 
co-cultured with JFH1-infected Huh7.5.1 cells at a 1:1 ratio for 20 hr.  The mixed cultures 
were immunostained against HCV core and analyzed by flow cytometry for target cells 
with CCCM HCV transfer (B).  Naïve Huh7.5.1 cells and pcDNA3-transfected NKNT3 
cells were included as controls in these experiments. NS: not significant. 
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Figure 20.  No CCCM HCV transfer from Huh7.5.1 to CYNK10-CLDN1.  CYNK10 
cells were transfected with pCMV-CLDN1.  At 48 hr post-transfection, the transfected 
cells were collected for analysis of CLDN1 expression by Western blotting (A). 
Simultaneously, these receptor-expressing NKNT3 cells were labeled with CMFDA and 
co-cultured with JFH1-infected Huh7.5.1 cells at a 1:1 ratio for 20 hr.  The mixed cultures 
were immunostained against HCV core and analyzed by flow cytometry for target cells 
with CCCM HCV transfer (B).  Naïve Huh7.5.1 cells and pcDNA3-transfected CYNK10 
cells were included as controls in these experiments. NS: not significant. 
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Figure 21.  No CCCM HCV transfer from Huh7.5.1 to 293T-SR-B1-CLDN1.  293T 
cells were transfected simultaneously with both pcDNA3-SR-B1 and pCMV-CLDN1.  At 
48 hr post-transfection, the transfected cells were collected for analysis of or SR-B1 and 
CLDN1 expression by Western blotting (A).  Simultaneously, these receptor-expressing 
293T cells were labeled with CMFDA and co-cultured with JFH1-infected Huh7.5.1 cells 
at a 1:1 ratio for 20 hr.  The mixed cultures were immunostained against HCV core and 
analyzed by flow cytometry for target cells with CCCM HCV transfer (B).  Naïve 
Huh7.5.1 cells and pcDNA3-transfected 293T cells were included as controls in these 
experiments. NS: not significant. 
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(Fig. 20B); ectopic expression of both SR-B1 and CLDN1 in 293T (Fig. 21A) gave rise 
to little CCCM HCV transfer from HCV-infected Huh7.5.1 (Fig. 21B).  Taken together, 
these results suggest that expression of all four major HCV receptors, CD81, SR-B1, 
CLDN1 and OCLN is essential but not sufficient for CCCM HCV infection. 
 
1.6 Roles of actin and microtubule cytoskeletons in CCCM HCV transfer 
To determine the roles of cytoskeleton in CCCM HCV transfer, we performed the co- 
culturing experiments in the presence of the actin polymerization inhibitor, cytochalasin 
D (228, 229).  The effects of cytochalasin D on actin polymerization were confirmed by 
immunofluorescence staining of F-actin.  As expected, in the absence of cytochalasin D 
treatment, all of the F-actin filaments were along the boundaries of adjacent cells where 
they made contact with each other (Fig. 22A).  When the cells were treated with 0.625 
μM cytochalasin D, F-actin filaments were polymerized on the tips of lamellipodia/ 
filopodia instead of being expressed at cell-cell contacts.  When the cytochalasin D 
concentration was further increased to 2.5 μM or 10 μM, F-actin filaments formed 
aggregates in the cytoplasm and lamellipodia/filopodia were not present.  In parallel 
experiments, a significant decrease in CCCM HCV transfer occurred in co-culture 
treated with 0.625 μM cytochalasin D and a complete abrogation of CCCM HCV transfer 
was apparent in co-cultures treated with 2.5 μM and 10 μM cytochalasin D (Fig. 22C).  
We also performed similar experiments in the presence of the microtubule 
depolymerizing agent, nocodazole (230, 231), and determined its effects on CCCM HCV 
transfer.  As expected, nocodazole treatment disrupted the microtubule cytoskeleton in a 
dose-dependent manner as determined by α-tubulin immunofluorescence staining, 
beginning with a gradual loss of the microtubule network, followed by more diffuse  
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Figure 22.  Actin and microtubule cytoskeletons and CCCM HCV transfer.  (A-E) 
JFH1-infected Huh7.5.1 donor cells were mixed with CMFDA-labeled target Huh7.5.1 at 
a 1:1 ratio and seeded.  Two hours post-seeding, cytochalasin D or nocodazole were 
added to the cultures at the indicated concentrations and the cells were cultured for an 
additional 18 hr.  (A) Cytochalasin D-treated co-culture were stained with phalloidin-
TRITC followed by DAPI, while (B) nocodazole-treated co-culture were immunostained 
with a mouse anti-tubulin antibody followed by goat anti-mouse IgG-Alexa555, and DAPI.  
(C, D) Both cytochalasin D- and nocodazole-treated co-culture were immunostained 
against HCV core and analyzed by flow cytometry for cells that underwent CCCM HCV 
transfer.  The number of core-positive target cells within the initial 2 hr post-seeding 
period was also determined and subtracted from the 20 hr number.  (E) Cytochalasin D-
treated co-culture were labeled with APC-conjugated Annexin V followed by propidium 
iodide (PI) and analyzed by flow cytometry for cells that underwent apoptosis (Annexin 
V+/PI-).  (F) Cytochalasin D’s effect on HCV production.  Huh7.5.1 cells were infected 
with JFH1 for three days and replated into 12-well plates at close to 100% confluency.  
At 2 hr post-seeding, culture media with indicated concentrations of cytochalasin D were 
changed and maintained for 18 hr.  Supernatants were then collected and HCV RNA 
was quantified by qRT-PCR. 
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tubulin staining patterns in the cytoplasm (Fig. 22B).  However, nocodazole treatment 
did not lead to significant changes in the level of CCCM HCV transfer in parallel 
experiments (Fig. 22D).  The inhibition of CCCM HCV transfer by cytochalasin D 
treatment (Fig. 22C) was not due to cytotoxicity of cytochalasin D ((232) and Fig. 22E), 
or any adverse effects of cytochalasin D on HCV secretion from HCV-infected donor 
cells (Fig. 22F).  Therefore, these results suggest that an intact actin network, but not 
the microtubule cytoskeleton may be required for CCCM HCV transfer. 
 
1.7 Live cell imaging of the CCCM HCV transfer in Huh7.5.1 cells: from conjugate 
formation to transfer 
 
1.7.1 Construction and characterization of recombinant JFH1-c177-GFP 
To directly dissect the spatial and temporal details of CCCM HCV transfer, we attempted 
to construct a fluorescently labeled HCV clone to characterize viral transfer in live cells.  
Among the three known HCV structural proteins E1, E2, and core, we decided to insert 
GFP to core in JFH1 right after the 177 aa.  There were two reasons for the selection of 
the insertion site.  (1). A part of the HCV 5’UTR extends into the N-terminus of core; 
considering the relatively large size of GFP (~700 nt), insertion of GFP to the N terminus 
could result in replication/ translation perturbation and would very likely affect virus 
production.  Hence we decided to insert GFP to the C-terminus of core.  (2). Translated 
core is processed by signal peptidase (SP) at 191 aa (the end of the C-terminus of core, 
also the junction of core and E1) and then by signal peptide peptidase (SPP) at 177 aa 
to generate the mature core protein.  A recent study (233) showed that at least the first 
177 amino acids were required to produce infectious HCV virions in J6/JFH1 strain.  
Therefore we decided to insert GFP at the 177 aa position of core to retain the infectivity 
of the recombinant virus and to avoid the cleavage of the fusion protein by SPP.  Before 
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the insertion of GFP into JFH1, we first tested whether the c177-GFP fusion protein 
could be expressed and whether it could be packaged into virion through trans-
complementation.  We cloned the 1-177 aa of JFH1 core into the N-terminus of the 
EGFP gene in pEGFP-N3 and obtained the pC177-GFP plasmid.  We transfected 
pC177-GFP and pJcore-GFP (a plasmid encoding full length core-GFP fusion protein 
that was constructed previously in our laboratory, unpublished data) into Huh7.5.1 and 
detected the expression of core-GFP fusion protein after two days by Western blotting.  
Cells transfected with pC177-GFP showed a clear band at 45 KD, which is the C177-
GFP fusion protein, without any leaking expression of GFP or core (Fig. 23A, arrow).  In 
contrast, the pJcore-GFP-transfected cells showed only distinctive GFP and core bands, 
but no GFP-core fusion protein (Fig. 23A), very likely due to the cleavage by SP or SPP.  
Microscopic examination showed that pC177-GFP-transfected Huh7.5.1 gave bright 
GFP fluorescence in both the nucleus and the cytoplasm (Fig. 23B) and that the pattern 
of cytoplasmic fluorescence (perinuclear “bubbles”) was very similar to HCV core 
immunostaining in infected cells (presumably core accumulation on the surface of lipid 
droplets, Fig. 10A).  To test whether the fusion protein can be incorporated into HCV 
virions, we performed trans-complementation experiment by transfection of JFH1-
infected Huh7.5.1 with pC177-GFP followed by detection of HCV core in both the cell 
lysate and culture supernatant with Western blotting.  However, even though C177-GFP 
fusion protein was readily detected in cell lysate, no fusion protein could be detected in 
the culture supernatant (arrow, Fig. 24 A), suggesting that the C177-GFP fusion protein 
could not be packaged into HCV virions in infected cells.  To ascertain this result, we 
also performed spinoculation (centrifugation of cells at 1000 x g and RT for 2 hr after 
addition of virus, refer to CHAPTER 3-3.4 of the Results section for details) of Huh7.5.1 
with the above culture supernatant and measured GFP fluorescence in those cells by 
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Figure 23.  Expression of C177-GFP fusion protein.  (A) Huh7.5.1 was transfected 
with pcDNA3, pEGFP-N3, pJcore-GFP, or pC177-GFP.  At 48 hr post-transfection, cells 
were collected and immunoblotted with anti-GFP, anti-Core and anti-β-actin antibodies.  
(B) pC177-GFP-transfected Huh7.5.1 cells were examined by fluorescent microscope 
for GFP fluorescence at 48 hr post-transfection.  BF: bright field. 
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Figure 24.  No incorporation of C177-GFP into JFH1 virions by trans-
complemetation.  Huh7.5.1 was infected with JFH1 virus at MOI = 0.2.  At 48 hr post-
infection, the cells were transfected with indicated amount of pcDNA3, pEGFP-N3 or 
pC177-GFP, and cultured for another 48 hr.  Cells were collected and immunoblotted 
with anti-GFP, anti-Core and anti-β-actin antibodies (A, cell lysate).  Culture 
supernatants were also collected, removed of cell debri by low speed centrifugation at 
2000 x g for 10 min, passed through 0.22 µm filter, and either ultracentrifuged at 250,000 
x g and 4°C for 90 min and immunoblotted for core and c177-GFP fusion protein 
expression (A, supernatants), or added to Huh7.5.1 cells, spun at 1000 x g, RT for 2 hr 
(spinoculation), cultured at 37 °C for 3 hr and analyzed by flow cytometry (B).  A 
histogram overlay of the GFP fluorescence intensity in Huh7.5.1 cells spinoculated with 
different supernatants was shown. 
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flow cytometry.  But consistent with the Western blotting result, no peak shift of GFP 
fluorescence intensity was observed between the pCore177-GFP samples and the 
pEGFP control (Fig. 24 B).  
 
The reason for the unsuccessful incorporation of C177-GFP into HCV virions by trans-
complementation could be the competition from of large amounts of wide type core 
proteins expressed during the infection.  Therefore, we constructed the JFH1-c177-GFP 
recombinant clone by inserting GFP into the JFH1 genome right after 177 aa of core.  
We transfected Huh7.5.1 cells with the wide type JFH1 RNA or the JFH1-c177-GFP 
RNA and determined HCV core and GFP expression by immunostaining followed by 
microscopic imaging.  JFH1-c177-GFP-transfected cells demonstrated very faint HCV 
core staining and no GFP fluorescence (Fig. 25).  Examination of HCV replication using 
strand-specific RT-PCR showed that JFH1-c177-GFP replicated at about the same level 
as wide type JFH1 in Huh7.5.1 (unpublished data from our laboratory).  Briefly, the 
recombinant JFH1-c177-GFP replicated well, expressed viral proteins at a lower level 
than wide type JFH1, but didn’t show any GFP fluorescence in transfected cells, likely 
due to the large size of the foreign GFP protein and subsequent perturbations in viral 
protein expression. 
 
1.7.2 Construction and characterization of recombinant JFH1-TCcore 
We therefore turned to the TC tag-biarsenical dye labeling system that has been 
successfully used to label and study several viruses in live cells [reviewed in (234)], 
including HCV (66, 208).  Compared to the GFP-core fusion protein strategy, this system 
only requires insertion of a short nucleotide sequence encoding a peptide of 12 aa, 
including the tetracysteine (TC) tag (-CCxxCC-), into the viral genome without affecting 
virus translation, replication, assembly, production and infectivity (66, 208, 234).  The 
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presence of the TC tag allows the tagged HCV core protein in the cells or in HCV to be 
detected live by microscopic imaging through its covalent binding to the cell membrane-
permeable non-fluorescent biarsenical compound and its ensuing fluorophore.  We 
constructed the HCV-TC clone in the context of JFH1, subsequently referred to as JFH1-
TCcore (Fig. 26A).  We transfected Huh7.5.1 cells with an equal amount of in vitro 
transcribed full-length JFH1 RNA or JFH1-TCcore RNA and monitored HCV replication 
and production using qRT-PCR.  Compared to JFH1, JFH1-TCcore showed a slightly 
delayed viral replication (Fig. 26B) and virus production (Fig. 26C) and a 2-4 fold lower 
maximal level of virus production (Fig. 26C).  Nevertheless, labeling of JFH1-TCcore-
transfected and infected cells with the biarsenical compound did not alter the HCV-
TCcore infectivity (66).  We then determined the labeling specificity of the biarsenical 
compound (ReAsH) and the subcellular localization of the TC-tagged core protein.  
Huh7.5.1 cells were transfected with in vitro transcribed full-length JFH1 or JFH1-TCcore 
RNA and stained with ReAsH and then anti-HCV core antibody.  ReAsH only labeled 
JFH1-TCcore-transfected cells and not JFH1-transfected cells (Fig. 26D).  There 
appeared to be a complete overlap of ReAsH labeling with HCV core staining, 
confirming that ReAsH specifically bound to the TC tag and that the tag did not alter the 
subcellular localization of HCV core.  Taken together, these results demonstrated the 
feasibility of using the JFH1-TCcore and ReAsH labeling system to track HCV core in 
live cells. 
 
1.7.3 Live cell imaging of CCCM HCV transfer 
We next performed live cell imaging to track CCCM HCV transfer with the JFH1-TCcore 
system.  We infected Huh7.5.1 cells with JFH1-TCcore for 3 days and then labeled the 
cells with ReAsH.  We used these ReAsH-labeled cells as donor cells and Huh7.5.1  
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Figure 25.  GFP and core expression in JFH1-c177-GFP RNA-transfected Huh7.5.1 
cells.  Huh7.5.1 cells were transfected with JFH1 or JFH1-c177-GFP RNA.  At three 
days post-transfection, the cells were subjected to immunostaining for HCV core and 
DAPI nuclear staining. 
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Figure 26.  Characterization of recombinant JFH1-TCcore HCV.  (A) JFH1-TCcore 
recombinant HCV clone.  A TC tag-containing 12 aa peptide was inserted after the third 
amino acid of HCV JFH1 core.  (B) & (C)  Huh7.5.1 cells were transfected with an equal 
amount of in vitro transcribed full-length HCV JFH1 RNA or HCV JFH-TCcore RNA.  
Transfection medium was replaced with fresh culture medium and the cells were 
extensively washed 6 hr after transfection.  RNA was isolated from the cells and the 
culture supernatants at indicated time points and was subjected to qRT-PCR to monitor 
HCV replication in the cells (B) and HCV production in the culture supernatants (C), 
respectively.  (D) ReAsH labeling specificity of TCcore in JFH1-TCcore RNA-transfected 
Huh7.5.1 cells.  Huh7.5.1 cells were transfected with JFH1 or JFH1-TCcore RNA.  At 
three days post-transfection, the cells were first labeled with ReAsH, then 
immunostained for HCV core and DAPI nuclei staining. 
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cells stably expressing GFP (Huh7.5.1-GFP) as target cells and performed the co-
culturing assay under live confocal imaging.  Red (ReAsH)/ green (GFP) fluorescence 
and DIC images in the selected fields were taken every 18 min throughout the 18 hr co-
culturing period.  One single HCV-infected ReAsH-labeled Huh7.5.1 donor cell (labeled 
as D, Fig. 27A) had three recorded sequential transfer events (yellow arrowheads) to 
three contacted target Huh7.5.1-GFP cells (labeled as T1, T2 and T3, Fig. 27A) during 
this time period.  For each transfer event, the donor cell either accumulated large 
numbers of viral puncta on the contact surface between the donor cell and the target cell 
(D and T1, Fig. 27A i & ii) or produced lamellipodium containing viral puncta at the 
contact sites (D and T2, D and T3, Fig. 27A iii & iv) prior to the transfer.  Simultaneous 
transfer was also recorded (Fig. 27B & C).  The orthogonal view (Fig. 27B) and 3D 
reconstruction of the transfer process (Fig. 27C) confirmed that the transferred viral 
puncta were located inside the target cell, as the viral puncta were visualized as yellow 
rather than red.  3D reconstruction of the donor-target contact sites for CCCM transfer in 
Fig. 27 further revealed that besides the obvious lamellipodium seen in some cases (Fig. 
27 A iii and iv), small and unapparent lamellipodium-like structures full of viral puncta 
were also present at the donor-target contacts sites for the ongoing transfer (Fig. 28) in 
the other cases (Fig. 27A i, ii, B and C).  The sizes of the pre-transfer viral puncta were 
estimated to be approximately 0.5 µm to 2 µm, suggesting that these puncta contain 
more than one single virus.  The number of core puncta that were transferred from one 
donor cell to one target cell could reach up to 100 puncta during the 18 hr co-culturing 
period.  Tracking the transfer of one single viral punctum revealed four distinct steps in 
the CCCM HCV transfer process: donor-target cell contact, viral punctum-target cell 
conjugate formation, transfer of viral punctum, and post-transfer (Fig. 29A).  The transfer 
began with contact initiated between the donor and target cells (Fig. 29A i).  Viral puncta  
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Figure 27.  Live cell imaging of CCCM HCV transfer (I) – sequential viral transfer 
from one donor to 3 targets and concurrent viral transfer between one donor and 
two targets.  JFH1-TCcore-infected ReAsH-labeled Huh7.5.1 donor cells (red) and 
Huh7.5.1-GFP target cells (green) were co-cultured and  imaged live for 18 hr.  (A) 
Sequential viral transfer from one donor to 3 targets.  The ReAsH-positive TCcore-
positive donor cell was labeled with “D” and the three GFP-positive target cells were 
labeled with T1, T2, T3 (outlined with white dotted lines).  The ReAsH/GFP/DIC overlay 
was shown in the left panel, from which the boxed area was magnified and examined in 
the middle (ReAsH only) and the right (ReAsH/GFP overlay) panels.  HCV transfer from 
the donor cell, D, to target cells T1 (i & ii), T2 (iii), and T3 (iv) was indicated by yellow 
arrowheads.  The yellow arrow (v) indicated T3’s lamellipodium towards D after viral 
transfer. Time was shown in hr: min.  (B) Concurrent HCV transfer from one donor cell to 
two target cells.  Orthogonal views are shown and the positions of the perpendicular 
planes are indicated as notches.  (C) 3D reconstruction of a transfer event between the 
donor cell and one target cell in (B).  This transfer event occurred at a later time than 
that shown in (B).   
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Figure 28.  Live cell imaging of CCCM HCV transfer (II) – lamellipodium-like  
structures at the donor-target contact sites during CCCM transfer.  The donor-
target contact sites of CCCM transfer (boxed area in the left column) in Fig. 27A i (i), ii 
(ii), B (iii) and C (iv) were converted into 3D images (right three columns).  
Lamellipodium-like structures were circled with white dotted lines.   
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Figure 29.  Live cell imaging of CCCM HCV transfer (III) – a four-step process.  The 
same co-culturing experiment as in Fig. 27 and 28 was performed.  (A) Transfer of a 
viral punctum (circled in the lower panel) into a target cell: (i) donor cell-target cell in 
contact before conjugate formation, (ii) formation of viral punctum-target cell conjugation, 
(iii) transfer of the viral punctum, and (iv) post-transfer.  The lower panel is a 3D 
reconstruction of the boxed area in the corresponding upper panel.  (B) Tracking of 
transfer events in 13 donor cells in one imaging field; each line represents one donor-
target pair. 
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were formed within the donor cell and transitioned to the contact site between the donor 
and the target cells (Fig. 29A i).  This was followed by the formation of viral punctum-
target cell conjugate (Fig. 29A ii).  The transfer took place when the viral punctum was 
localized in the target cell (Fig. 29A iii).  The viral punctum likely dissipated into a few 
smaller puncta in the target cell (Fig. 29A iv), and presumably disappeared as viral 
uncoating took place.  A single transfer event was estimated to take approximately 18 
min to complete.  To further understand the transfer process, we analyzed the transfer 
events in the entire tracked field (450 µm x 450 µm).  There were a total of 33 ReAsH 
positive donor cells and 160 Huh7.5.1-GFP target cells in the field at the beginning of 
tracking (t = 0).  During the 18 hr of tracking, 13 cells (13/33 = 39%) formed conjugates 
with target cells, 7 donor cells showed transfer (7/33 = 21%) and a total of 8 transfer 
events occurred (Fig. 29B).  Each of these processes was confirmed with 3-dimensional 
reconstruction, as shown in Fig. 27 B & C.  The average time duration of viral puncta-
target cell conjugation between a donor cell and a target cell was calculated to be 408 
min; and the average time for the actual transfer was calculated to be 171 min.  The 
latter was much longer than the 18 min time for a single transfer event as estimated 
above; this is because there were more than one viral puncta transferred between one 
donor cell and one target cell.  Taken together, these results provide the temporal and 
spatial details of CCCM HCV transfer and demonstrate the high efficiency of this 
transmission route. 
 
1.8 CCCM transfer and productive HCV infection 
 
1.8.1 Strategy I: Extended co-culture assay with neutralizing antibodies 
To determine whether CCCM HCV transfer leads to productive HCV infection, we took 
advantage of a neutralizing HCV antibody CBH-5 that has been shown to be very 
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effective in blocking free HCV infection (235, 236).  We first confirmed that CBH-5 
neutralized free HCV infectivity in the supernatant from co-culture assay by over 99% at 
a concentration of 5 µg/ml while CCCM HCV transfer were not affected by it (Fig. 30).  
We then performed the above-mentioned co-culture HCV transfer assay in the presence 
of 5 µg/ml CBH-5 or a control isotope-matched R04 antibody (235, 236) and determined 
the percentage of HCV core-positive target cells at 24, 48 and 72 hr of co-culturing. The 
percentage of HCV core-positive target cells increased over time (Fig. 31A & B).  
Compared to the control R04, CBH-5 showed a slightly lower but still significant 
percentage of HCV core-positive cells and significant increases in the percentage of 
HCV core-positive cells over time.  In addition, the mean fluorescence intensity of the 
core-positive cells exhibited increases over time in both R4 and CBH-5 treated co-
cultures (Fig. 31C).  Increases in the percentage and the mean fluorescence intensity of 
HCV core-positive target cells over an extended period of time in the presence of the 
neutralizing HCV antibody CBH-5 suggest that CCCM HCV transfer leads to productive 
HCV infection and replication.  Culture supernatants were collected from co-cultures that 
were treated with each of the antibodies and tested for their infectivity.  Very few HCV 
core-positive cells were detected with CBH-5-treated culture supernatants at each time 
point (Fig. 31D), confirming the HCV neutralizing capacity of the CBH-5 antibody.  
 
1.8.2 Strategy II: FACS sorting of newly CCCM transferred target cells and continued 
culturing 
To ascertain the productive nature of CCCM HCV transfer, we set up CCCM HCV 
transfer using stable GFP-expressing Huh7.5.1 as the target cells in the co-culture 
experiments.  Following the initial 20 hr co-culturing in the presence of 5 µg/ml CBH-5 
antibody, we used FACS to sort out the GFP-positive target cells and then monitored  
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Figure 30.  Neutralization of cell-free HCV infectivity with CBH-5 in the co-culture 
assay.  Huh7.5.1 cells were infected with JFH1 virus at MOI = 1 and cultured for 3 days.  
Co-culture of the infected Huh7.5.1 donor cells and Huh7.5.1-GFP target cells were 
performed at 1:1 D: T ratio for 20 hr with the presence of culture media (Mock), 10 µg/ml 
R04 (isotype control antibody) or different concentrations of nAb CBH-5.  Both the cells 
and supernatants were collected at the end of the co-culture.  The cells were 
immunostained for HCV core and analyzed by flow cytometry for core-positive target 
cells (the amount of CCCM transfer, left Y axis, bar graph).  The supernatants containing 
both nAbs and cell-free HCV viruses released from the infected cells during the co-
culture were tested for cell-free virus infectivity by inoculating naïve Huh7.5.1 cells for 
three days and then core immunostaining followed by flow cytometry for core-positive 
cells (right Y axis, solid line). 
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Figure 31.  CCCM HCV transfer leads to productive HCV infection (strategy I).  
Infected Huh7.5.1 cells were co-cultured with GFP-expressing Huh7.5.1 cells at 1: 4 
ratio in the presence of 5 µg/ml neutralizing antibody CBH-5 or a control antibody R04. 
The co-culture was replated every 24 hr and fresh antibodies were added.  Meanwhile, 
aliquot of cells were collected for core staining followed by flow cytometry analysis for 
GFP+ and core-positive cells (A-C); the supernatants were collected and assayed for 
their infectivity by inoculating uninfected Huh7.5.1 and core immunostaining after three 
days for percentage of infected cells by flow cytometry. (D).  (A) Representative kinetics 
of GFP+ and core+ cells; (B) data from multiple repeats; (C) the difference in mean 
fluorescence intensity (dMFI) of core staining in GFP+ cells from multiple repeats. 
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HCV replication in these sorted cells.  The FACS yielded more than 97% GFP-positive 
cells, of which about 2% were HCV core-positive cells (Fig. 32 A & B).  Similarly, the 
percentage of HCV core-positive and GFP-positive cells showed increases over an 
extended period of time up to 7 days.  In parallel, there was a significant increase of 
HCV RNA in these cells between day 4 and day 7 (Fig. 32C) and the infectivity of the 
culture supernatants between day 4 and day 7 (Fig. 32D).  These results confirmed HCV 
RNA replication in, and infectious virus production from the target cells following CCCM 
HCV transfer. 
 
1.8.3 Strategy III: Selective elimination of donor cells and continued culturing of target 
cells 
To further validate the productive HCV infection after CCCM transfer, we performed one 
day co-culturing of the infected Huh7.5.1 donor and the G418- resistant Huh7.5.1-GFP 
target cells followed by a six-day G418 killing of donor cells (total 7 days) to obtain pure 
target cell culture.  Five microgram per milliliter CBH-5 was present throughout the co-
culturing and the G418 killing to ensure that only CCCM, but not cell-free HCV infection 
took place.  Complete killing of donor cells was confirmed by monitoring the percentage 
of GFP-positive cells in the culture (Fig. 33A), which reached 95% at D7, the same as 
that in Huh7.5.1-GFP cells (the “GFP only” bar).  Similarly to the previous two strategies, 
continued culturing of the G418-selected target cells showed an increase of the 
percentage of HCV infected cells from D7 to D9 (Fig. 33 B & C).  The percentage of 
infected target cells was still very high at D11 but slightly decreased compared to that at 
D9, likely due to high level of infection and ensuing cytopathic effects observed after D9.  
In parallel, large amounts of HCV virus production in the culture supernatants from D8 to 
D11 was confirmed (Fig. 33D).  Taken together, results from all of the three strategies 
support the notion that CCCM HCV transfer leads to productive infection and replication. 
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Figure 32.  CCCM HCV transfer leads to productive HCV infection (strategy II).  
Infected Huh7.5.1 cells were co-cultured with GFP-expressing Huh7.5.1 cells at 1: 4 
ratio in the presence of 5 µg/ml neutralizing antibody CBH-5.  GFP+ target cells were 
sorted out from day one (D1) of co-culturing and further cultivated for an extended period 
of time.  Core+ cells in the purified GFP+ cell population were determined at day 4 (D4) 
and 7 (D7) by core immunostaining.  (A) Representative kinetics of GFP+ and core+ 
cells; (B) data from multiple repeats.  D1#: co-cultured cells prior to sorting.  Cells and 
their culture supernatants were also collected at D4 and D7 and assayed for HCV RNA 
in the cell by qRT-PCR (C) or infectivity in the supernatant (D) as described in Fig. 29D, 
respectively.   
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Figure 33.  CCCM HCV transfer leads to productive HCV infection (strategy III).  
Co-culturing of infected Huh7.5.1 donor cells with G418-resistant Huh7.5.1-GFP target 
cells was performed at 1: 4 donor: target ratio for one day with the presence of 5 µg/ml 
of the neutralizing antibody CBH-5.  The co-culture was then treated with 750 µg/ml 
G418 and 5 µg/ml CBH-5 for six days to selectively kill the donor cells and obtain pure 
culture of target cells.  (A) G418 killing efficiency in the co-culture was monitored by 
percentage of GFP + cells with flow cytometry (white bar) and killing of a control mixed-
culture consisting of uninfected cells and Huh7.5.1-GFP cells was also monitored (grey 
bar).  (B-D) D7 culture consisting of pure target cells were further cultivated under 200 
µg/ml G418 for four days.  Cells were collected every other day and immunostained 
against core for percentage of newly infected target cells (representative dot plot in B 
and triplicated results in C, D1 co-culture before killing was also included).  Supernatants 
were collected every day and HCV RNA was measured by qRT-PCR (D).  Numbers in B 
represent the percentage of cells in the upper right quadrat (newly infected target) out of 
total cells.   
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CHAPTER 2: Exosome-Associated Hepatitis C Virus and Its Infectivity 
 
2.1 HCV infection did not alter exosome secretion in hepatocytes 
To understand the relationships between HCV and exosomes, we first determined 
whether HCV infection affected exosome secretion.   Huh7.5.1 cells were infected with 
HCV JFH1 exosome secretion in the culture supernatants was monitored.  HCV infection 
was confirmed by immunoblotting for HCV core expression in the cells (Fig. 34A).  
Exsosome secretion was determined by measuring the activity of acetylcholinesterase 
(AchE), an exosome marker (106, 218).  There was no difference of exosome secretion 
between HCV-infected cells and Mock-infected control cells within 60 hours post HCV 
infection (Fig. 34B).  We next determined whether HCV infection affected the size 
distribution of exosomes using iodixanol (Optiprep) density gradient ultracentrifugation. 
Concentrated exosomes were prepared from the culture supernatants of Mock- or HCV-
infected Huh7.5.1 cells and then fractionated through a 6-18% iodixanol density gradient 
by ultracentrifugation (218).  The AchE activity assay of each fraction showed similar 
distribution patterns of exosomes from Mock- and HCV-infected cells, which peaks at 
fractions 2-4 (Fig. 35).  Taken together, these results indicate that HCV infection does 
not result in significant changes in exosome secretion from hepatocytes. 
 
2.2 Association of HCV with exosomes 
 
2.2.1 Optimization of iodixanol concentration for fractionation of HCV 
Considering the heterogeneous nature of the exosomes, the findings that HCV infection 
does not affect the overall exosome size distribution does not necessarily rule out the 
possibility that HCV is associated with exosomes.  To address this possibility, we  
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Figure 34.  HCV infection does not affect exosome production.  Huh7.5.1 cells were 
infected with HCV for 2 hr, removed of unbound viruses, extensively washed with PBS, 
and then added with complete culture medium.  Conditioned medium (Mock) was used 
as a control.  The complete culture medium was changed to bovine exosome-depleted 
medium at 2, 10, 20 and 40 hr post- infection and cells and supernatants were collected 
at 10, 20, 40 and 60 hr post- infection, respectively.  The cells were lysed and 
immunoblotted for HCV core and β-actin (the loading control) (A).  The supernatants 
were analyzed by AchE assay (B) for exosome production.  AchE activities in culture 
supernatants (B) were normalized to the total cellular protein in panel A.   
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Figure 35.  HCV infection does not affect exosome size distribution.  Huh7.5.1 cells 
were infected with HCV or conditioned medium (Mock) for 72 hr and the culture medium 
was changed to bovine exosome-depleted medium and kept for another 24 hr.  The 
culture supernatants were then collected, removed of cell debris by centrifugation at 
3000 x g for 10 min, passed through a 0.22 m filter, and concentrated by 
ultracentrifugation at 250,000 x g and 4°C for 90 min.  The pellet was suspended in 500 
µl PBS, loaded onto a 5 ml 6-18% iodixanol gradient and fractionated by 
ultracentrifugation at 250,000 x g and 4°C for 90 min in a SW55Ti rotor.  Twelve 450 µl 
fractions were collected from top to bottom of the gradient; 15 µl of each fraction was 
used for AchE assay. 
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performed the similar ultracentrifugal fractionation as above but detected both exosome 
and HCV.  However, the gradient centrifugation conditions above were originally 
designed for exosome detection only.  Therefore, we first optimized the concentration of 
the iodixanol gradient to accommodate the density range of HCV in addition to that of 
exosome.  Culture supernatants from HCV-infected Huh7.5.1 cells were concentrated 
and fractionated as above through a 6-18% iodixanol gradient and Western blotting 
against HCV core showed only the first half of a complete peak (Fig. 36 upper panel).  
We then increased the concentration of iodixanol gradient to 6-20% and still found an 
incomplete peak of HCV core (Fig. 36 middle panel).  Lastly we found the iodixanol 
concentration of 6-24% able to accommodate HCV virions of all different sizes/densities 
(Fig. 36 lower panel); a 6-24% iodixanol gradient was used for further experiments. 
 
2.2.2 Detection of HCVcc/patient plasma-derived HCV in exosome-containing fractions   
With the optimized protocol, we performed the fractionation of Huh7.5.1-derived 
exosomes and HCV, determined AchE activity in each fraction, isolated RNA from each 
fraction and determined HCV RNA level in each fraction using qRT-PCR.  Similarly, the 
AchE activity assay showed exosomes in fraction 2-4 (open bars, Fig. 37A).  In 
comparison, qRT-PCR analysis exhibited two peaks of HCV RNA (line graph, Fig. 37A): 
a major peak at fraction 7-10 and a minor one at fraction 2-4 that coincided with the 
exosome fractions.  The exosome fractions were further confirmed by Western blotting 
using antibodies against two other exosome markers Hsp70 and CD63 (upper two 
panels, Fig. 37B).  Consistent with the qRT-PCR results of HCV RNA, Western blotting 
using antibodies against HCV proteins E2 and core showed two peaks: one in fraction 2-
4 and another in fraction 7-10 (lower panels, Fig. 37B).  The size difference of E2 in 
exosome-associated HCV (fraction 2-4) and exosome-free HCV (fraction 7-10) could be  
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Figure 36.  Optimization of iodixanol concentration for HCV fractionation.  
Huh7.5.1 cells were infected with HCV; the culture supernatants were collected, purified 
and concentrated as described in Fig. 35.  The resulting pellet was suspended in 500 µl 
PBS and fractionated on 5 ml 6-18% (the upper panel), 6-20% (the middle panel), or 6-
24% (the lower panel) iodixanol gradient with the SW55Ti rotor.  Twelve 450 µl fractions 
(the upper panel) or eleven 500 µl fractions (middle and lower panels) were collected 
from top to bottom of the gradient and each fraction was immunoblotted for HCV core. 
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Figure 37.  Detection of HCV in exosome-containing fractions.  Huh7.5.1 cells were 
infected with HCV; the culture supernatants were produced and processed as described 
in Fig. 35 except that a 6-24% iodiaxanol gradient was used instead of 6-18% iodixanol 
and that the ultracentrifugation fractionation was performed for 2 hr instead of 90 min.  
Besides the AchE activity (A, open bar), RNA was extracted from each fraction and used 
for qRT-PCR for HCV RNA (A, line, vge: viral genome equivalent).  Meanwhile, the 
fractions were subjected to Western blotting using anti-Hsp70, CD63, HCV E2, or core 
antibody (B).  Please note that there were a total of 11 fractions collected with each 500 
µl, while there were 12 fraction collected with each 450 µl in Fig. 35.  The data were 
representative of multiple independent experiments. 
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due to several reasons (see Discussion below for details); the reason for two HCV peaks 
and only one HCV core peak in Fig. 36 is that the total volume of culture supernatant 
was increased from 30 ml to 120 ml.  To confirm the co-fractionation of HCV and 
exosomes is not related to the method used for concentration or the rotor used for 
fractionation, we performed similar experiments but with PEG 8000 exosome/HCV 
precipitation (Fig. 38) or using the vertical rotor NVT65 for gradient ultracentrifuge (Fig. 
39) and obtained similar results.  Exosome-associated HCV was also detected in HCV-
positive patient plasma (Fig. 40).  It is interesting to point out that 3-20 fold more HCV 
RNA was detected in exosome-associated viruses than exosome-free viruses (Fig. 40C), 
suggesting that more HCV virions occur in the exosome-associated forms in patient 
plasma. Taken together, these results demonstrated that both HCV RNA and viral 
structural proteins core and E2 were detected in exosome fractions of cell culture 
produced HCV and suggest the presence of a subpopulation of exosome-associated 
HCV.  
 
2.3 Exosome-associated HCV was infectious 
To determine whether exosome-associated HCV was infectious, we performed the focus 
formation assay using each fraction obtained from gradient ultracentrifugation.  Infection 
of Huh7.5.1 cells with both exosome-associated HCV fractions (fraction 2-4, Fig. 41) and 
exosome-free HCV fractions (fraction 7-10, Fig. 41) led to the formation of infection foci.  
The peak specific infectivity, expressed in foci formation units per viral genome 
equivalent (FFU/vge), of the former was estimated to be about 10 fold lower than that of 
the latter.  These results showed that exosome-associated HCV was infectious but less 
effective than exosome-free HCV.   
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Figure 38.  Detection of HCV in exosome-containing fractions with PEG 
exosome/HCV precipitation.  Huh7.5.1-derived HCV and exosomes were produced, 
purified, concentrated, and fractionated as described in Fig. 37 except that 
HCV/exosomes were concentrated by PEG precipitation instead of ultracentrifugation, 
i.e. overnight incubation with 1/4 vol. of PEG 8000 at 4°C followed by centrifugation at 
3500 x g and 4oC for 30 min.  The collected fractions were assayed for AchE activity 
(open bars) or HCV RNA by qRT-PCR (line graph). 
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Figure 39.  Detection of HCV in exosome-containing fractions using the NVT65 
rotor for gradient centrifugation.  Huh7.5.1-derived HCV and exosomes were 
produced, purified and concentrated as described in Fig. 37.  The resulting 
HCV/exosomes pellet was suspended in 1 ml PBS and fractionated on a 10 ml 6-24% 
iodixanol gradient at 250,000 x g and 4°C for 60 min with the NVT65 rotor.  Eleven 1 ml 
fractions were collected from top to the bottom of the gradient; each fraction was 
assayed for AchE activity (A, open bars), HCV RNA by qRT-PCR (A, line graph), or 
exosome marker Hsp70, and HCV core by Western blotting (B). 
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Figure 40.  Exosome-associated HCV in HCV-positive patient plasma.  Plasma from 
chronic hepatitis C patients (140 µl each from five patients P1, P2, P3, P4, and P5) were 
diluted with PBS to 500 µl and fractionated on a 6-24% iodixanol gradient as described 
above.  An aliquot of each fraction was used for AchE assay (A, data were fit to 
Gaussian distribution).  Then the fractions containing the exosomes (F1-F4) were pooled 
(exosome-associated HCV  –  E+H), while the fractions free of exosomes (F7-10) were 
pooled (exosome-free HCV  –  H).  These pooled samples were used for AchE assay (B) 
or RNA isolation followed by qRT-PCR for HCV RNA (C).  
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Figure 41.   The infectivity of exosome-associated HCV.  Huh7.5.1 were infected with 
HCV, the culture supernatants were produced, processed and fractionated as described 
above.  An aliquot of each fraction was assayed for HCV infectivity by serial dilution 
followed by foci formation assay (open bars) and qRT-PCR for HCV RNA.  The 
infectivity was expressed as the specific infectivity, i.e., foci-forming units (FFU) per viral 
genome equivalent (vge). 
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CHAPTER 3: Hepatitis C Virus (HCV) Interaction with Astrocytes: Non-productive 
Infection and Induction of IL-18 
 
3.1 Establishment of human fetal brain primary cell cultures  
Human fetal brain primary cells cultures have been widely used as a surrogate model 
system to study interaction of human brain cells with various pathogens and external 
insults (209, 237-239).  Thus, we began by establishing these cultures in the laboratory.  
Briefly, aborted human fetus cortex of 12-20 weeks old was obtained from Advanced 
Bioscience Resources Inc (Alameda, CA) and used to prepare single cell suspension.  
Cells were then cultured in either primary neuron medium or DMEM, which gave rise to 
neuron only cultures or neuron/astrocyte mixed cultures, respectively.  
Immunofluorescence staining with neuron marker microtubule-associated protein 2 
(MAP-2) and astrocyte marker glial fibrillary acidic protein (GFAP) showed that more 
than 99% cells in the primary neuron cultures were neurons (Fig. 42, the upper panel), 
and that the mixed cultures had both neurons and astrocytes with about 50% of each 
cells(Fig. 42 the middle panel).  Continuous passing of the mixed cultures gave rise to 
more astrocytes, e.g., 95% astrocytes at passage 4 (Fig. 42 lower panels).  Therefore 
these primary human astrocytes (PHA) between passage 4 and 10 were used 
throughout this study.   
 
3.2 Few astrocytes are infected by cell-free or CCCM HCV infection 
To determine whether astrocytes are susceptible to HCV infection, we infected PHA with 
newly established cell culture-produced infectious JFH1 (HCVcc) and monitored the 
level of intracellular HCV RNA over 72 hr.  qRT-PCR showed that HCV RNA increased 
by about 1000 fold in HCV-susceptible Huh7.5.1 cells over 72 hr, while there was little  
 
  
 
 
 
 
 
 
 
 
160 
 
161 
 
 
 
 
 
 
 
 
 
Figure 42.  Human fetal brain primary cell cultures.  Primary neurons (upper panels), 
mixed brain cell culture (middle panels), and primary human astrocytes (PHA, p4: 
passage 4, lower panels) were immunostained with normal IgG control, antibodies 
against the neuron marker MAP-2 (green), or the astrocyte marker GFAP (green).  DAPI 
counterstaining (blue) was performed for nuclei; all images at 100X.   
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changes in HCV RNA in PHA (Fig. 43A).  It is interesting to note that with the same 
amount of input virus inoculum, there was about 5 fold less HCV RNA detected in PHA 
than that in Huh7.5.1 at 2 hr post- infection (Fig. 43A).  Consistent with the qRT-PCR 
results, immunostaining showed many HCV proteins core+/E2+ Huh7.5.1 cells but fewer 
HCV core+/HCV E2+ PHA at 72 hr post-infection (Fig. 43B).  These results suggest that 
PHA are refractory to HCV infection, probably due to inefficient binding and/or entry into 
these cells. 
 
Cell-cell contact-mediated HCV transfer has been shown to be an important route of 
HCV infection and transmission [CHAPTER 1 and (98, 211)].  Thus, we next examined 
whether cell-cell contact would lead to HCV infection of PHA.  HCV-infected infiltrating T 
cells monocytes/macrophages have been stipulated to be the likely virus carriers into the 
CNS and the initial sources of HCV for astrocyte infection in vivo; these cells should be 
used in the cell-cell contact experiments.  However, great difficulties have been 
experienced in establishing HCV infection in these cells using both HCVcc and HCV-
positive patient sera [our own unpublished data and (181)].  As a proof-of-concept 
experiment, we used HCVcc-infected Huh7.5.1 that were labeled with the green CMFDA 
dye as donor cells and unlabeled PHA as target cells and performed cell-cell contact 
HCV transfer experiment as described in CHAPTER 1.  Unlabeled Huh7.5.1 cells were 
included as the positive control for cell-cell contact-mediated HCV transfer.  
Immunostaining of HCV core of the mixed cells followed by flow cytometry analysis 
showed more than 45% core+/CMFDA- Huh7.5.1 cells, representative of both CCCM 
HCV transfer and cell-free HCV infection but only a background level of core+/CMFDA- 
PHA at 48 hr post co-culture (Fig. 44).  These results suggest that PHA are not also 
susceptible to cell-cell contact-mediated HCV transfer and infection.  
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Figure 43.  HCVcc does not infect astrocytes by cell-free virus infection.  (A) PHA 
and Huh7.5.1 were infected with HCVcc (Input) for 2 hr, removed of unbound viruses, 
extensively washed with PBS, and then harvested, or allowed to culture for 72 hr and 
then harvested for total RNA isolation, followed by qRT-PCR for the HCV RNA level.  
vge: viral genome equivalents.  (B) PHA and Huh7.5.1 were infected with HCVcc 
(HCVcc) as in panel A.  Conditioned medium (Mock) was used as a control.  Cells were 
fixed 72 hr post-infection and immunostained against HCV core (green) and E2 (red).  
DAPI counterstaining (blue) was performed for nuclei.  Micrographs were taken at 100X. 
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Figure 44.  Cell-cell contact does not lead to HCV infection of astrocytes.  HCV-
infected Huh7.5.1 cells were labeled with 1.25 μM CMFDA and then used as donor cells 
to incubate with target cells –  uninfected Huh7.5.1 or PHA –  at a 1:1 ratio for 48 hr.  The 
mixed cells were then immunostained for HCV core and analyzed for the percentage of 
newly infected target cells in the mixed population, i.e., Core+CMFDA- cells (upper left 
quadrant) by flow cytometry.  A. A representative dot plot; B. Aggregate data from three 
independent experiments.  
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3.3 HCV receptors expression on primary astrocytes 
To assess the specific step(s) in HCV life cycle at which HCV infection of PHA is 
restricted, we began with HCV binding to cellular receptors (15).  We determined the 
expression of all four known HCV receptors in PHA: CD81(25), scavenger receptor class 
B type I (SR-B1) (27), claudin-1 (CLDN1) (28) and occluding (OCLN) (29).  Different 
detection methods were used based on the availability of specific antibodies.  Surface 
labeling with α-CD81 antibody showed that CD81 was expressed on the surface of 50% 
PHA and at a very high level (Fig. 45A & B).  Immunoblotting showed that SR-B1, 
CLDN1 and OCLN were all expressed in PHA but at a much lower level compared to 
Huh7.5.1 (Fig. 45C).  Immunostaining followed by microscopic imaging showed that 
expression of SR-BI, CLDN1 and OCLN in PHA exhibited a diffused pattern in the 
cytoplasm, whereas expression of these receptors in Huh7.5.1 exhibited different 
subcellular localizations: mostly cytoplasmic for SR-B1, both cytoplasmic and on the 
plasma membrane for CLDN1, and mostly on the plasma membrane for OCLN (Fig. 
45D, 14C, 15C). 
 
3.4 Insignificant HCV entry into astrocytes 
 
3.4.1 HCVpp infection and spinoculation of brain cells 
To directly assess whether PHA are susceptible to HCV entry, we utilized the single-
round pseudotyped HCVpp strategy (refer to the Introduction section, Fig. 3A, for 
details).  Briefly, HCVpp is composed of an envelope (replication)-defective, reporter 
gene (Luc or GFP)-expressing HIV core and a functional HCV envelope; it allows single-
round infection, so HCV glycoproteins-mediated cell entry can be accurately determined  
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Figure 45.  Expression of HCV receptors on astrocytes.  CD81 expression in PHA 
was determined by cell surface labeling with α-CD81 antibody followed by flow cytometry 
analysis for the percentage of CD81-positive cells (red line, A) and the mean 
fluorescence intensity of CD81 staining (dMFI, B).  An isotype-matched IgG was 
included as a control (black line, A). SR-B1, CLDN1, and OCLN expression were 
determined by Western blotting (C) and immunofluorescence staining followed by 
microscopic imaging (D).  Huh7.5.1 and 293T cells were included as controls (A-D).  β-
actin loading control was included for Western blotting (C) and an isotype-matched 
staining control was included for flow cytometry (A & B) and immunofluorescence 
staining (D).  Images were taken at 100X; DAPI staining was performed for nuclei (blue, 
D). 
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using the luciferase or GFP reporter gene assay.  Env-pp containing no envelope protein 
and VSVpp containing VSV-G envelope were included as the negative and positive 
control, respectively.  HIV-Luc was first used to determine HCV entry into PHA.   
Compared to Env-pp, HCVpp infection led to significantly higher luciferase activity in 
Huh7.5.1 cells, but little changes in PHA (Fig. 46A).  It is interesting to note that unlike 
Huh7.5.1 cells, the luciferase activity in both Env-pp- and HCVpp-infected PHA were 5 
fold higher than Mock-infected PHA.  This is likely a result of, envelope-independent 
uptake, e.g., nonspecific endocytosis of viral particles by PHA.  To determine whether 
enhanced binding would lead to increase in the viral entry, we performed the infection 
using spinoculation, a well-established strategy to enhance the binding of virus particles 
to cellular receptors and thereby more viral entry (240).  Similar patterns of data on viral 
entry were obtained except that a generally higher level of the luciferase reporter gene 
activity was detected in Env-pp- and HCVpp-infected Huh7.5.1 and PHA (Fig. 46B).  
Human astrocytoma U373, human neuroblastoma SH-SY5Y, and the primary human 
fetal brain culture were also included in the spinoculation experiments, but none of these 
cells showed significant HCVpp entry (Fig. 46B).   
 
In addition, we also used the HIV-GFP reporter virus system to infect Huh7.5.1 and PHA 
and determined HCV entry by fluorescence microscopic imaging or flow cytometry for 
GFP expression.  GFP expression was detected in both HCVpp and VSVpp-infected 
Huh7.5.1 cells (Fig. 47A).   In contrast, GFP expression was only detected in VSVpp-
infected PHA through normal inoculation as well as through spinoculation (Fig. 47B).  
Use of flow cytometry for GFP expression in PHA was due to strong autofluorescence 
associated with PHA, which made it difficult to discern weak GFP-expressing PHA from 
autofluorescent PHA by fluorescence microscopic imaging.  Taken together, HCV 
envelope-mediated HCVpp entry into PHA appears to be minimal. 
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Figure 46.  Insignificant HCVpp (Luc) entry into astrocytes.  293T cells were 
transfected with HIV-Luc reporter alone (Env-pp), or in combination with HCV 
Con1E1/E2 env (HCVpp), or VSV-G env (VSVpp).  The supernatants were collected 48 
hr post-transfection and used to infect target cells by incubation at 37o for 2 hr (Normal 
inoculation, A) or through centrifugation at 1000 g, room temperature for 2 hr 
(Spinoculation, B).  The cells were allowed to culture for 72 hr before harvest for 
luciferase activity assay.  Mixed culture: primary human mixed brain cell culture; LUC: 
the luciferase activity.  Conditioned medium (Mock) was included as a negative control 
as well.  All pseudotyped reporter viruses were quantitated by reverse transcriptase 
assay, and 200,000 cpm reverse transcriptase activity-equivalent Env-pp and HCVpp 
and 2000 cpm reverse transcriptase activity-equivalent VSVpp were used in all the 
infections. 
  
    
 
 
 
 
   
 
 
   
 
173 
 
174 
 
 
 
 
 
 
 
 
Figure 47.  Insignificant HCVpp (GFP) entry into astrocytes.   Huh7.5.1 and PHA 
were infected as described above in Fig. 46 except for that HIV-GFP reporter was used 
and that virus entry was assessed based on GFP expression by microscopic imaging (A, 
Huh7.5.1 spinoculation, images at 16X) or flow cytometry (B, PHA normal inoculation 
and spinoculation).  Conditioned medium (Mock) was included as a negative control as 
well.  All pseudotyped reporter viruses were quantitated by reverse transcriptase assay, 
and 200,000 cpm reverse transcriptase activity-equivalent Env-pp and HCVpp and 2000 
cpm reverse transcriptase activity-equivalent VSVpp were used in all the infections.
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3.4.2 Unsuccessful VSV-G pseudotyping of HCVcc 
To bypass viral entry and study the downstream steps of HCV life cycle in astrocytes, we 
attempted to pseudotype the JFH1 HCVcc virus with VSV-G by trans-complementation.  
We first infected Huh7.5.1 with JFH1 virus and then transfected these cells with VSV-G; 
it was expected that the culture supernatants contain both wide type HCV virus and HCV 
virus coated with VSV-G protein (VSV-G-HCVpp).  However, western blotting of HCV 
core and VSV-G demonstrated that albeit VSV-G expression in the transfected cells, no 
VSV-G pseudotyped HCV could be detected in the supernatant (Fig. 48A).  To ensure 
that the undetectable VSV-G in the supernatant was not due to the relatively low 
sensitivity of western blotting, we also determined and compared the infectivity of 
supernatants collected from pcDNA3-transfected, HCV infected cells (containing only 
HCV) and that from different amount of VSV-G plasmid-transfected, HCV infected cells 
(containing HCV and presumably VSV-G-HCVpp).  No difference in the infectivity of 
these supernatants was found by HCV core immunostaining of the infected cells (Fig. 
48B) or quantification of HCV RNA in the infected cells (Fig. 48C).  The unsuccessful 
pseudotyping of JFH1 with VSV-G could be due to competition from wide type HCV 
envelope proteins and/or lower incorporation efficiency of VSV-G (241).   
 
3.5 HCV RNA translation in astrocytes and its enhancement by miR122 
Immediately following virus entry and uncoating, HCV RNA translation takes place and 
virus proteins are synthesized (15).  Therefore, we next examined whether PHA would 
support HCV RNA translation.  We utilized a bicistronic HCV-Rluc subgenomic replicon 
that has been widely used in the study of HCV translation and replication (163).  In HCV-
Rluc, the HCV structural proteins downstream of HCV IRES are replaced with the renilla 
luciferase reporter gene, so the translation of Rluc is under the control of HCV IRES.  
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Figure 48.  VSV-G pseudotyping of HCVcc.  Huh7.5.1 was infected with HCV JFH1 
virus for 3 days and then transfected with 0 (JFH1), 1 (VSV-G-JFH1-1), 2 (VSV-G-JFH1-
2), or 8 (VSV-G-JFH1-8) µg of the VSV-G-encoding pHCMV-G plasmid.  At 72 hr post-
transfection, cells were collected and lysed and cell lysates were immunoblotted for 
VSV-G, HCV Core and β-actin (A, cell); culture supernatants were also collected and 
subjected to centrifugation concentration followed by Western blotting (A, sup).  
Meanwhile, the culture supernatants were tested for infectivity by inoculating naïve 
Huh7.5.1 for 2 hr and collecting cells at 48 hr followed by HCV core immunostaining and 
flow cytometry analysis for the percentage of core + cells (B).  Alternatively, the 
infectivity of the supernatants were determined by Huh7.5.1 inoculation and cell 
collection at 4, 24, and 48 hr post-inoculation, and RNA isolation followed by qRT-PCR 
analysis of HCV RNA (C).  Only 0 and 1µg pHCMV-G plasmid-transfected cells and 
supernatants were included in A and B.  HCV RNA in the culture supernatants were also 
quantified and included as “input” in C. 
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Meanwhile, the encephalomyocarditis virus (EMCV) IRES is inserted upstream of HCV 
nonstructural proteins, translation of these proteins is under the control of ECMV IRES 
(Fig. 49A).  We transfected the cells with the HCV-Rluc RNA and determined the 
luciferase activity of cells 6 hr post-transfection, which was used as an indicator of HCV 
IRES-mediated translation.  A significant level of the luciferase activity was detected in 
all cells tested including PHA, although all cells had lower luciferase activities than 
Huh7.5.1 (Fig. 49B). 
 
Several studies have recently shown that the expression of a liver-specific microRNA, 
miR122, is crucial for stimulation of HCV RNA translation in different non-hepatic cells 
(42-44).  We compared constitutive miR122 expression in PHA with Huh7.5.1 and other 
cells.  PHA, 293T and U373 all had extremely low miR122 expression, which were about 
106 fold lower than that in Huh7.5.1 and 104 fold lower than that in HepG2 (Fig. 49C).  
We then determined whether increased miR122 expression would lead to further 
improvement in HCV IRES-mediated translation in PHA.  Exogenous miR122 was 
introduced to PHA by transfection (Fig. 49D); its expression led to increases in the 
luciferase activity (Fig. 49E).  Taken together, the results show that HCV IRES-mediated 
RNA translation is supported in PHA and can be further enhanced by exogenous 
miR122 expression. 
 
3.6 HCV replication in astrocytes and the effect of miR122 
In addition to HCV translation stimulation, miR122 is also suggested to positively 
regulate HCV infection by stabilizing HCV RNA (45-47) and promoting HCV replication 
(37, 48-50).  Therefore we next determined the overall impact of miR122 on HCV 
translation, RNA stability, and replication in astrocytes by measuring luciferase activity at  
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Figure 49.  HCV RNA translation in astrocytes and its enhancement by miR122 
expression.  (A & B) A HCV genotype 1b subgenomic replicon HCV-RLuc DNA (A) was 
linearized and used as a template for in vitro transcription and RNA synthesis.  The RNA 
was transfected into PHA together with pcDNA3-GFP plasmid (transfection efficiency 
control).  The cells were cultured for 6 hr before harvest for the luciferase assay (B).  
Huh7.5.1, 293T, HepG2 and U373 were included for comparison in the experiments.  
For each cell, the luciferase activity was normalized to the transfection efficiency, which 
was determined by measuring the percentage of GFP-positive cells with flow cytometry 
at 72 hr post-transfection.   (C) Endogenous miR122 expression in PHA.  Total RNA was 
isolated from the cells for miR122 expression level by qRT-PCR.  miR122 expression 
was normalized by U6 small nuclear RNA expression and expressed as fold change 
relative to PHA.  (D & E) PHA were transfected with pcDNA3-GFP plasmid (Ctrl) or 
pcDNA3-GFP-miR122 plasmid (miR122) and cultured for 24 hr.  The cells were then 
transfected with HCV-Rluc RNA and cultured for 6 hr before harvest for miR122 
expression analysis by qRT-PCR (D) and the luciferase activity assay (E).  
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72 hr post HCV-Rluc RNA transfection.  Significant increases of luciferase reading were 
found in all of U373, PHA, 293T and HepG2 cells with exogenous miR122 expression 
(Fig. 50A), suggesting an overall positive role of miR122 in all these cells.  To confirm 
this enhancing effect, we also compared U373 stable clones selected from miR122- and 
empty vector- transfected cells.  Among the selected three miR122-expressing single 
clones, only clone 2 (miR122-SC2) gave significantly higher (3 fold) luciferase readings 
than the negative controls (cDNA3-SC2/SC4) at 72 hr post HCV-Rluc RNA transfection 
(Fig. 50B).  Quantification of miR122 in these clones with qRT-PCR revealed that clone 
2 expressed 20 fold more miR122 than the controls, but this expression level was 
actually 10 fold lower than clone 1 and 3 (miR122-SC1/ SC3) (Fig. 50C).  The apparent 
discrepancy between clone 2 and clone 1 and 3 could be a result from random insertion 
of miR122 into chromosomes during clone selection and possible subsequent disruption 
of important cellular pathway(s) involved in the miR122/microRNA metabolism or 
miR122’s interaction with HCV RNA.  Thus, to minimize the interference from random 
miR122 genome insertion, we compared the miR122-expressing U373 pooled clones 
(miR122-PC) with the control U373 pooled clones (cDNA3-PC).  The results showed that 
6 fold higher miR122 expression in miR122-PC (Fig. 50E) led to a 3 fold increase in 
luciferase signal (Fig. 50D), confirming that miR122 expression has an overall positive 
impact on HCV RNA stability, translation and replication in astrocytes. 
 
A recent study reported that miR122 expression in non-hepatic cell lines was sufficient to 
facilitate efficient and continuous HCV replication (49).  Therefore we next monitored 
HCV replication kinetics in astrocytes to determine whether or not the virus could self-
replicate with or without the help of miR122 in astrocytes.  We used the same bicistronic 
HCV-Rluc subgenomic replicon as above except for that the luciferase activity was  
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Figure 50.  Effect of miR122 on HCV RNA stability, translation and replication in 
astrocytes.  (A) PHA and other cells as indicated were transfected with HCV-Rluc RNA 
and pcDNA3-GFP plasmid (Ctrl) or pcDNA3-GFP-miR122 plasmid (miR122).  Cells were 
cultured for 72 hr before harvest for the luciferase activity assay.  For each cell, the 
luciferase activity was normalized to the transfection efficiency, i.e., the percentage of 
GFP-positive cells with flow cytometry.  (B-E) U373 cells stably expressing miR122 
(single clones U373-miR122-SC1/ SC2/ SC3 in B & C, pooled clones U373-miR122-PC 
in D & E) were generated and transfected with HCV-Rluc RNA and pEgr1-Fluc plasmid, 
cultured for 72 hr and assayed for Rluc and Fluc activities (B, D) and miR122 expression 
by qRT-PCR (C, E).  U373 cells stably expressing the backbone vector pcDNA3-GFP 
(single clones U373-cDNA3-SC2/ SC4 in B & C, and pooled clones U373-cDNA3-PC in 
D & E) were included as control.  Rluc activities were normalized to Fluc activities to 
ensure comparable transfection efficiency (B & D).  miR122 expression was expressed 
as fold change relative to cDNA3-SC2 (C) or cDNA3-PC (E). 
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monitored for an extended period of 120 hr post-transfection.  We first found that even 
without miR122 expression in Huh7.5.1 cells, the luciferase activity gradually increased 
and maintained at a relative stable level after a brief decline due to degradation of input 
transfected RNA, likely resulting from HCV RNA replication (open diamond, Fig. 51A). In 
contrast, the luciferase activity in all other cells including PHA showed a continued 
decline during 120 hr (open diamond, Fig. 51B-E), suggesting abortive HCV replication 
in these cells without exogenous miR122 expression.  We next introduced miR122 into 
these cells and determined its effects on HCV replication in these cells.  Compared to 
Huh7.5.1 without miR122 transfection, expression of miR122 in Huh7.5.1 gave rise to an 
overall higher level of luciferase activity but maintained the similar kinetics (closed 
diamond, Fig. 51A).  As expected, miR122 expression in PHA and U373 showed 
generally enhanced luciferase activity until 72 hr post RNA transfection; however, it was 
not able to rescue the declining kinetics (closed diamond, Fig. 51B & C).  Consistent 
with other studies (49, 242), miR122 expression in 293T and HepG2 led to increased 
luciferase activity from 48 hr post-transfection (closed diamond, Fig. 51D & E).  These 
results showed that PHA did not support HCV replication regardless of miR122 
expression and suggest that HCV replication is likely blocked in PHA.  
 
3.7 Effect of cytokines/chemokines/LPS on HCV replication in astrocytes 
Viral infection of the brain usually causes inflammation in the CNS (243).  Priming of 
brain cells with proinflammatory cytokines in cell cultures, which mimics the inflammatory 
environment in virus-infected brain, could enhance virus infection of brain cells (244-247).  
Therefore, we decided to test whether exposure of PHA to various 
cytokines/chemokines/bacterial LPS could pre-dispose these cells to support HCV 
replication.  Among those tested include bacterial LPS, chemokine MCP-1, and pro- 
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Figure 51.  HCV replication in astrocytes with or without exogenous miR122 
expression.  Huh7.5.1 (A), PHA (B), U373 (C), 293T (D) and HepG2 (E) were 
transfected with HCV-Rluc RNA and pcDNA3-GFP control plasmid (Ctrl, open diamond) 
or pcDNA3-GFP-miR122 plasmid (miR122, closed diamond).  Cells were harvested at 6, 
24, 48, 72 and 120 hr post-transfection for the luciferase activity assay.  For each cell 
type, the luciferase activity was normalized to the transfection efficiency, i.e., the 
percentage of GFP-positive cells at 72 hr post-transfection with flow cytometry. 
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inflammatory cytokines IL-1β, IL-4, IL-6, IL-10, TNF-α and INF-γ.  The concentrations of 
these agents were determined based on previous studies (244, 245) and they were all 
between 10-100 EC50 of these agents according to the manufacturer.  Interestingly, 
none of these pre-treatments led to enhanced HCV-Rluc expression in U373 (Fig. 52A).  
Instead, IL-1β, TNF-α, INF-γ and LPS pre-treatments led to significant inhibition of HCV-
Rluc expression.  Similarly, IL-1β treatment inhibited HCV-Rluc expression in PHA, while 
IL-4 gave rise to no effects (Fig. 52B).  These results are not unexpected, considering 
the antiviral nature of IFN-γ and INF-γ-like effects of IL-1β, TNF-α, and LPS.  It is 
possible that the interactions between HCV infection and the signaling pathways of 
cytokines being tested are different from those in other viral infections of cells that are 
able to be primed by cytokine pre-treatments. 
 
3.8 HCV-induced IL-18 expression in astrocytes 
Even though astrocytes do not support HCV entry and replication, the possibility cannot 
be excluded that HCV interaction with astrocytes leads to changes in astrocytes and 
eventual neuron demise.  Astrocytes have been shown to be important in evoking 
inflammatory response in the CNS in response to invaded pathogens and physical injury 
(195, 196, 200).  Thus, we performed HCV infection of PHA as described above, i.e., 2 
hr incubation and removed the viruses and determined the expression levels of several 
selected pro-inflammatory cytokines 24 hr post-infection.  Interestingly, among all the 
cytokines tested (IL-1α, IL-1β, IL-6, IL-8, IL-18 and TNF-α), only IL-18 expression was 
significantly induced, i.e., by about 2 fold, compared to the conditioned medium mock 
treatment (Fig. 53A).  To further verify these findings, we included IFN-γ in these 
experiments, as IFN-γ is known to induce IL-18 expression (248, 249).   Compared to 
the mock treatment or the treatment with fresh culture medium, like IFN-γ treatment,  
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Figure 52.  Effect of cytokines/chemokines/LPS on HCV replication in astrocytes.  
(A) U373 cells were treated with culture medium (Medium), 5 ng/ml IL-1β, 10 ng/ml IL-4, 
10 ng/ml IL-6, 10 ng/ml IL-10, 100 ng/ml MCP-1, 10 ng/ml TNF-α, 10 ng/ml INF-γ or 100 
ng/ml LPS for 24 hr, transfected with HCV-Rluc RNA and pcDNA3-GFP-miR122 plasmid, 
cultured for 72 hr, and harvested for the luciferase activity assay.  (B) PHA were treated 
with culture medium, 5 ng/ml IL-1β or 10 ng/ml IL-4 for 24 hr, and then transfected with 
HCV-Rluc RNA and pcDNA3-GFP-miR122 plasmid, cultured for 72 hr, and harvested for 
the luciferase activity assay.  All cytokines/chemokines/LPS were diluted in the culture 
medium.  The luciferase activity was expressed as the percentage of that of the Medium 
control.  
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Figure 53.  Induction of IL-18 expression in astrocytes following HCV exposure.  
(A) PHA were cultured in a 6-well plate and then added 6 ml HCVcc (viral titer: 1.84 x 
108 vge/ml by qRT-PCR) or conditioned medium (Mock) and incubated for 2 hr.  HCV 
was removed and the cells were then extensively washed with PBS and cultured for 24 
hr before harvest for total RNA isolation and qRT-PCR for cytokine expression.   
Expression of each cytokine was first normalized to that of β-actin and its relative level in 
the control (Mock) was set to 1.  (B) PHA were treated with PHA culture medium 
(Medium), 50 ng/ml IFN-γ, conditioned medium (Mock) or HCV virus (HCVcc) for 24 hr.  
The expression level of IL-18 in these cells was determined by qRT-PCR and expressed 
as fold change relative to that of Medium treatment. 
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HCV exposure led to robust IL-18 expression in PHA (Fig. 53B).  These results suggest 
that HCV could alter astrocyte function in the absence of productive HCV infection and 
replication.  
 
3.9 HCV direct neurotoxicity   
IL-18 is an important regulator in neuroinflammation and neurodegeneration (250). To 
determine whether HCV interaction with astrocytes such as IL-18 induction could have 
any detrimental effects on neurons, we performed the same HCV infection experiment 
as above, collected the culture supernatants, and determined their effects in neuron 
survival (+PHA).  The MTT assay showed that none of the PHA supernatants including 
the one from HCV infection affected neuron viability (Fig. 54A).  The negative results 
could be due to the lower level of IL-18 in the supernatants.  The other possibility that 
HCV could affect the CNS is through its direct interaction with neurons.  To address this 
possibility, HCV was directly exposed to neurons in the absence of PHA (-PHA).  To our 
great surprise, compared to the conditioned medium mock treatment, the culture 
medium alone or IFN-γ treatment, HCV exposure led to a significant decrease of neuron 
survival, i.e., by about 35% (Fig. 54B).  The neurotoxicity appeared to maintain up to 4-
fold dilution of the input virus (Fig. 54C), which corresponded to a viral titer of 4.7 x 107 
vge/ml. 
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Figure 54.  Neurotoxicity induced by direct HCV exposure.  (A) PHA were treated 
with PHA culture medium (Medium), 1 µg/ml IFN-γ, conditioned medium (Mock) or HCV 
virus (HCVcc, viral titer: 1.84 x 108 vge/ml by qRT-PCR) as described in Fig. 53.  The 
culture supernatants from each of these treatments were collected 24 hr after the 
treatment and added onto SH-SY5Y cells (+PHA).  SH-SY5Y cells were cultured for 72 
hr and then subjected to the MTT assay.  Results were expressed as the percentage of 
PHA culture medium control (A).  Meanwhile, SH-SY5Y cells were directly exposed to 
each of these four treatments (-PHA) and cultured for 72 hr, followed by the MTT assay 
(B).  (C) Dose-dependent HCVcc neurotoxicity.  Two-fold serial dilutions of HCVcc (viral 
titer: 1.88 x 108 vge/ml by qRT-PCR) were added onto SH-SY5Y cells as described.  
MTT assay was performed 72 hr post HCV exposure.  Conditioned medium (Mock) was 
included as a control, and the results were expressed as the percentage of that of the 
Mock control. 
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DISCUSSION 
 
Summary of the results   
In CHAPTER 1, we characterized CCCM HCV infection of hepatocytes.  We first 
demonstrated that a HCV infection in cell culture leads to the formation of clustered 
infected cells; the infectious foci, evident under low MOI and high cell density, are highly 
suggestive of cell-cell contact-mediated HCV transmission (Fig. 6).  Replating of HCV-
infected cells at different densities leads to density-dependent HCV spread, with foci 
formation observed at only high cell densities, indicating that HCV foci formation results 
from CCCM HCV transmission, not the proliferation of infected cells (Fig. 7, 8).  We then 
established a co-culture assay and directly demonstrated CCCM HCV transmission in 
hepatocytes, including primary human hepatocytes (Fig. 10, 11).  To understand the 
relative contributions of CCCM and cell-free virus infection in the 20 hr co-culture assay, 
we compared the kinetics of HCV infection in the co-culture assay to that of cell-free 
virus infection only in a transwell assay.  The results show that CCCM HCV infection 
occurs at as early as 3 hr in the co-culture assay while cell-free virus infection only in the 
transwell assay is not detected until beyond 20 hr (Fig. 12 A-C).  These results reveal 
the rapid kinetics of the CCCM HCV transmission and confirm that the observed newly 
infected cells in the 20 hr co-culture assay result from solely CCCM, not cell-free virus 
infection.  In addition, we also characterized the roles of the four known HCV receptors 
(CD81, SR-B1, CLDN1, and OCLN), and the actin and the microtubule cytoskeletons in 
CCCM HCV transmission based on the co-culture assay.  Knock-down of each of the 
HCV receptors individually by siRNAs all greatly inhibit the CCCM HCV infection, 
indicating an important role of each of these receptors in this process (Fig. 14).  
Importantly, concomitant knock-down of all four receptors almost completely abolishes 
the CCCM infection, suggesting that these receptors may work in a coordinated manner 
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(Fig. 15).  Attempts to introduce susceptibility to CCCM HCV infection into cells missing 
or expressing a low level of one or more HCV receptor(s) (293T cells, HepG2, NKNT3, 
and CYNK10 hepatoma cells) by ectopic expression of the missing/ minimally-expressed 
HCV receptors in these cells all fail (Fig. 18-21), likely due to the lack of unknown 
facilitating factors or the presence of unkown inhibitory factors in these cells.  Treatment 
of the co-cultures with the actin depolymerizing agent cytochalasin D inhibits the CCCM 
infection in a dose-dependent manner, while treatment with the microtubule 
depolymerizing agent nocodazole does not affect it (Fig. 22), indicating that the actin 
cytoskeleton, not the microtubule, plays an essential role in CCCM HCV infection.  
Furthermore, we adapted the tetracysteine-biarsenical dye labeling strategy in 
combination with 3-dimensional live cell fluorescence microscopic imaging and dissected 
the spatial and temporal details of the CCCM HCV transfer process.  Sequential HCV 
transfer from one donor to multiple targets and concurrent transfer between one donor 
and multiple targets were observed (Fig. 27).  Lamellipodium/ lamellipodium-like 
structures at the contact sites for each of the observed transfer events in Fig. 27 were 
found with a close examination of those sites by 3D reconstruction, indicating that 
lamellipodium may play a role in the CCCM HCV transfer process (Fig. 28).  The 
transfer of one single µm-sized HCV core punctum into target cells in real time was also 
confirmed and the four steps in CCCM HCV transfer are illustrated: donor cell-target cell 
contact, formation of viral punctum-target cell conjugation, transfer of the viral punctum, 
and post-transfer (Fig. 29).  Lastly, using three different strategies including extended 
co-culturing time in the presence of nAbs, FACS sorting of target cells and G418 
selective killing of donor cells, we demonstrated that the CCCM HCV transfer in the co-
culture assay leads to productive infection in the target cells (Fig. 31-33).  Taken 
together, CCCM HCV transfer is rapid, HCV receptors- and actin cytoskeleton-
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dependent and productive in nature, and it constitutes an important and effective route 
for HCV infection and dissemination in hepatocytes. 
 
In CHAPTER 2, we characterized the relationship between exosomes and the infectious 
HCV virions.  We first demonstrated that HCV infection does not affect exosome 
secretion or size distribution on an iodixanol density gradient (Fig. 34, 35).  But 
interestingly, we next showed that cell culture-produced exosomes and a subpopulation 
(about 1-10%) of HCV from HCV-infected hepatocytes were co-fractionated on the 
iodixanol gradient – the “exosome-associated HCV” (Fig. 37).  The co-fractionation was 
also confirmed using different methods for concentrating virus and exosome (PEG 
precipitation and ultracentrifugation), as well as different rotors for the density gradient 
fractionation (SW55Ti and NVT65) (Fig. 38, 39).  Importantly, the HCV-exosome co-
fractionation was also observed in HCV-positive patient plasma and the amount of HCV 
RNA that was detected in exosome-containing fractions were much higher than that in 
exosome-free fractions (Fig. 40).  Furthermore, the exosome-associated form of HCV 
contained both viral RNA and vial capsid (core) and envelope (E2) proteins; it also 
retained its infectivity to hepatocytes, abeit less effective than the exosome-free form of 
HCV (Fig 41).  Taken together, the results here suggest that exosome-associated HCV 
constitutes an alternative route for HCV infection and spread.    
 
In CHAPTER 3, we characterized the interaction between HCV and astrocytes, one of 
the abundant CNS cells and one of the putative HCV target cells in the brain.  First, 
using the HCVcc system, we showed that primary human astrocytes were not 
productively infected either by cell-free or CCCM HCV infection (Fig. 43 & 44).  We then 
examined different steps of HCV life cycle in astrocytes and determined possible 
restriction steps in these cells.  Using the HCVpp system and spinoculation, we showed 
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that there was no HCV envelop-mediated entry into PHA, although all the four known 
HCV receptors were expressed in PHA (Fig. 45-47).  Using the bicistronic HCV-Rluc 
subgenomic replicon, we showed that HCV RNA translation was supported in PHA and 
further enhanced by the expression of a liver-specific microRNA, the miR122 (Fig. 49).  
However, albeit an overall positive effect of miR122 on HCV translation, RNA stability, 
and replication on astrocytes (Fig. 50), introduction of miR122 expression was not able 
to rescue the abortive HCV-Rluc RNA replication in PHA (Fig. 51).  Next, we attempted 
to prime PHA with cytokines/chemokines/LPS for higher HCV replication, but it was 
found that pre-treatment of astrocytes with proinflammatory cytokines such as IL-1β, 
TNF-α and IFN-γ inhibited HCV RNA expression in PHA (Fig. 52).  Furthermore, our 
examination of the expression of various proinflammatory cytokines in PHA following 
HCV challenge showed that HCV specifically stimulated IL-18 expression in PHA (Fig. 
53), suggesting potential roles of IL-18 and astrocytes in HCV-related CNS abnormalities.   
Lastly, we demonstrated that HCV itself was sufficient to cause neurotoxicity in a dose-
dependent manner (Fig. 54).  Taken together, the results here suggest that astrocytes 
are not productively infected by HCV and they support HCV translation but not entry and 
replication.  However, HCV-induced IL-18 expression in astrocytes and HCV direct 
neurotoxicity may contribute to HCV-related CNS abnormalities. 
 
CCCM HCV infection in vivo 
Despite significant advances since the establishment of the JFH1-Huh7 HCV cell culture 
system in 2005 (70-72), the process of HCV transmission and spread in the liver 
following infection remains poorly understood.  Liver is one of the organs with extremely 
high cell density [2-3.0 x 105 hepatocytes/cm2 (99)], which provides HCV with numerous 
cell-cell contact sites.  In chronically HCV-infected liver, viral replication and intrahepatic 
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HCV RNA level are very low (7-64 genomic equivalent per cell) (97, 251) and nAbs and 
other immunological responses are often present (100).  However, even with the 
presence of those nAbs that are capable of neutralizing cell-free virus infectivity in vitro 
(203), prevalence of infected hepatocytes in the liver of chronic patients is normally high 
(96, 251).  In this study, we showed that HCV infection in cell culture led to foci formation 
(Fig. 6) and that cell-cell contact facilitated HCV spread among hepatocytes (Fig. 7, 8 & 
10) including primary human hepatocytes (Fig. 11).  We further showed that CCCM HCV 
infection is a rapid process compared to cell-free HCV infection (Fig. 12).  Previous 
studies show similar infectious foci in patient liver biopsies and a gradient dispersion of 
viral genome around the center of the focus (95-97); CCCM HCV infection is found 
relatively less sensitive to nAbs and neutralizing patient sera than cell-free HCV infection 
[Fig. 30, 31 and (98)].  Taken together, it is highly conceivable that CCCM HCV occurs 
in vivo, and it could even be more favorable than cell-free HCV infection given the 
compact nature of the liver.  Thus, CCCM HCV transmission should be considered when 
designing any future anti-HCV vaccines and therapeutics. 
 
Roles of HCV receptors in the CCCM HCV infection 
CD81, the first discovered HCV receptor identified by screening for HCV E2-binding 
activity (25), is believed to mediate cell-free HCV virus entry in both an early E2-binding 
step and a late post-binding step in association with CLDN1 (30, 33, 34).  SR-B1, 
another E2-binding HCV receptor, also mediates cell-free HCV virus attachment and 
entry in an early step in this multi-step entry process (252-255).  The other two HCV 
receptors, CLDN1 and OCLN, are both tight junction proteins recently identified by 
screening for cellular determinants able to confer HCVpp entry into non-susceptible cells 
(28, 29).  To determine the roles of each of these four HCV receptors in CCCM HCV 
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infection, we first used a siRNA strategy to knockdown the expression of each of them 
individually in Huh7.5.1 target cells and found between 46% to 72% decreases in CCCM 
HCV infection, suggesting a fundamental role of each of them in this process (Fig. 14).  
Furthermore, simultaneous knockdown of all of them almost completely abolishes 
CCCM HCV infection, suggesting that they may mediate CCCM HCV infection in a 
combinatorial mechanism (Fig. 15).  To further understand the roles of the four receptors 
in CCCM infection, we performed the co-culture assay using CD81-negative HepG2, low 
CLDN1-expressing NKNT3 and CYNK10, and low SR-B1, no CLDN1-expressing 293T 
(Table 1 and Fig. 16).  All these cell lines are refractory to both cell-free and CCCM 
HCV infection (Fig. 17).  However, ectopic expression of the missing/ low-expressing 
receptor(s) does not render these cells susceptible to CCCM HCV infection (Fig. 18-21).  
These results together suggest that all four HCV receptors are essential but not 
sufficient for CCCM HCV infection.  Consistent with our findings, previous studies show 
that SR-B1 antagonists, an anti-CLDN1 serum, and OCLN knockdown by shRNA all 
inhibit CCCM HCV infection (256), suggesting that all three of them are required for this 
process.  However, the role of CD81 in the CCCM HCV infection appears to be 
controversial in the literature.  One study shows that CD81 is dispensable for CCCM 
infection using a mutant JFH1 carrying CD81 binding-deficient E2 glycoprotein (257).  
Interestingly, this study does not show convincingly that the mutant JFH1 absolutely 
cannot infect hepatocytes by cell-free virus infection; their co-culture assay does not 
include any nAb and the time of co-culturing is not indicated, but very likely longer than 
24 hr.  Under those conditions, the “CD81-dispensable CCCM transmission” observed in 
their co-culture assay could be a result of leaking cell-free virus infection, as we showed 
that cell-free HCV infection can be detected in the co-culture after 24 hr if performed 
without nAbs (Fig. 31).  On the other hand, consistent with our findings, another group 
demonstrates the absolute requirement for CD81 in CCCM infection using the 
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combination of a Huh7-derived low CD81-expressing Lunet cell and an anti-CD81 
antibody to ensure that no CD81-mediated cell-free virus infection occurs in their co-
culture assay (256).  Taken together, results from our study in CHAPTER 1 and the 
second study mentioned above suggest that CD81 is required for the CCCM HCV 
infection. 
 
Difficulties of CCCM HCV infection of cells other than Huh7.5.1 cells and primary 
hepatocytes 
In this study, we show successful CCCM HCV transmission from infected Huh7.5.1 to 
Huh7.5.1 itself and primary human hepatocytes (Fig. 10, 11); we also show no CCCM 
HCV transmission from infected Huh7.5.1 to 293T cells, HepG2, NKNT3, CYNK10 
hepatoma cells, or primary astrocytes, even when the missed and/or low-expressing 
receptor(s) are introduced into these cells (Fig. 17-21, 44).  There are several possible 
reasons for this apparent inconsistency.  First, though it is not clear about NKNT3 and 
CYNK10 cells, 293T, HepG2 or PHA do not support HCV replication due to the lack of 
miR122 expression for all and also other unknown reasons for PHA (Fig. 51).  Even if 
CCCM HCV transmission may still occur without HCV replication in the target cell, it is 
very likely that efficient viral replication in the target cells following CCCM transfer can 
facilitate the detection of the transfer.  Therefore, the lack of support for HCV replication 
in these cells may contribute to difficulties in the detection of CCCM HCV transmission in 
them.  Second, even though cell-free virus entry into 293T and HepG2 cells are efficient 
when all the four receptors are expressed (258, 259), it is not guaranteed that these four 
are also sufficient for the CCCM HCV transfer since the mechanisms underlying it 
(discussed in details later) are still not completely clear.  It is possible that other factors 
besides the four known receptors, facilitating or inhibitory, are missing or present in 
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those cells that fail to be transferred.  Alternatively, it is also possible that the specific 
type of contact or structure (refer to the discussion of mechanism) that is required for the 
CCCM HCV transfer cannot form well or efficiently between the donor Huh7.5.1 and 
those target cells.   
 
The role of actin cytoskeleton in CCCM HCV infection  
CCCM infection has been shown in many different animal viruses, and its role in immune 
evasion and rapid viral dissemination has recently gained more attention (74).  CCCM 
viral transmission in animal cells can occur in a variety of ways.  Among the known are 
through virological synapses (HIV-1 and HTLV-1), nanotubes (HIV-1), viral transfer 
across tight junctions (HSV), and viral induction of actin tails (VV) (74).  Interestingly, all 
the above CCCM routes involve actin and/or microtubule cytoskeletons.  In addition, 
CCCM spread have also been found very common in plant virus infection and usually 
involves targeting of virus-encoded movement protein(s) (MP) to plant-specific 
organelles plasmodesmata (PD), which are narrow tunnels in the cell wall for 
intercellular communication (75).  Movement strategies for CCCM viral spread differ 
upon viruses and MPs.  In tobacco mosaic virus (TMV) infection, MP binds and 
chaperones genomic RNA in the virus replication complexes (VRC) and targets the 
whole VRC to PD for CCCM viral spread (260).  In the grapevine fanleaf virus (GFLV) 
infection, MP recruits the PD receptor plasmodesmata located protein (PDLP) to PD to 
mediate the formation of tubules through which the assembled virions traverse PD (so-
called “tubule-forming virus”) (261).  Interestingly again, in virtually all CCCM plant virus 
infections, movement of MP, VRC, virions, or other essential cellular co-factors to and/ 
or through PD all require an intact cytoskeleton, particularly the actomyosin moter 
system (260-263).  Thus, we further determined the roles of actin and/or microtubule 
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cytoskeletons in CCCM HCV infection.  Actin cytoskeleton has been shown to be 
involved in interaction with multiple steps of cell-free HCV infection including virus entry 
(228, 264) and replication (265, 266).  In agreement with these findings, our results show 
that an intact actin network is required for CCCM HCV transfer, as treatment with actin 
polymerization inhibitor cytochalasin D in the co-culture assay prevents CCCM HCV 
transfer (Fig. 22 A, C). Based on the known function of cytochalasin D and our finding 
that HCV secretion from infected cells is not affected by the treatment (Fig. 22 F), 
cytochalasin D likely inhibits the transfer process at the donor cell-target cell contact 
sites or during the uptake of viral puncta by the target cells.  On the other hand, 
treatment of the co-culture with the microtubule depolymerizing agent, nocodazole, at a 
concentration sufficient to disassemble microtubules [Fig. 22B and (230)], has little 
effect on CCCM HCV transfer (Fig. 22D).  In contrast to our studies, other studies find 
that nocodazole treatment inhibits microtubule-dependent transport of the HCV 
replication complex and initiation of productive HCV infection and, as a result, HCV RNA 
replication (265, 267, 268).  Moreover, two recent reports show that post-assembly 
vesicular HCV core puncta traffics via microtubules, which is inhibited by nocodazole 
treatment (66, 208).  It is interesting to point out that the above-mentioned studies all use 
much higher concentrations of nocodazole, mostly 10 - 40 times higher than what are 
used in our studies.  These extremely high concentrations of nocodazole used in those 
studies could be the main reason for the discrepancies. 
 
Temporal and spatial details of CCCM HCV transmission by 3D live imaging 
It is believed that HCV virus is released from infected cells through the secretory 
pathway (269).  After translation and processing on the ER membrane, the mature HCV 
core is relocated to the surface of lipid droplets (270).  When the RNA genome produced 
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from the replication complex on the membranous web and envelope proteins (E1/E2) on 
the ER are ready, viral budding towards the ER lumen takes place on the ER outer 
membrane in close proximity to the lipid droplets (another proposed mechanism believes 
budding occurs on LD) (66).  These intracellular viruses become infectious upon 
envelopment; they are thought to be loaded into secretory vesicles that egress via the 
ER-trans Golgi secretory pathway and released to the extracellular space upon fusion of 
the vesicles with the plasma membrane (208).  However, the actual “fusion” or “release” 
process has never been captured with fluorescence or electron microscopy.  Our live cell 
imaging studies show that during CCCM HCV transmission, large amounts of mobile 
viral puncta move to the contacted surfaces between the donor and target cells, form 
conjugates with the target cell, and then transfer into the target cell (Fig. 27-29).  These 
core puncta are µm-sized and are unlikely single viral particles, but more likely vesicles 
loaded with virus particles (100-1000 virions/ punctum based on size) (66, 208).  The 
transfer of a single core punctum takes 18 min (Fig. 29A); the transfer process lasts for 
171 min on average (Fig. 29B).  Moreover, the transfer events can occur at multiple 
donor-target cell contact sites (Fig. 27A ii) or concurrently between one donor and 
multiple targets (Fig.27 B).  Therefore, during the entire CCCM transfer process, a great 
number of viral puncta, which correspond to an even greater number of viral particles, 
can be delivered into the target cell, contrasting the cell-free virus infection, in which one 
virion enters one target cell at a time.  It is not guaranteed that each of the viral particles 
in each of the transferred puncta proceeds through the downstream viral life cycle in the 
target cell, yet the high input of CCCM viral transfer certainly leads to productive 
infection of the target cell (Fig. 31-33).  
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Potential mechanism(s) of CCCM HCV infection – the possible involvement of 
lamellipodium 
As discussed above, CCCM viral transmission can occur in a variety of ways.  According 
to our live cell imaging data, no cell protrusions resembling actin tails in poxvirus-
infected cells are observed, so CCCM HCV infection does not appear to take place by 
inducing actin tail formation.  Similarly, no cell fusion or syncytium formation is noticed: 
CCCM HCV infection unlikely occurs through plasma membrane fusion of infected and 
uninfected cells.  Cell-free HCV virus infection requires two receptors belonging to tight 
junction (TJ) proteins, CLDN1 and OCLN.  However, recent studies demonstrated that 
HCV entry into hepatocytes does not occur at the site of functional TJs, but basolateral 
CLDN1 pools outside of TJ (264, 271, 272).  Functional TJs are one of the important 
characteristics of hepatocyte polarization; interestingly, HCV infection depolarizes 
primary hepatocytes and HepG2 hepatoma cells (273) and in turn, polarization in HepG2 
hepatoma cells restricts HCV infection (272).  Thus, the requirement of both CLDN1 and 
OCLN for CCCM HCV transmission (Fig. 14D) does not necessarily indicate that HCV 
adopts the strategy of “transfer across TJ” like HSV for its CCCM infection; direct 
evidence is needed to address the possibilities in the future.  Our results show that 
CCCM HCV infection relies on cell density (Fig. 7, 8) and mainly occurs between 
adjacent cells (Fig. 27-29), not cells apart from each other and connected by nanotubes 
or filopodia.  Therefore the transfer is unlikely to occur in a way similar to HIV-1’s 
traveling on nanotubes or MLV’s traveling on filopodia.   
 
Lamellipodium is broad, sheet-like protrusion of the cell, which contains a branched 
network of actin filaments (274).  In the live images of CCCM HCV transfer, 
lamellipodium filled with viral puncta in donor cells is frequently observed.  This 
phenomenon is sometimes very obvious (Fig. 27A iii, iv) and sometimes less apparent 
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(Fig. 27A i, ii, C and D).  But after close examination with higher magnification and 3D 
re-construction in the latter cases, lamellipodium-like protrusions in the frontier of donor-
target contact surface are also observed (Fig. 28).  In addition, it is interesting to point 
out that in one recorded transfer event, after the donor cell pulls back its lamellipodium 
and the CCCM transfer is complete (Fig. 27A iv), the target cell (T3) extends out a 
lamellipodium towards the donor cell (Fig. 27A v).  These observations suggest that 
lamellipodium or lamellipodium-like cell protrusions may be the specific form of cell-cell 
contact involved in the CCCM HCV transmission, though further experiments with 
lamellipodium-specific markers, such as GFP-tagged actin (275) or the Rac small 
GTPase (276), are needed to prove or disprove this hypothesis.  This model is also 
consistent with the requirement of the actin cytoskeleton for CCCM HCV transfer (Fig. 
22), as actin is integral in lamellipodium dynamics and function (274).  Nevertheless, in 
some of the transfer events, especially those with single viral punctum (Fig. 29 A), no 
apparent lamellipodium is observed on the donor-target contact surface, suggesting that 
other yet to be identified mechanism(s) could also be involved in CCCM HCV infection.   
 
Although the above model about the central role of lamellipodium in CCCM HCV transfer 
merits further investigation, it is evident that the mechanisms of CCCM HCV 
transmission are different from most of those discovered for other viruses.  It is not only 
because no actin tail, nanotubes, or uninfected cell-derived filopodia are observed during 
the live imaging of CCCM HCV transmission, but also due to the lack of some pre-
requisites for those forms of CCCM transmission.  On one hand, many of the viruses 
that transmit via CCCM route, e.g., VV, HIV-1 and MLV, bud at the plasma membrane; 
some of the budded viruses adhere to the plasma membrane and then can either be 
projected to uninfected cells by actin tail (VV), or travel along a nanotube (HIV-1) or 
filopodium (MLV) to reach and infect uninfected cells (74).  On the other hand, viral 
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envelope proteins of many of those viruses are expressed on the plasma membrane, 
where they have an opportunity to bind to receptors on an uninfected cell; importantly, 
the binding of the viral envelope to receptor(s) is required for the anchoring of uninfected 
cell-derived filopodia by infected cells (MLV) and the formation of VS (HIV-1), and 
thereby CCCM viral transmission (74).  However, neither of these two is true for HCV.  
First, HCV does not bud from or attach to the plasma membrane after release; it buds 
into ER and transits through the secretory pathway to reach the plasma membrane for 
release (66, 270, 277).  Our live imaging data demonstrate both the intracellular 
trafficking and the CCCM transfer of HCV virus in the form of viral puncta containing 
more than one viral particle (Fig. 27-29), suggesting that HCV CCCM transfer is not a 
single viral particle-based event like those in HIV-1, MLV and VV CCCM transmission.  
Nevertheless, how are HCV particles bundled and transferred in the form of puncta 
which do not collapse during the transfer is to be answered in future studies.   Second, 
HCV envelope proteins are expressed on ER (278, 279) and in MVB (144) but not the 
plasma membrane, which disallows the interaction between viral envelopes on infected 
cells and receptors on uninfected cells.  Therefore the HCV CCCM transmission is very 
likely a result from exploratory protrusions in the absence of directional stimulation, in 
contrast to HIV-1 transmission across VS and MLV CCCM transmission along filopodia, 
both of which are guided by the binding of viral envelope proteins on infected cells to 
receptors on uninfected cells. 
 
Taken together, the mechanisms of CCCM HCV transmission appear to be different 
from most of the other CCCM viral transmissions; exploratory lamellipodium and other 
undetermined mechanism(s) may be involved.   
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“Trojan exosomes” for HCV 
Our results in CHAPTER 2 show that a subpopulation of HCV virions from both cell 
culture and patient plasma can be co-fractionated with exosomes (Fig. 37-40) and that 
these exosome-associated HCV remain infectious to hepatocytes (Fig. 41).  Even 
though it cannot be completely excluded that the observed co-fractionation is due to the 
same density of some HCV virions and exosomes, a recent study demonstrates by cryo-
electron microscopy that 5.6% of cell culture-produced HCV particles are surrounded by 
an additional layer of “envelope” and that each of these “envelope” contains one or more 
HCV virions (146).  The biological nature of this extra “envelope” was not further 
investigated in the study but it was described as “exosome-like”.  Results from the 
above-mentioned report and our present study are consistent and suggest a potential 
role of “Trojan exosomes” in delivering HCV virions to uninfected cells and thereby 
mediating HCV infection. 
 
During the fractionation of cell culture-produced exosomes and HCV, about 1-10% HCV 
RNA and HCV core protein were detected in exosome fractions (fraction 2-4) (Fig. 37-
39). But about 50% of HCV E2 protein was detected in exosome fractions and it 
appeared to be 20 KD larger on the immunoblot than that detected in HCV alone 
fractions (fraction 7-10) (Fig. 37-39).  There are several possibilities for the size 
difference of E2 protein and the non-proportional distribution of HCV E2 protein and 
HCV RNA/core protein in the exosome fractions and virus-alone fractions.  Different 
post-translational modifications may occur for the exosome form of E2, which may lead 
to a larger molecular weight.  HCV E1 E2 envelope proteins have been shown to be 
secreted in exosomes when expressed alone in mammalian cells without HCV infection 
(143); it is possible that with HCV infection, some E2 protein is also expressed on the 
exosome membrane, leading to relatively more E2 detection in exosome fractions than 
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HCV core protein and RNA.  Interestingly, different from cell-culture produced HCVcc, 
HCV-positive patient plasma were found to contain more HCV RNA in exosome fractions 
than exosome-free fractions (Fig.40), potentially suggesting an important role of 
exosome-associated HCV and its infection in vivo.   
 
Exosome biogenesis occurs through at least three pathways: ESCRT-dependent, 
ceramide-dependent and tetraspanin-dependent pathways (101, 107).  The latter two 
pathways are still at an early stage of investigation and it is currently unclear whether 
they are involved in HCV secretion.  Interestingly, components in ESCRT complexes like 
Hrs, TSG101, Alix, VPS4B, and CHMP4b have all been demonstrated to be essential for 
HCV production (144, 280, 281), suggesting that an ESCRT-dependent pathway is also 
involved in HCV secretion.  HCV envelopment is believed to occur on ER and 
intracellular HCV virus becomes infectious upon the envelopment (233, 270); previous 
studies with immunofluorescence staining and live cell imaging have demonstrated the 
egress of intracellular HCV core puncta (presumably infectious HCV particles) via the 
cellular secretory pathway including various endocytic compartments (e.g., early, late, 
and recycling endosomes, which are also the origin of exosomes) (208, 282).  In addition, 
HCV core and E2 proteins, as well as the intracellular HCV particles have been found to 
localize in MVB by electron microscopy (144, 282, 283).  Therefore, the secretion of 
HCV in exosome is very likely due to their similar biogenesis pathways.  Nevertheless, it 
warrants further investigation whether HCV usurps the ESCRT-dependent exosome 
biogenesis pathway for its own secretion or it is merely a coincidence during their 
trafficking towards the plasma membrane. 
 
Our results demonstrated that the exosome-associated HCV remained infectious to 
hepatocytes (Fig. 41) but the specific infectivity of the exosome-HCV was about 10-fold 
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lower compared to that of HCV alone (Fig. 41); there could be a few possibilities.  HCV 
E2 – the HCV envelope protein that is believed to be responsible for receptor binding 
during HCV entry – is about 20 KD larger in the exosome-HCV than HCV alone; if post-
translational modifications are underlying the molecular weight change of E2, they may 
also mark the binding sites on E2 for cellular receptors and thereby hindering the uptake 
of exosome-HCV by target cells.  A recent study has demonstrated that HCV-infected 
hepatocytes produce exosomes containing HCV RNA (145).  Therefore, the exosome-
associated HCV fractions may have a lower efficiency per viral genome to establish a 
productive infection than HCV alone fractions.  Moreover, the specific infectivity is also 
dependent on the average number of HCV virions per exosome and the binding affinity 
of the exosome-associated HCV to its target cells.  Taken together, the molecular 
mechanism of exosome-associated HCV cell entry merits further investigation. 
 
As a new route of HCV infection and transmission, exosome-associated HCV infection 
will unsurprisingly add another layer of complexity and flexibility to HCV transmission 
and pathogenesis.  A recent study has shown that hepatitis A virus, a non-enveloped 
RNA virus causing acute enterically transmitted hepatitis, hijacks the exosome pathway 
to acquire for itself a host-derived cellular membrane, which protects the virus from 
neutralizing antibodies in the circulation (284).  During our present study, a report was 
published demonstrating that exosome-mediated HCV infection is more resistant to 
three out of eight patient-derived neutralizing sera than cell-free HCV infection (285), 
suggesting a role of exosome-mediated transmission in HCV immune evasion.  
Nevertheless, it is not clear in that report how cell-free HCV virions and exosome-HCV 
were separated in their experiments because the strategy used by them – serial 
centrifugation without density gradient purification – is incapable to achieve the 
separation as we showed (Fig. 37-39).  
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Cell-free, CCCM and exosome-mediated HCV infection 
Throughout this study, three different routes of HCV infection and transmission were 
examined: cell-free virus infection, CCCM infection and the exosome-mediated infection.  
All the three routes very likely share similar requirements for HCV replication once inside 
the target cells but they have their own characteristics during cell entry and exit.  Cell-
free virus entry is well-characterized and is basically receptor-mediated endocytosis (Fig. 
2).  Cell entry of CCCM HCV transmission is featured by receptors- and actin- 
dependency (Fig. 14, 15, 22), a time course similar to endocytosis (18 min, Fig. 29), and 
transfer in the form of puncta instead of single virion (Fig. 27-29).  The mechanism of 
exosome-mediated HCV cell entry and whether this process is HCV receptors-
dependent are currently unclear, though theoretically the expression of HCV 
glycoproteins on exosome is possible.  For HCV release/cell exit, convergence of cell-
free HCV and exosomes-associated HCV can occur at or immediately after assembly 
and/or during HCV egress in the secretory pathway, especially in MVB.  Intracellular 
trafficking of assembled HCV particles in the form of viral puncta (could be MVB filled 
with HCV particles) has been observed in both cell-free HCV secretion (66, 208) and 
CCCM HCV transmission (Fig. 27-29).  Therefore it seems that the difference between 
cell-free HCV release and CCCM HCV transmission emerges during the “exit” step itself: 
depending on whether the site for release is facing body fluids/culture supernatant or a 
neighboring cell, cell-free virus release or CCCM transmission takes place.  Interestingly, 
it is currently unclear whether there is a mechanism for the HCV-infected donor cell to 
distinguish between uninfected and infected neighboring cells.   
 
Albeit different in their mechanisms of action, the three HCV transmission routes all 
contribute to HCV infection and spread in their own ways.  Cell-free virus infection is 
usually responsible for host-to-host transmission (the possible role of CCCM HCV 
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transmission cannot be excluded if infected blood cells are also involved) and initial 
infection of target cells/tissue (presumably liver because no data is available about how 
early immune cells and the CNS are infected).  CCCM HCV transmission and exosome-
mediated HCV transmission are then responsible for viral spread and dissemination in 
the host in the presence of immune effectors, especially nAbs; HCV spread within the 
high-cell-density likely mainly relies on CCCM transmission, while long-distance spread 
of HCV to a different tissue/organ is possible through exosome-mediated transmission.  
Based on whether exosome-mediated HCV infection is dependent on HCV receptors for 
cell entry, this transmission route may also have the advantage of bypassing HCV entry 
receptors and the ability to infect cells unsusceptible to cell-free HCV infection.  CD5, 
which is not among the four known HCV receptors required for hepatocyte infection, has 
been identified as the receptor for HCV infection of T lymphocytes (179); exosome-HCV 
and its possible different membrane composition/cell entry mechanism may be 
underlying the extra-hepatic HCV tropism and different receptor-dependency.  Moreover, 
recent studies also demonstrate the ability of exosomes to cross various biological 
barriers including the blood-brain barrier (286, 287); it cannot be excluded that HCV may 
enter the CNS in the “Trojan exosomes”. 
 
HCV entry into the CNS – the infection of BBB, Trojan PBMC, or Trojan exosomes? 
CNS abnormalities are observed in more than 50% HCV patients, regardless of the 
severity of liver diseases.  How does HCV cross the blood-brain barrier and enter the 
CNS is one of the central questions in understanding HCV brain infection.  A few recent 
studies demonstrate successful infection of neuroepthelioma and neuroendothelial cell 
lines with cell culture-produced HCVpp and HCVcc and propose that HCV may cross the 
BBB and enter the CNS by infecting endothelial cells in BBB and releasing HCV virions 
into the CNS (288-290).  However, this hypothesis awaits further in vivo evidence such 
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as immunostaining for viral proteins and HCV RNA detection in the BBB endothelial cells 
of patient samples.  On the other hand, the “Trojan PBMC” hypothesis is proposed 
based on the detection of productive HCV infection in patient PBMC, sequence 
similarities between PBMC- and brain- isolated HCV, and the known ability of PBMC to 
cross the BBB (170, 172, 183, 185).  However, this hypothesis also awaits further 
evidence for the actual process of infected PBMC to cross the BBB; the newly 
developed humanized mouse model (291, 292) for HCV infection may provide direct 
evidence for it in the future.  Last but not least, based on our findings that HCV can 
transmit in the form of exosome (Restults section, CHAPTER 2) and recent discoveries 
of exosome’s ability to cross the BBB (286), it is possible that HCV enters the CNS in the 
form of “Trojan exosomes”.  However, this hypothesis is beyond the scope of the current 
study and future experiments are needed to test it.  Taken together, all of the three 
proposed entry paths for HCV infection of the CNS are possible, yet each of them and 
their relative contributions require further examination.    
 
HCV and astrocytes  
Previous studies with patient autopsy brain samples have identified astrocytes as one of 
the main HCV target cells in the brain by showing the presence of both HCV (+)-strand 
RNA and viral proteins in astrocytes (186, 187), whereas our results show that neither of 
the two most used HCV laboratory models, the HCVcc or HCVpp, were able to 
productively infect astrocytes (Fig. 43, 44, 46, 47).  Our step-wise examination of HCV 
life cycle in astrocytes provided a better understanding of HCV’s interaction with/ non-
productive infection of astrocytes.  At the cell entry step, even though all the four known 
HCV receptors are expressed in PHA, their expression levels were much lower 
compared to Huh7.5.1 and their subcellular localizations were not always on the plasma 
membrane (Fig. 45), which may likely account for the functional defects of these 
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receptors.  These findings were further verified by single-round HCVpp assay showing 
no HCV envelop-mediated pseudotyped virus entry into PHA (Fig. 46A).  But 
interestingly, the luciferase activities in both Env-pp- and HCVpp- infected PHA were 
more than 5 fold higher than mock-infected PHA, which was not observed in Huh7.5.1 
(Fig. 46A), suggesting non-specific endocytosis of Env-pp and HCVpp by PHA.  
Consistent with this finding, we also found that about 0.01% of HCVcc RNA is detected 
in PHA immediately following infection (Fig. 43A, 2 hr), which is likely a result of binding 
of HCVcc to PHA and subsequent uptake of HCVcc by PHA.   The binding/uptake could 
be non-specific, as it’s very inefficient compared to Huh7.5.1 (5-fold less RNA at 2 hr, 
Fig. 43A), which is known to take up HCV by receptor-mediated endocytosis.  
Astrocytes are well-known for their active endocytosis activity (293); HIV-1 is shown to 
enter astrocytes by endocytosis and very few of the endocytosed virions are able to 
escape from endosomal degradation to establish latent infection in astrocytes (294, 295).  
Therefore, it is possible that HCV can non-specifically and thus inefficiently bind to 
astrocytes and then be endocytosed.  
 
At the RNA translation and replication step, our results show that (+)-strand HCV 
genomic RNA can be detected in astrocytes 72 hr after virus removal (Fig. 43A) and that 
astrocytes support HCV IRES-dependent translation (Fig. 49B) but not HCV RNA 
replication (Fig. 51B & C).  These results are consistent with previous findings from 
patient brain samples that HCV (+)-strand RNA and viral proteins (evidence for 
translation) are present in astrocytes but no (–)-strand HCV RNA (evidence for 
replication) can be detected (186, 187).  Importantly, HCV (+)-strand RNA were only 
detected in astrocytes from HIV-1/HCV co-infected patients but not from HCV mono-
infected patients, even though HCV viral proteins are detected in both patient groups 
(186, 187).  Therefore, HCV infection of astrocytes in vivo seems to be inefficient, at 
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least when without co-factors such as HIV-1 co-infection.  This may also help explain 
why no HCV structural proteins core or E2 can be detected in our three day infection 
experiment (Fig. 43B): a result from the combination of low infection efficiency (no active 
replication), no continuous virus input and relatively low sensitivity of HCV core/ E2 
immunostaining.  In addition, we found that miR122, the essential microRNA for HCV 
RNA stability and replication (37, 46, 47), is expressed at extremely low level in PHA 
(Fig. 49C).  We also showed that miR122 ectopic expression can enhance HCV RNA 
translation and overall HCV RNA stability and replication in PHA (Fig. 49 & 50).  
However, its expression alone was insufficient to enable astrocytes to support HCV 
replication (Fig. 51B & C), raising the possibility that astrocytes lack facilitating factors 
besides miR122 or have inhibitory factors for HCV replication.  Furthermore, even if HCV 
free-vrius infection and CCCM transmission both fail to infect astrocytes, it cannot be 
excluded that exsosome-associated HCV may do so;  it is also likely that there is 
potential compartmentalized HCV evolution in the CNS (183, 185, 296), while the HCV 
strains used in the current study are not neurotropic and do not afford the astrocyte 
infection (refer to the Perspective section for details).     
 
Even though HCV infection of astrocytes is non-productive, its interaction with astrocytes 
including binding to and maybe endocytosis by astrocytes can still lead to changes in 
astrocytes.  Our data demonstrated that PHA challenge with HCV for 2 hr stimulated IL-
18 expression in PHA (Fig. 53A).  Interestingly, a very recent report has also shown that 
HCV stimulates IL-1β and IL-18 expression in macrophage and HCV p7 protein is 
identified to be responsible for the induction of IL-1β (297).  HCV HCV RNA is shown to 
be present in the form of exosomes (102) and trigger INF-α secretion in plasmacytoid 
dendritic cells (145).  Human astrocytes express a panel of Toll-like receptors, with TLR3 
expressed at a particularly high level (200).  Activation of TLR3 by endosomal double-
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strand RNA, which is commonly seen during RNA virus infection including HCV, usually 
leads to the production of proinflammatory cytokines in astrocytes, including IL-18 (200, 
298).  Nonetheless, further experiments are needed to understand how HCV-induced IL-
18 production in astrocytes is triggered and which component(s) of the HCV virus is 
responsible for the induction.  Besides astrocytes, microglia could also play important 
roles in HCV-related CNS abnormalities.  Microglia from HCV-infected subjects are 
found to be positive for both (+)- and (-)-strand HCV RNA and viral proteins, indicating 
active viral replication and productive HCV infection in microglia (186, 187).  In addition, 
microglia in HCV-infected brain are found to be highly activated and produce 
proinflammatory cytokines such as TNF-α, IL-1β and IL-8 (188); in vitro infection of 
primary macrophage with HCV patient plasma also induces TNF-α and IL-8 production 
(178).  Thus, HCV interactions with both astrocytes and microglia could contribute to 
HCV-associated CNS abnormalities.     
 
Our finding that HCV exposure induced IL-18 expression in astrocytes should be 
considered highly significant in HCV interaction with astrocytes.  IL-18 is a 
proinflammatory cytokine that belongs to the IL-1 family (e.g. IL-1β) (299).  It is mainly 
produced by macrophage in the peripheral and its expression is upregulated in a number 
of virus infections including influenza A virus, adenovirus and murine cytomegalovirus 
(300-302).  IL-18 induces strong IFN-γ production via NF-κB activation in a toll-like 
receptor (TLR) signal-dependent manner (303, 304); IFN-γ, in return, also induces more 
IL-18 expression, thus forming a positive feedback and eliciting an proinflammatory and 
anti-viral response (300, 302, 305).  Recently, IL-18 polymorphisms are shown to be 
associated with the outcomes of HCV infection and treatment (306-308).  In HCV 
patients, elevated sera and intrahepatic IL-18 levels and IL-18 receptor expression in 
liver are correlated with increased chronicity of the infection, higher levels of liver 
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inflammation, higher frequency of fibrosis, cirrhosis, and hepatocellular carcinoma, and 
worse disease outcome (309-311).  These previous studies suggest that IL-18, as an 
integral part of HCV-induced immune response, contributes to HCV’s disease 
progression in the liver.  In the brain, IL-18 and its receptor are found expressed on 
astrocyte, microglia and neurons; they have been shown to be key players in 
neuroinflammation and neurodegeneration (250, 312).  During Japanese Encephalitis 
virus infection, microglia and astrocytes both produce IL-18 and IL-1β, which induces the 
release of more proinflammatory cytokines and impairment of neuronal survival (313). It 
is clear that the roles of IL-18 in HCV-associated CNS abnormalities merit further 
investigation. 
 
IL-18 was shown to be induced in HCV-stimulated PHA (Fig. 53).  We naturally followed 
up to determine that whether conditioned media from these astrocytes (presumably 
containing IL-18 and possibly other yet to be identified neurotoxic factors) were 
neurotoxic; they were not (Fig. 54A).  But it is important to point out that the IFN-γ-
stimulated PHA conditioned media didn’t exhibit neurotoxicity, either (Fig.54A).  The 
negative results could be simply explained by the low level of IL-18 in the culture 
supernatant or IFN-γ used.  Nevertheless, undetectable neuron viability change does not 
necessarily indicate that increased IL-18 level is not able to affect neuron functions in 
more subtle ways, considering its critical role in neuroninflammation (250).  However, it 
was very surprising that HCV itself was sufficient to cause neurotoxicity at the viral titer 
of 4.7 x 107 vge/ml (Fig. 54B & C).  Whether this viral titer required for neurotoxicity is 
physiologically relevant or not is unknown at present; to our knowledge there is no 
literature about the amount of viral RNA in brain samples of HCV-infected subjects.  
Recombinant HCV core protein (subtype 1b) has been recently shown to cause 
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neurotoxicity in both cell culture and mice (314), suggesting that HCV core protein 
contributes to HCV neurotoxicity.  But it does not exclude the possibility that other 
components of the virus such as the envelope proteins and viral RNA may also 
contribute to HCV neurotoxicity; further experiments are needed to address this question.  
In addition, recent studies find that neurons also express TLRs including TLR-3 and they 
are able to mount anti-viral IFN response upon various virus infection/stimulation (315), 
suggesting a potential mechanism of how virus components may lead to neuronal cell 
death. 
 
Conclusions 
In summary of this study, we characterized the CCCM HCV transmission by 
demonstrating its dependency on HCV receptors and actin cytoskeleton, its rapid and 
productive nature, and its spatial and temporal details under live cell imaging.  We also 
showed evidence that a subpopulation of HCV virions in both infected-cell culture-
supernatants and patient plasma co-fractionated with exosomes and these exosomes-
associated HCV were infectious to hepatocytes, suggesting a new route of HCV 
transmission: exosomes-associated HCV infection.  These findings about alternative 
routes for HCV transmission provide new insights into HCV infection and shall aid in the 
development of new and effective strategies for preventing and treating HCV infection.  
Furthermore, with available HCV cell culture model systems, we characterized the 
interaction between HCV and astrocytes, one of the putative HCV target cells in the 
brain.  We demonstrated that astrocytes support HCV translation but not entry and 
replication.  We also showed that HCV exposure stimulated IL-18 expression in 
astrocytes and that HCV itself exhibited direct neurotoxicity.  These findings shall add to 
our understanding of HCV infection of the CNS and possible contributions to HCV-
induced CNS abnormalities.  All in all, the current study shall aid in the future 
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development of new therapies for preventing HCV infection and treating HCV infection in 
the periphery and the CNS. 
 
  
220 
 
PERSPECTIVE 
 
Future directions 
Base on the current study, future studies can be conducted to further understand the 
different transmission routes of HCV, HCV-related CNS abnormalities, and how our 
findings can benefit the prevention and treatment of HCV infection and related diseases.  
Even though our results suggest a potential role of lamellipodium (Fig. 27-29), the 
underlying mechanisms of CCCM HCV transmission remain largely unclear.  The same 
live cell imaging experiment as in Fig. 27-29 but with donor cells also labeled with 
lamellipodium-specific markers, such as GFP-tagged actin (275) or the Rac small 
GTPase (276), can be performed (the target cells can be labeled with cell-tracking dyes 
of other colors) to test the possible involvement of lamellipodium.  In addition, similar live 
imaging with GFP-tagged actin or HCV receptors in the presence of cytochalasin D may 
clarify the specific roles of actin in CCCM transfer; live imaging with MVB markers may 
reveal the true identity of the viral puncta; live imaging with the tagged TJ marker zonula 
occludens-1 (ZO-1) together with tagged CLDN1 or OCLN may reveal whether the 
CCCM HCV transfer is mediated by CLDN1 and OCLN inside functional TJs and thereby 
whether HCV adopts the “transfer across TJ” strategy for its CCCM transfer.  
 
In addition, further experiments are needed to confirm the association/ inclusion of HCV 
virions in exosomes and to characterize this alternative route of HCV transmission.  For 
instance, experiments can be performed to inhibit exosome production and determine its 
effect on HCV production, to immunocapture exosomes and determine whether HCV is 
co-captured, and to test whether cell entry of exosome-HCV is dependent on HCV 
receptors.  The contribution of this new route of HCV transmission to viral spread and 
systemic infection can also be examined.  For instance, it can be determined whether 
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exosome-associated HCV can bypass the HCV receptors and contribute to extra-hepatic 
HCV infection, and whether “Trojan exosome” can cross the BBB and bring HCV into the 
CNS.   
 
Moreover, based on our finding that HCV exposure leads to direct neurotoxicity (Fig. 54), 
future studies can be performed to understand the underlying mechanisms.  Neither 
HCV RNA nor viral proteins were found in neurons from post-mortem HCV patient brain 
samples, suggesting that HCV does not infect neurons (186, 187).  Therefore, HCV’s 
direct neurotoxicity must be caused by one or more of its structural components, which 
include HCV RNA, core protein, envelope proteins E1, E2 and maybe the viroporin p7.  
All of HCV core, E1, E2, and p7 proteins have been suggested to induce apoptosis when 
expressed alone or in the context of HCV infection in hepatocytes and immune cells 
[reviewed in (316)], but not much is known when they are exposed to cells without 
intracellular expression or productive infection.  The only exception is a recent study 
showing that exposure to recombinant HCV core protein led to neurotoxicity (314), but 
the underlying mechanisms are not clear.  Therefore, to understand HCV direct 
neurotoxicity, the first step is to determine which structural component(s) of HCV are 
responsible for it; recombinant HCV proteins E1, E2, p7, and in vitro synthesized HCV 
RNA can be tested.  Follow-up experiments can be performed to determine the cellular 
signaling pathways underlying the observed neurotoxicity: TLR pathways, Fas-/TNF-
/tumor-necrosis-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis, 
autophagy-induced cell death, or some other pathways.  Injection of the neurotoxic HCV 
component(s) directly into mouse brain can also be performed to determine whether 
neurotoxicity and/or behavior changes are observed. 
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Furthermore, our study showed that HCV exposure leads to IL-18 production in PHA 
(Fig. 53); future studies can be conducted to characterize this process and explore its 
potential impact on neuron functions.  Our results showed HCV-induced IL-18 
expression at the transcriptional level, but IL-18 is also well-known to be regulated at 
post-translational level by caspase-1 (303).  Therefore, it can be first determined 
whether HCV also induces pro-IL18 cleavage to increase the level of bioactive IL-18.  
The time course of HCV-induced IL-18 production can then be determined by, e.g., 
collecting PHA at 6, 12, 24, 48 hr post HCV exposure.  To confirm HCV-stimulated IL-18 
production in astrocytes in vivo, IL-18 expression at both mRNA and protein level may 
be examined by astrocytes isolation with LCM from post-mortem HCV patient brain 
samples followed by qRT-PCR or enzyme-linked immunosorbent assay (ELISA).  HCV 
component(s) responsible for IL-18 induction can be determined next.  Since our results 
showed that IL-18 was inducted within 24 hr post-exposure, HCV structural component(s) 
are very likely responsible for it; recombinant core, E1, E2, p7 and in vitro synthesized 
HCV RNA may be tested.  Cellular signaling molecules/pathways involved in this 
process can also be determined: TLRs, caspases, NF-kB signaling, or maybe something 
else.  After characterization of HCV-induced IL-18 production in PHA, its potential role in 
neuron function can be explored next.  Even though HCV-stimulated PHA conditioned 
medium didn’t cause direct neurotoxicity (Fig. 53), it may still lead to neuron dysfunction 
by affecting, e.g., action potential firing, synapse formation, or dendritic spine formation.  
Thus, the role of HCV-stimulated PHA conditioned medium in neuron function should be 
examined more comprehensively and nAb against IL-18 may be used in combination to 
understand the potential role of IL-18 during this process.  Besides possible direct effect 
on neuron functions, HCV-stimulated astrocytes may also exert its impact on neurons 
through interactions with microglia, another important player in neuroinflammation.  
Therefore, it is also interesting to expose microglia to HCV-stimulated PHA conditioned 
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medium and then examine changes in proinflammatory cytokines production in treated 
microglia and whether conditioned medium from these microglia may lead to any demise 
on neuron functions or not.   
 
Lastly, future studies can also focus on the interaction between HCV and microglia, the 
other putative HCV target cells in the brain, and the possible impact of this interaction on 
neurons.  Besides cell-culture produced HCV model systems, patient sera and a 
lymphotropic HCV strain, the SB strain (refer to “Extra-hepatic HCV tropism” below for 
details), may also be tested. 
 
Towards a “cure” for chronic hepatitis C 
HCV drug development has greatly advanced since the establishment of HCVcc system 
in 2005; the first two direct-antiviral agents (DAA), the NS3/4A protease inhibitors 
telaprevir and boceprevir, were approved in May 2011 and more DAAs targeting 
different viral proteins and cellular co-factors in different steps of HCV life cycle are 
currently under clinical trials (317).  It is expected that a combina-tory therapy composed 
of different DAAs, similar to the HIV-1 HARRT therapy, will eventually become the new 
SOC of HCV treatment in the near future.  Such a combinatory therapy is expected to 
meet at least the following two require-ments.  First, it must be free of interferon α, which 
leads to very severe adverse effects and high discontinuation rates.  Secondly, it must 
have as high as possible cure rates, which is a benefit from the combinatory design of 
the therapy that minimal viral resistance exists when DAAs targeting different viral life 
cycle steps are administrated simultaneously.  The cure rate of a therapy is indicated by 
the percentage of patients achieving sustained virological response (SVR): SVR12 
indicates undetectable HCV RNA level in 12 weeks post-treatment.  At the American 
Association for the Study of Liver Diseases (AASLD) meeting in November 2012, cure 
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rates of up to 100% from a multitude of interferon-free HCV clinical trials were presented.  
The AVIATOR trial from Abbott Laboratories, the AI444-040 trial from Bristol-Myers 
Squibb/Gilead Sciences, and the ELECTRON trial from Gilead Sciences, all of which are 
phase II trials, are the most promising.  They show SVR12 in between 84-100% in the 
treatment-naïve group with HCV subtype 1 and the AVITOR trial also shows 89-93% 
SVR12 in the treatment-experienced group with HCV subtype 1 (318-320).  Among HCV 
subtype 2 and 3 patients, the AI444-040 trial shows the highest cure rates: 88-100% 
SVR24 in the treatment-naïve group (319).  Further clinical trials with the above 
promising candidates are moving forward; early stages of interferon-free clinical trials for 
other HCV subtypes are also ongoing.  However, the above clinical trials mainly focus on 
patients with no or mild liver damages; HCV treatment in patients with severe liver 
diseases such as compensated cirrhosis is more complicated due to poor tolerability and 
high discontinuation rates (321, 322).  Treatment of HCV in HIV-1-co-infected patients 
and post-liver transplant patients are also more difficult because of the potential drug-
drug interactions between HCV drugs and HIV-1 drugs or immunosuppressant.  
Nevertheless, researches and clinical trials for both situations are ongoing and the 
results are promising (323-327).  Since the discovery of HCV in 1989, we had never 
been closer to a cure for HCV than we are now; the results from the ongoing clinical 
trials grant us reasons to believe that chronic hepatitis C, a disease that claims more 
than 350,000 lives annually, may be cured with three months of oral antiviral drugs in the 
near future. 
 
HCV mouse models 
Despite intense research efforts on small animal models for HCV in last two decades, 
chimpanzees are still the only complete animal model for HCV infection, which 
recapitulates the full viral life cycle and host immune response.  They remain the best 
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model for studying HCV-related innate and adaptive host immune responses and testing 
HCV vaccines, though it is not considered a good model for the study of chronic liver 
diseases and HCC (291).  Great advances have been made in the development of HCV 
mouse models in recent years.  Generally, two strategies for humanized mouse models 
are adopted: to genetically humanize cellular factors required for a complete HCV life 
cycle in mouse hepatocytes, or to replace mouse liver and/or immune cells with human 
hepatocytes and/ or leukocytes engraftment.  For the first strategy, a recent report 
shows that with blunted innate immunity, abundant miR-122, and expression of 
HCV receptors, mouse liver-derived cell lines can be infected with HCV and produce 
infectious virus (328).  But there is still a distance from a cell-culture model to a mouse 
model.  For the second strategy, the uPa-SCID mice (urokinase-type plasminogen 
activator-severe combined immunodeficiency) and the FRG mice [Fah (fumeral 
acetoacetate hydrolase)-/-Rag2-/-IL2rg-/-] are developed based on the combination of 
immunodeficient mice, genetic modifications to degrade mouse hepatocytes, and 
transplantation of primary human hepatocytes (329-331).  These two models 
demonstrate high levels of HCV infection in the liver and high titers of viremia; they are 
thereby used to test antivirals before chimpanzee study and clinical trial (329, 332-334).  
However, due to their immunodeficiency background, both of these two models lack 
adaptive immune response against HCV.  Therefore a new mouse model was developed 
recently to overcome this issue: the AFC8 (albumin promoter)-hu HSC/hep mice (292).  
Cell death of mouse hepatocytes is induced in the mice and co-transplantation of human 
hematopoietic stem cells (HSC) and hepatocyte progenitors is performed, resulting in 
liver repopulation with human hepatocytes and immune reconstitution with human 
leukocytes.  Therefore, this model features HCV-specific cellular immune response, 
hepatitis and liver fibrosis.  It constitutes the first small animal model of HCV infection 
suitable for studying adaptive immunity and pathogenesis.  Though limitations of the 
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current model are present that no HCV viremia can be detected in the infected mice, 
likely due to the low level of human hepatocytes engraftment (~15%), it is possible that 
the problem can be solved by future optimization of the model.  More importantly, as the 
only available small animal HCV model with both human hepatocytes and human 
immune system, this model may be utilized to study HCV infection of the immune cells, 
and to test the “Trojan PBMC” and the “Trojan exosome” hypotheses for HCV entry into 
the CNS.   
 
HCV infection of PBMC and its contribution to the pathogenesis of HCV-related 
diseases 
The association of HCV infection with immune dysfunction and LPD has been 
established for a long time (164-168).  Active replication of HCV in PBMC, after decades 
of debates, is also accepted now based on two lines of evidence.  On one hand, HCV (-
)-strand RNA, the replication intermediate, is successfully detected in PBMC with 
improved methodology (156, 157, 335).  On the other hand, viral RNA persists in 
mononuclear blood cells inoculated into SCID mice for up to two months and a second in 
vivo passage of HCV-RNA-positive cells to other mice is successful (336).  The 
contribution of HCV infection of PBMC to the pathogenesis of HCV-related diseases 
include its impact on immune system functions, its involvement in LPDs, and its role in 
the persistence of HCV infection and HCV recurrence.    
 
First, immune responses in chronic hepatitis C patients have been well-studied, though 
seldom do studies explore the role of HCV infection of PBMC in immune system function, 
likely due to the small percentage of infected cells and relatively low viral replication in 
PBMC (16).  The few available studies show some interesting results.  One of them 
suggests that endogenous presentation of HCV antigens by infected B-cells and 
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monocytes may contribute to immune tolerance of HCV and viral persistence (177).  The 
other two studies from one group demonstrate that HCV infection and replication in T 
cells leads to impaired IFN-γ signaling, reduced proliferation and enhanced Fas-
mediated apoptosis.  These results suggest that HCV replication in T cells may play a 
role in both the disturbance of Th1 commitment/ Th1 hyporesponsiveness and the 
regulation of T cell proliferation and apoptosis (337, 338).  Future studies are needed to 
further understand the impact of HCV infection of PBMC on immune system functions. 
 
Second, even though the association of HCV with LPDs is established, the underlying 
mechanisms are not completely understood.  But it is believed that the activation of the 
oncogene bcl-2 plays a critical role.  The frequency of bcl-2 rearrangement is 
significantly higher in chronic HCV infection, especially in cases evolved to MC and LPD 
(339, 340).  Bcl-2 recombination [translocation (14;18)] leads to the activation of the bcl-
2 oncogene and the inhibition of B-cell apoptosis, resulting in progressive accumulation 
of lymphocytic cells and eventually LPD (341, 342). 
 
Lastly, as one of the extra-hepatic reservoirs harboring viral replication, it is suggested 
that HCV infection of PBMC contribute to persistent HCV infection and HCV recurrence 
in spontaneously or therapeutically cleared patients and patients with liver 
transplantation (156, 157, 172).   
 
Extra-hepatic HCV tropism 
In spite of detection of viral RNA and proteins in patient PBMC and successful infection 
of PBMC with HCV patient plasma, entry, infection and replication of cell-culture 
produced HCV in PBMC and lymphocytic cell lines have been unsuccessful [(181, 182) 
and our unpublished data].  Similarly, infection of and replication in primary human 
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astrocytes are not detected with HCVpp/ HCVcc/ HCV-Rluc, though RNA translation is 
supported in PHA (Results section, CHAPTER 3).  Interestingly, sequence analysis of 
HCV RNA isolated from different patient tissues shows that RNA sequence from the 
CNS is closer to that from PBMC, but not serum or liver (183, 185), indicating 
compartmentalization of viral quasispecies.  The four known HCV receptors are 
expressed on PHA (Fig. 45) and subsets of, if not all, PBMC (181), though at varying 
levels.  But HCVpp entry into PBMC or PHA does not occur [Fig. 46, 47 and (181)].  In 
addition, CD5 is recently identified as the receptor mediating entry of patient plasma-
derived HCV into T lymphocytes (179, 180): it seems that different HCV receptors are 
mediating HCV entry into different cells.  Comparison of HCV RNA isolated from 
different tissues show sequence differences between liver and lymphoid/ brain isolates 
in both the hypervariable region (HVR) of the glycoprotein E2 and the 5’UTR, which are 
critical regions for receptor binding/ cell entry and RNA replication, respectively (185, 
296).  Collectively, the above information is suggestive of a model of extra-hepatic 
(PBMC and CNS) HCV infection, that intrinsic sequence differences between current 
cell-culture produced HCV and patient-derived HCV define the different tissue tropisms: 
liver or lymphoid/ brain.  Most of the cell-culture produced HCV strains are selected and 
widely used based on their high infectivity of hepatocytes, which may explain their 
inability to infect extra-hepatic cells.  Interestingly, a lymphotropic strain of HCV, the SB 
strain, was established ten years ago; it is cultured in a B-cell line (SB cells) derived from 
an HCV-infected non-Hodgkin’s B-cell lymphoma (343).  The SB strain belongs to HCV 
subtype 2b and it can productively infect B-cells and to a less extent, T cells (337, 338, 
343, 344).  Nevertheless, the genome of the SB strain is not sequenced; its infection of 
other PBMC subsets or hepatocytes is not yet tested.  With more characterization in the 
future, the SB strain may become a good cell culture model system for studying extra-
hepatic HCV infections/ manifestations.  It may also provide a powerful tool for testing 
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antivirals for the treatment of extra-hepatic infections and contribute to further 
understanding of HCV infection of PBMC/ brain and HCV-related extra-hepatic diseases.  
 
Treatment of HCV in PBMC and the CNS 
HCV recurrence is sometimes observed in patients receiving liver transplantation and 
patients spontaneously or therapeutically cleared of HCV (156, 157, 165, 171).  
Sequence analysis of HCV RNA before and after recurrence/ transplan-tation suggests 
that the relapse can be from undetectable HCV in the liver (“occult” infection) or viral 
reservoir in PBMC (156, 345, 346).  It is expected that new HCV treatment regimens 
with combinations of DAAs can achieve SVR in up to 100% patients.  Unfortunately, 
SVR does not necessarily always lead to a true cure.  It remains unknown whether the 
upcoming new “cocktail therapy” can completely eradicate occult HCV and HCV 
reservoirs at extra-hepatic sites, such as PBMC and the brain.  Two major concerns 
exist.  On one hand, all the DAAs are screened in HCV-infected hepatocytes due to the 
lack of a widely accepted lymphotropic HCV strain and a corresponding HCV-PBMC cell 
culture model.  Considering the potential differences between hepatic and extra-hepatic 
HCV strains, it cannot be guaranteed that these DAAs will be as effective treating HCV 
infection of PBMC/ brain cells as they are for hepatocytes.  On the other hand, even 
though the new regimen is able to clear HCV in the periphery, HCV reservoir in the 
privileged brain remains a risk factor for relapse.  Therefore the problem of HCV 
reemergence after the achievement of peripheral SVR may still exist.  Future studies on 
HCV infection of brain cells such as microglia and its impact on neuron functions are 
needed to further understand the mechanisms of HCV infection of the CNS and how it 
can be treated to accomplish a true systemic cure for HCV in the new “cocktail therapy” 
era.  Last but not least, with “Trojan exosomes” as a potential route for HCV entry into 
230 
 
the CNS, in turn, “Trojan exosomes” loaded with anti-HCV drugs may be used as a 
method to cross the BBB and deliver the antivirals into the brain.     
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